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resumo 
 
 
A hipertensão arterial pulmonar (HAP) é uma doença crónica rara, caracterizada 
pelo aumento da resistência vascular pulmonar (RVP) com sobrecarga 
progressiva e remodelagem do ventrículo direito (VD), o que pode levar à 
insuficiência cardíaca do ventrículo direito (ICVD). Estas perturbações surgem 
na sequência de uma alteração metabólica na oxidação da glicose, um processo 
designado por efeito de Warburg, que afeta o metabolismo da glicose a nível 
sistémico. A neuregulina-1 (NRG1), uma proteína que demonstrou ter efeitos 
benéficos na hipertrofia do VD causada pela HAP, está também associada à 
regulação do metabolismo da glicose dado seu papel na modulação da 
expressão dos transportadores de glicose (GLUTs). 
Neste estudo, o nosso objetivo tinha por base a avaliação do efeito do 
tratamento crónico com rhNRG1 na expressão de genes da via da glicólise no 
VD e em músculo esquelético num modelo animal de HAP induzida por 
monocrotalina (MCT) e num um modelo crónico de hipoxia/Sugen5416, que 
reproduz algumas das principais características fisiopatológicas da HAP 
humana. 
Verificamos que a expressão de mRNA do GLUT1 e do GLUT4 no VD está 
alterada na HAP e que se demonstrou semelhante entre os modelos animais 
MCT e hipoxia/Sugen5416, estando relacionada com o desenvolvimento de 
hipertrofia do VD (HVD). No entanto, o tratamento com rhNRG1 apenas atenuou 
a expressão dos GLUTs para valores próximos aos normais no modelo de HAP 
induzida por MCT. Enquanto que a expressão do GLUT1 e do GLUT4 está 
correlacionada com marcadores cardíacos da doença, os genes da via glicolítica 
demonstraram estar correlacionados com as alterações morfofisiológicas 
resultantes do desenvolvimento da HAP no modelo MCT. A partir da análise de 
alguns genes da via glicolítica, concluímos que, para além dos GLUTs, alguns 
genes estão relacionados, não só com o efeito de Warburg, mas também com 
a progressão da doença. Verificamos também que o tratamento com rhNRG1 
atenuou as alterações de expressão em alguns genes da via glicolítica, 
resultando numa melhoria do metabolismo da glicose. A avaliação da tolerância 
à glicose revelou que os animais com HAP de ambos os modelos são resistentes 
à insulina e que o tratamento com rhNRG1 regulou a concentração sistémica de 
glicose em ambos os modelos animais. 
Em conclusão, os efeitos terapêuticos da NRG1 na HAP experimental podem 
dever-se, em parte, à regulação das alterações metabólicas que estão 
associadas à progressão da HAP e à disfunção do VD, e que se refletiram na 
reversão do fenótipo ventricular da doença. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
keywords 
 
Pulmonary arterial hypertension; right ventricle; neuregulin-1; Warburg effect; 
metabolism. 
 
abstract 
 
Pulmonary arterial hypertension (PAH) is a chronic rare disease, characterized 
by increased pulmonary vascular resistance (PVR) with progressive overload 
and remodelling of the right ventricle (RV), that eventually leads to right 
ventricular heart failure (RVHF). These derangements arise from a metabolic 
switch from glucose oxidation towards glycolysis, the Warburg effect, affecting 
glucose metabolism at the systemic level. The neuregulin-1 (NRG1), a protein 
that has been shown to play beneficial effects on PAH and RV hypertrophy, has 
also been associated with the regulation of glucose metabolism given its role in 
modulating the expression of glucose transporters (GLUTs). 
In this study we aimed to evaluate the effect of rhNRG1 chronic treatment on 
glycolysis pathway genes expression in the RV and skeletal muscle in a 
monocrotaline (MCT)-induced PAH animal model and in chronic 
hypoxia/Sugen5416 model that also reproduces key pathophysiological features 
from human PAH. 
We have found that RV GLUT1 and GLUT4 mRNA expression is altered in PAH 
and was similar between the MCT and hypoxia/Sugen5416 animal models, being 
this related with the development of RV hypertrophy (RVH). However, the 
treatment with rhNRG1 only attenuated GLUTs expression toward normal values 
in MCT-induced PAH model. The expression of GLUT1 and GLUT4 is correlated 
with cardiac markers of disease, while the glycolytic pathway genes are 
correlated with the morphophysiological changes resulting from the development 
of PAH in MCT model. From the analysis of some glycolytic pathway genes, we 
conclude that beyond GLUTs, several genes are related, not only with the 
Warburg effect, but also with the disease progression.  We also found that the 
treatment with rhNRG1 attenuated the changes in some glycolytic pathway 
genes, resulting in an improvement of glucose metabolism. The glucose 
tolerance evaluation revealed that the animals with PAH from both models are 
insulin resistant and that the treatment with rhNRG1 regulated systemic glucose 
concentration in both animal models. 
In conclusion, the therapeutic effects of NRG1 in experimental PAH may be due, 
in part, to the regulation of metabolic changes associated with PAH progression 
and RV dysfunction, which were reflected in the reversion of the ventricular 
phenotype of the disease. 
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Introduction 
1. Cardiovascular diseases and Pulmonary Hypertension 
 Cardiovascular diseases are a group of disorders of the heart and blood vessels, and 
the first cause of death globally.1 Pulmonary hypertension (PH) is a hemodynamic and 
pathophysiological abnormality that is found in many clinical conditions, most commonly 
cardiopulmonary diseases.2,3 PH is characterised by pathologies on pulmonary vasculature 
with resulting elevations of pulmonary arterial pressure4, defined as a mean pulmonary artery 
pressure (mPAP) of 25mmHg or more with a normal pulmonary capillary wedge pressure 
(PCWP) of 16mmHg (pre-capillary PH)2,5, while the normal values for mPAP are 14 ± 
3mmHg at rest.5,6 According to World Health Organization (WHO),  the current clinical PH 
classification can be subdivided into five groups based on the etiology of the disease (Table 
1).1,7 These five groups were defined in the fifth World Symposium on Pulmonary 
Hypertension (5th WSPH) which took place in Nice, France, in 2013, aggregating the 
multiple aspects of PH.8 
 
1.1. Pulmonary arterial hypertension   
 Pulmonary arterial hypertension (PAH), that belongs to the Group 1 of PH subtypes9, 
is very rare and could be more serious than systemic arterial hypertension.10 As it is a rare 
disease, the globally reported incidence of PAH is about a 1.1 to 7.6 per million of adults for 
each year, while the prevalence of this pathophysiology varies between 6.6–26.0 per million 
of adults, affecting mostly women.11–18 PAH is a progressive, fatal5,19, complex and 
multifactorial cardiopulmonary disorder3 that may progress to right ventricular (RV) heart 
failure (HF) and lead to death in 2.8 years if isn't correctly treated.3,6,19 However, the 
prognosis depends on a variety of factors, such as the age of the patient or the severity of 
PAH, and the studies demonstrated a range of survival between 1 and 7 years with 
treatment.18,20 The most common signs and primordial symptoms are dyspnoea (a shortness 
of breath during physical exertion), fatigue and syncope,13,20,21 and as the condition 
progresses, the patients may also experience an increase in cardiac frequency, chest pain, 
oedema of the ankles or legs and dizziness.20 The Registry to Evaluate Early and Long-term 
Pulmonary Arterial Hypertension Disease Management (REVEAL Registry), a multicentre 
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observational cohort study of WHO Group 1 PAH, also revealed that around 25% of the 
patients manifested depressive symptoms or even depression.22,23 Although there are 
currently several treatments that contribute to the improvement of the symptoms of the 
disease and that allow the increase of the survival of patients with PAH, the cure for this 
disease has not yet been found.24,25  
 Based on diverse etiologies26, PAH is a pulmonary vascular remodelling pathology 
that affects both the pulmonary vasculature and the heart.27 It is characterized by pre-
capillary PH28 reflected by a continuous and notable elevation in mPAP, greater than 25 
mmHg at rest or greater than 30 mmHg during exercise2,3,29,30, PCWP inferior to 12 mm Hg 
and pulmonary vascular resistance (PVR) above or equal to 3 Wood units. 2,3,13,19 PAH is 
characterized by vascular remodelling, PVR, RV hypertrophy (RVH), progressive RV heart 
failure (RVHF) and, ultimately, death.2,3,13,19,26,29–31 The clear increase in PVR is a limiting 
factor for the rate at which the RV can pump blood through the lungs, what causes a 
deficiency of breath and reduces the functional capacity.32 Furthermore, although the 
underlying mechanisms of this syndrome in the RV are poorly understood33, it is known that 
the RV function is an imperative determinant of survival in many cardiovascular diseases.34–
36 Indeed, the RV function is the most relevant prognosis determinant in PAH and the RV 
dysfunction (RVD) is characterized by abnormal energy metabolism.37,38 The metabolic 
derangements originated evolve from the progress of this disease to the end-stages4, 
encompassing not only the RV but several tissues of the organism, such as pulmonary artery 
(PA), left ventricle (LV) or skeletal muscle.39  
  In clinical terms, RVHF concerns to the inability of the RV to perfuse the lung 
circulation effectively to maintain LV filling at low venous/diastolic pressures.40 The 
transition from RVH to RVHF involves a huge variability of RV adaptations among patients 
which are exposed to chronic PH according to the aetiology of the PH.41,42 Due to the 
persistent increase on afterload caused by the progression of the disease, the RVH is usually 
accompanied by ischemia, myocardial apoptosis and excessive fibrosis, as well as by 
increased expression of non-contractile proteins that lead to diastolic dysfunction and 
inefficient coupling, triggering a decrease in RV systolic function followed by an acute RV 
dilatation and that can culminate in RVHF.39,43–45 Once RV ischemia may lead to the 
generated metabolic switches in carbon utilization, that are associated with maladaptive 
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hypertrophy, it might potentiate the “hypoxia-like” program of gene expression44 activating 
genes such as hypoxia inducible factor (HIF) and vascular endothelial growth factor 
(VEGF), who plays a central role in modulation of myocyte development and in myocardial 
angiogenesis.43 
 The Dana Point Clinical Classification, elaborated in association with WHO, 
categorized PH into five different subgroups with base on the etiologies of this 
pathophysiology, allowing the identification of the several forms of PH described in Table 
1.46,47 All of the subgroups of PAH share common changes not only in the signalling 
pathways but also in histological findings, as the solid remodelling of non-muscularised PA48 
and with regard to pathology, there is greater difference between the different WHO 
groups.49 The actual classification groups patients with base in analogous pathological 
findings, hemodynamic profiles, and management strategies of the disease, emphasizing the 
different origins of the disease.9,47  
 Previously known as Primary PH46, the Group 1 of PH comprises the several 
disorders that are responsible for the development of PAH. In a general way, this group is 
characterized by the hypertrophic PA remodelling with arteriolar muscularization49,50, 
intimal fibrosis49,51,52, in situ thrombosis with neovascularization53–55, reduced pulmonary 
vascular compliance52, and disorganized growth of endothelial cells (EC)39,56, that in late 
stages evolves to angioproliferative plexiform lesions56,57, morphologic hallmarks of severe 
PAH, that are complex and glomeruloid-like vascular structures which are originated from 
the pulmonary arteries58, that lead to the characteristic increase in vascular resistance within 
the pulmonary system and eventually to maladaptive responses of the RV due the increased 
pressure load.49,54  
 
 
2. Pathophysiological and Metabolic alterations in Pulmonary Arterial Hypertension  
 From foetal development to the birth, the RV suffers structural remodelling instigated 
by metabolic alterations: during the foetal development their walls are thick, as well as the 
pulmonary arteries; the pressure of ejection of blood is high, once the pulmonary circulation 
has a low-flow, and a high-resistance circuit results in a reduced venous flow to the left 
heart.59,60 At birth, the remodelling starts, the walls get thinner, decreasing PVR and thus a 
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decrease in RV afterload,  and the blood pressure becomes lower, which alters the 
metabolism in RV and leads to RVH regression.43,59–61 During the foetal development, the 
glucose oxidation (GO) and glycolysis are the two major sources of cardiac ATP, and the 
circulating levels of fatty acids are low.62 At child-birth occurs the transition to fatty acid 
oxidation (FAO) as the primary source of energy for the heart, promoted by an increase in 
the expression of genes that encode for the enzymes from the FAO pathway.63 At this time, 
it also starts the increase in vasodilation through the enhanced release of vasodilators, as 
nitric oxide (NO), contributing for an increase in oxygen and ventilation, and prostacyclin 
(PGI2), that is responsible for the modulation of changes in pulmonary vascular tone at 
birth.43 This process is accompanied by a decrease in the secretion of vasoconstrictors as 
endothelin-1 (ET-1)41,43, leading to an increase in systemic vascular tone and a progressive 
decrease in RV wall thickness.41 When a heart is hemodynamically or metabolically stressed, 
as it occurs in PAH, a regression to the foetal metabolism pattern usually occurs, reactivating 
the genetic packaging yore modified.64  
 All the types of PAH share pathological characteristics, such as the remodelling of 
the PA walls, as a consequence of the metabolic alterations inherent to the pathology, and 
activation of the foetal genetic package. These changes result in the proliferation of a myriad 
of cells, such as PA endothelial cells (PAEC), PA smooth muscle cells (PASMC), fibroblasts 
and myofibroblasts activation, differentiation and migration, that at the peak of the disease 
exhibit a proliferative and antiapoptotic phenotype similar to cancer cells, altering the 
contraction capacity of the vessels and increasing inflammatory conditions.21,39,64,65 
Furthermore, the existing imbalance between proliferation and apoptosis, that occurs among 
the three layers constituting of the vessels, play a crucial role in PAH development and 
progression66, and it has been demonstrated that all of these cells acquire significant genetic 
characteristics that alter their normal cell course.67 The metabolic derangements originated 
evolve from the beginning of this disease to the end-stages4, encompassing not only the RV 
but several tissues of the organism, such as PA, LV or skeletal muscle.39 Apart from the 
changes in LV, signs show that the RV of the patients with PAH is also hypertrophied, 
enlarged and subjected to ischemia45, due to a compensatory mechanism for the alterations 
on LV68, and this is the primary determinant of death for PAH.69 The crosstalk between 
dysfunctional EC and the other cells that compose the pulmonary vascular wall are the key 
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feature of PAH pathogenesis3,39, once the EC release a variety of vasoactive molecules that 
interact with blood elements but also with vascular smooth muscle.70 
 Recent studies on genetic and metabolism have generated important mechanistic 
insights into established disturbances of endothelial function and smooth muscle cell 
proliferation.57 PASMC proliferation is also a pivotal part in the pathological vascular 
remodelling of PAH, whose mechanism is still a source of controversy.31,39 
 
2.1. Alterations on endothelial cells 
2.1.1. Vessels endothelium alterations  
The EC compose the inner layer of the vessels, the intima71,72, and are responsible 
for the paracrine and autocrine function, as well as vasomotion, thrombosis, platelet 
aggregation and inflammation inside de vessels.71 The abnormalities in structure and 
function of the endothelium occur in conjunction with growth of neointimal, preceding the 
growth of medial layer, constituted by smooth muscle cells (SMC) (Figure 1) and adventitial 
layers, establishing regions of neovascularization.46,228 Sometimes, those alterations may 
culminate in an occlusive arteriopathy, due to exacerbated proliferation of EC leading 
progressively to obliteration of the vessel lumen39,61,73,74, and resulting in a progressive 
increase in vascular resistance.74,75 The intimal modifications, that include endothelial injury 
or the invasion of this cell layer by fibroblasts and myofibroblasts and lead to fibrotic 
changes in the vessel walls53,76, may prompt progressively the formation of atherosclerotic 
plates77, vascular obliteration21,39, hypertrophy of the medial layer and arteriolar 
muscularization (Figure 2).9,50  
In most cases of PAH, the EC exhibit a disorganized growth39,56 that in late stages 
evolves and gives rise to complex vascular lesions, the angioproliferative plexiform 
lesions.56,57 The plexiform lesions, morphologic hallmarks of severe PAH, are composed by 
proliferating EC, matrix proteins and fibroblasts, constituting complex and glomeruloid-like 
vascular structures which are originated from the pulmonary arteries58 and that can obliterate 
vascular lumen.53 They are one of the causes of the pathogenicity of PAH39,78,79 and may 
also induce the thickening of the walls of the RV and a responsible for the increase on his 
diameter.69 Metabolic aberrations in EC also mediate vascular disturbances associated with 
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the pathogenesis of several disorders80, and endothelial dysfunction, that occurs in early 
stages of PAH, may control the development of the disease.81 Pulmonary vascular injuries 
origin endothelial dysfunction and apoptosis, thereby weakening endothelial-mediated 
suppression of quiescent SMCs57, playing an integral role in mediating the structural changes 
in the pulmonary vasculature.82 
 
Figure 1 Cellular structure of the pulmonary artery. The pulmonary artery (PA) is composed by three layers: (i) the 
inner layer, designated by intima, which is composed by endothelial cells (EC); (ii) the media layer, composed by smooth 
muscle cells (SMC); (iii) the adventitial layer, constituted by connective tissue. 
 
 
 
 
  
Figure 2 Vascular remodelling in pulmonary artery. The vascular remodelling in pulmonary artery (PA) can culminate 
in heart failure (HF). The abnormalities in structure and function of the endothelium occur in conjunction with growth of 
neointimal, preceding the growth of media layer. Due to vascular remodelling and intima growth is triggered progressively 
the obliteration of the vessel lumen. This remodelling will lead to an increase in mean pulmonary arterial pressure (mPAP) 
and pulmonary vascular resistance (PVR), that will drive to alterations on right ventricle (RV) that may culminate in HF 
and death. Adapted from McLaughlin, V. V., Shah, S. J., Souza, R. & Humbert, M. 2015. “Management of pulmonary 
arterial hypertension”. 
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 Pulmonary endothelium seems to underpin many of the cellular changes seen in 
PAH53 and plays an important role in vascular homeostasis and in ventilation perfusion 
matching, enabling an efficient gas exchange in the lungs.83 One of the features for 
endothelial dysfunction in PAH is reflected not only by reduced production of the 
vasodilators or growth inhibitors as NO and PGI2, but also by increased production of the 
vasoconstrictor/co-mitogens as ET-1 and thromboxane A2 (TXA2).53,75,76,84 These 
mediators are responsible for the regulation of the diameter of the pulmonary vessel, 
inducing either vasodilatation (NO and PGI2) or vasoconstriction (ET-1)70, being cyclic 
guanosine monophosphate (cGMP), a second messenger, also implicated in this 
mechanism.85  
 The deficit in NO in PAH can be triggered by the decreased expression of endothelial 
NO synthase (eNOS)61,69 that produces NO endogenously from the amino-acid L-
arginine71,86, the inhibition of eNOS enzymatic activity or inactivation of NO by superoxide 
anion53,75,84,87, or by the increased arginase activity, that competes with NOS for L-arginine 
substrate.88,89 eNOS is responsible for synthesis of NO in vascular EC and plays an important 
role in the control of vasomotor tone53,83, and PAH is undoubtedly related with a decrease in 
NO bioavailability.49,75 The inactive eNOS bound to caveolin protein, and when receives a 
stimulus from increase in Ca2+, eNOS detaches from caveolin and become activated, 
initiating the production of NO.71 The increasing oxidant stress and the reactive oxygen 
species generation triggered by the decrease in bioavailability of NO may be due to the high 
levels of aldosterone, what relates this molecule with the endothelial dysfunction. Indeed, 
aldosterone also increases the activity of NADPH oxidase in the heart, which contributes to 
myocardial endothelial dysfunction54, but some investigations on PAH patients found that 
the NO synthesis is more depleted or altered in the lungs.89  
 PGI2, who belongs to prostanoid family, is also synthesized by EC in response to 
vascular damage or stress, being released in a paracrine mode to exerts its action on nearby 
vascular SMCs, platelets, and other EC.49 In normal situations, EC physiologically preclude 
platelet activation by producing NO and PGI266 and, since PGI2 analogues induce a rapid 
decrease in PVR and increase cardiac output, they have been used as treatment for PAH.90  
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2.1.2. Cardiac endothelium alterations 
 The adrenergic receptors (ARs) are the main regulators of the cardiovascular system 
and cardiac EC functioning.91 Two classes of ARs have been identified: α and β, and the 
βAR are the ones present in the cardiac endothelium and involved in PAH.92,93 The 
adrenergic system is responsible for several metabolic pathways, including the modulation 
of insulin production by pancreatic β-cells and the levels of fatty acids in plasma, being 
related with metabolic variations such as insulin resistance, altered glucose and 
mitochondrial dysfunction.93  
 In PAH, it has been demonstrated that occurs an overstimulation on βAR, which is 
related with maladaptive RV remodelling92, cardiac hypertrophy94 and HF.93 Thus, some  
βAR antagonists are used as a treatment for chronic HF94, since the chronic stimulation of 
βAR induces insulin resistance, as the β2AR modulates glucose metabolism and 
homeostasis, as well as fatty acid metabolism.93 It is known that sustained β adrenergic 
stimulation induces insulin resistance, and the acute treatment with β2AR blockers increased 
glucose uptake in myocytes and skeletal muscle to similar values to those seen after de 
insulin stimulation.95 Furthermore, βAR has the ability to affect insulin signalling by 
activating phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) (PI3K/Akt) and its 
downstream pathway in cardiomyocytes. βAR stimulation induces PI3K activity94 and an 
increase in heart weight as well as contractile abnormalities and myocardial fibrosis96, which 
are characteristics of PAH. Moreover, the β2AR appears to display a title-role in systemic 
glucose homeostasis through its action on pancreatic islet hormone secretion, liver and 
muscle glucose transport metabolism.97 
 In healthy heart, endothelium either produces neuregulin 1 (NRG1), that has been 
shown to diminish the myocardial inotropic response to adrenergic stimulation, playing 
effects on the reducing of cardiac output and blood pressure due the activation of NO 
production via eNOS stimulation98, being the increased expression of the NRG1 in PAH 
documented by a study in an hypoxia animal model for PAH.99 In disease state, cardiac 
endothelium also increases the production of molecules as ET-1, what is correlated with 
alterations and modulation of right atrial pressure, RV overload, increased inotropy, PVR 
and oxygen saturation.100 The increased ET-1 production, verified in both human and rat 
hypertrophied RV, is also responsible to maintaining cardiomyocyte survival in situations of 
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a sustained increase in β-adrenergic stimulation as it occurs in PAH.101 An in vitro study 
with genetically manipulated cardiomyocytes also revealed that NRG1 treatment is 
responsible for their protection by the activation of βAR through parasympathetic 
modulation, still relating the suppression of NRG1 gene with the increased risk of heart 
failure in human diseased hearts102, highlighting the role of NRG1 in the regulation of AR. 
   
2.2. Alterations on smooth muscle cells 
 In hypoxia conditions, as the ones that exist in PAH, the PASMC present a 
hyperproliferative behaviour54, which is a significant feature of PAH76, and the mutations on 
bone morphogenetic peptide receptor II (BMPRII) that may occur in idiopathic PAH (IPAH) 
and hereditary PAH (HPAH) may be in the basis of this behaviour.51 The abnormal PASMC 
proliferation results from the dysregulation of cytokines activity, which are produced by 
several cells, including vascular cells.103 Furthermore, the patients with IPAH are affected 
by significant morphological and functional skeletal muscle changes that affect their 
exercising capacity.104–106 In experimental models106 and patients with PAH107, changes as 
muscle atrophy106,107, a decrease in oxidative metabolism in muscle cells and mitochondrial 
alterations106 have been described. The impairment of mitochondrial function in skeletal 
muscle precedes the RV pressure overload, however, the mechanisms behind these changes 
are not fully explained yet.104 
 Increased expression and accumulation of α-smooth muscle actin (α-SMA) by an 
enlarged number of cells usually occurs due to the remodelling of the pulmonary arteries 
and the occlusive lesions in patients with PAH108,109 and this can be an indicator of 
endothelial to mesenchymal transition (EndMT) in PAH.51 The cytokine interlukin-6 (IL-6) 
levels are also elevated in both patients and animal models with PAH in response to BMPRII 
gene disruptions, promoting pulmonary vascular remodelling and an elevation on right 
ventricular pressures under normoxic conditions, which causes a severe PH phenotype in 
hypoxic conditions.55,110 In PAH, the increase in PVR is caused by remodelling of the distal 
pulmonary vasculature, not by the increase in vascular tone.74 
 According with the studies carried out, there are myriads of molecular origins for 
PH that promote remodelling of the pulmonary vasculature, with hyperproliferation of 
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vascular smooth muscle cells (VSMC) and increased cellular survival.4,29,111 Disturbances in 
Ras homolog family member A (RhoA)-Rho kinase (ROCK) and in RhoA/ROCK pathway 
are one of the molecular origins for PAH due to their effects on vasoconstriction and vascular 
remodelling, once RhoA is evolved on growth and hypertrophy of PASMC induced by 
vasoconstrictors during vascular remodelling.112 A recent study showed that in PAH, the 
RhoA/ROCK pathway along with Ca2+ and ET-1, are the main responsible for the 
hyperconstriction in PAH, what can be attenuated by RhoA/ROCK inhibitors.113 
Furthermore, the forkhead transcription factor (forkhead box protein O – FoxO) have also 
been implicated in vascular structural maintenance and the FoxO1 is involved in the 
hyperproliferative and apoptosis-resistant phenotype of PASMCs.114  
 In remodelled vessels, angiotensin signalling favours PASMC proliferation and 
vasoconstriction, existing evidences of angiotensin type 1 (AT1)  receptor upregulation.
54,115 
To compensate the low cardiac output characteristic of patients with IPAH, the renin-
angiotensin-aldosterone system (RAAS) is upregulated.116 Via RAAS, aldosterone supports 
the blood pressure through its effects on the kidney, regulating sodium reabsorption and 
water balance, having effect on peripheral blood vessels to increase systemic vascular 
resistance, contributing as well to vascular stiffening.54,117 Aldosterone elevated levels 
activate the mineralocorticoid receptors, which are cytoplasmic receptors that function as 
transcription factors that regulate gene and protein expression, which are expressed in EC, 
VSMC, cardiomyocytes and macrophages.115 In vascular and cardiac cells, this binding of 
aldosterone to mineralocorticoid receptor (MR) will induce signalling pathways that 
promote vascular remodelling, an increase in RV systolic pressure (RVSP) and in PA 
systolic pressure (PASP), impairing vascular reactivity and contributing to RV cardiac 
dysfunction associated with the disease.54,117 Furthermore, aldosterone induces vascular 
insulin resistance through desensitization of proteins involved in insulin pathways, such as 
insulin receptor substrate 1 (IRS1), PI3K, Akt and NOS.115 Some studies proven that RAAS 
pathway is associated to cardiopulmonary vascular phenotype in PAH models and humans 
due to overexpression of aldosterone, designed by hyperaldosteronism, and this may occur 
due an increase in angiotensin converting enzyme (ACE)54,118 owing to a polymorphisms on 
this protein gene and to increased adrenal production of aldosterone.116,119 Due to vascular 
remodelling characteristic of the disease, the actual therapies mainly focus on dilating the 
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partially occluded vessels trough antiproliferative agents3,55 as losartan, captopril or 
spironolactone, that act on RAAS.54,118  
 The NO produced in EC has vasodilatory, anti-proliferative and anti-thrombotic 
effects in SMC.75 NO operates by activating soluble guanylate cyclase (sGC) in vascular 
SMCs as a catalyser for the conversion of guanosine triphosphate (GTP) into cGMP.49,53,75,89 
It diffuses to the VSMC to promote the relaxation of smooth muscle contractile filaments 
and vasodilation, through the decrease in calcium influx thus inhibiting proliferation of 
SMCs, and the reduction in NO bioavailability may contribute to vasoconstriction and to the 
increase on PAP.49,75,86 It was also discovered that cGMP-specific phosphodiesterase type 5 
(PDE5) activity is upregulated in pulmonary vascular smooth muscle in PAH, and the 
inhibition of PDE5, with PDE5 inhibitors as sildenafil which is used in the treatment of PAH, 
results in vasodilatory and antiproliferative effects.86,120 Abnormalities in both K+ channels 
and Ca2+ channels have been linked  induction of fibroproliferative sequelae, particularly in 
SMCs.76 
 Despite being predominantly expressed on vascular EC, ET-1 is also expressed by 
arterial SMC and is a potent vasoconstrictor, stimulating Ca2+ entry to the cytoplasm, also 
performing duties in proliferation.25,49 On the other hand, PGI2 is a vasodilator and anti-
aggregating substance, whose effects are enhanced by the presence of NO53, having the PGI2 
signalling pathway effects on the attenuation of the smooth muscle proliferation and 
antithrombotic effects.121  In SMCs, PGI2 triggers the decrease in cytosolic calcium and an 
increase in the breakdown of myosin light chains, leading to vasodilation.49,75  
 
2.3. Intervention of platelets in pulmonary arterial hypertension 
 Due to their prothrombotic potential, platelets play a central role in pathophysiology 
of atherothrombotic cardiovascular diseases, and in diseases as PAH is documented the 
existence of an higher volume of platelets.122  Platelets derive from megakaryocytes, and is 
proven that cytokines as IL-6 influence megakaryocytes66 promoting the production of extra 
active and larger platelets122; once IL-6 is increased in patients with PAH55,110, it can be a 
cause for the increased volume of platelets in this pathology122, being this mechanism 
potentiated by the inflammatory environment of PAH.66 Furthermore, the existence of larger 
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platelets and in hyperfunctioning, together with TXA2, enhances the platelet aggregation, 
what increases the possibility of thrombosis.123 
 The platelets release growth factors as platelet-derived growth factor (PDGF) and 
VEGF, which pathways are upregulated in PAH.108,66 VEGF is a crucial regulator of vascular 
development, and the increase in this GF results in alterations in ligand VEGF-A and in 
VEGF receptor 2 (VEGFR) from the signalling cascade, potentiating endothelial 
proliferation, survival, motility, and angiogenesis, which was proved by histology of lung 
tissue with plexiform lesions.108   
 The shifts in the pathway of arachidonic acid towards an alternative product to cyclic 
adenosine monophosphate (cAMP), that induces vasodilatation, were also reported in cases 
of diabetes and atherosclerosis associated with PAH.66,90 In those cases, the TXA2 produced 
will lead to platelet aggregation, vasoconstriction and cellular proliferation121, due to a 
downregulation on PGI2, once the PGI2 synthase activity is diminished in the lungs of PAH 
subjects.51,66 However, there are evidences who relate the possible communication between 
vascular cells and platelets in PAH by the activation of toll-like receptor 4 (TLR4), whose 
deletion will lead to an attenuation on the effects of PAH, like RV hypertrophy66, being 
evidenced the inhibition of platelet aggregation through the inhibition of TXA2, what may 
ameliorate PAH symptoms.49,75 
 
2.4. Inflammatory reaction in pulmonary arterial hypertension 
 Beyond the remodelling of the vessels, the vasoconstriction, the intimal proliferation, 
and medial hypertrophy, PAH is accompanied by illicit recruitment of inflammatory cells 
which release factors that enhance cell proliferation and elastin fibers degradation.51 The 
maladaptation of the immune response is related with the accumulation of perivascular 
inflammatory cells and the overabundance of chemokines and cytokines55 as IL-1β, IL-2, 
IL-4, IL-6 and IL-8.124  
 The hypoxia conditions resulting from PAH induce a specific inflammatory milieu 
in the PA, with lymphocytes accumulation in the lungs, which may also contribute to 
vascular remodelling112 promoting neointimal formation, thrombosis, and luminal 
obliteration.54,55 Thus, the inflammation is a common feature of PAH due to the presence of 
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mononuclear cells that infiltrate the vessels through the perivascular areas around them74 and 
the proinflammatory state of the vessel walls suffer an increment along with the progression 
of PAH.125  Furthermore, the generated hypoxic environment in PAH stimulates ET-1 
expression72, which is also involved in inflammatory process.25,70 However, some cytokines 
may act as anti-inflammatory, such as IL-10, displaying compensatory mechanisms.124  
 Once PAH is related with metabolic disruptions, some studies report that this disease 
is associated with chronic inflammation due to the activation of proinflammatory cytokines, 
as the IL-6, which is associated with the permeation of adipose tissue to macrophages and 
lymphocytes potentiating inflammatory process.50,126,127 A group of investigators also 
discovered that in individuals affected by IPAH, IL-6 is consistently increased in the lungs 
and serum, activating VEGF, the mitogen-activated protein kinase (MAPK) pathway with 
increase in MYC proto-oncogene (cMyc) transcription, along with downregulation of 
transforming growth factor-ß (TGF-β) and pro-apoptotic kinases, contributing the alteration 
on this gene to the development of pulmonary proliferative arteriopathy and the progress 
toward PAH127, which is sustained by the same findings in animal models.127,128 
 PAH is characterized by fluctuating degrees of perivascular inflammatory infiltrates, 
encompassing T- and B-lymphocytes, macrophages, dendritic cells and mast cells, who are 
usually present in plexiform lesions.55,124 Aldosterone increases endothelial cell adhesion 
molecule expression, facilitating the activation and vascular infiltration of monocytes, 
macrophages, and T- and B-lymphocytes that also induce inflammation.54   
 Medical reports from biopsies to organs of patients with PAH, such as lungs, account 
the existence of mononuclear cells in plexiform lesions, mainly T cells, macrophages, and a 
lesser extent of B cells50,  which is in accordance with the studies that refer to the existence 
of T helper 17 cells who play a key role in the development of PAH due to chronic 
hypoxia.112 Moreover, the percentage of regulatory T cells expressing the leptin receptor, 
related with the promotion of pathogenesis of autoimmune diseases129, was increased in 
PAH, with reduced function of these cells, which indicates a leptin-dependent 
immunomodulatory effect in PAH.111 It occurs, in part, due the action of the nuclear factor 
of activated T cells (NFAT), a transcription factor that promotes cytokine gene transcription, 
which is upregulated in PAH, leading to increased levels of cytokines, a main feature of 
PAH. 29,39,68 
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 The numerous forms of bone morphogenetic peptide (BMP) are on the basis of 
several metabolic pathways, being essential on the correct functioning of cellular context 
and maintaining tissue homeostasis, and disturbances on BMP family may lead to 
inflammatory responses, vascular diseases and cancer.51 The BMPRII is a transmembrane 
serine/threonine kinase receptor of BMP that is essential for maintaining the barrier function 
of the PAEC lining, displaying a vital role in the development of T cells from 
thymocytes.51,55 Dysfunctions on his signalling pathway may be seen in all forms of PAH 
and can lead to unsuitable expression of growth factors and pro-inflammatory responses in 
vascular cells,55 triggering an increase on endothelial inflammatory responses thereby 
contributing to adverse vascular remodelling.51 Either the increased number of macrophages 
present in pulmonary lesions from patients with severe PAH induce the production of pro-
inflammatory cytokines such as tumour necrosis factor α (TNFα) and interleukins (IL1β, IL6 
and IL8)50,51, monocyte chemoattractant protein (MCP)-1, and fractalkine55, that will induce 
the expression of micro RNAs (miRNA) that inhibit BMPRII expression.51 IL1β and TNFα 
function as biomarkers for the accumulation of extracellular matrix proteins such as 
fibronectin.130 
 
2.5. Fibrosis development in pulmonary arterial hypertension 
 Fibroblasts, the main responsible for fibrosis, are mesenchymal cells that can be 
activated by several chemical stimulus that promote their proliferation and differentiation in 
myofibroblasts, who are involved in various cellular processes as inflammation, 
angiogenesis and pathological tissue fibrosis.131,132 The fibroblasts deposit type I and III 
collagen fibrils as they move through the extracellular matrix to maintain their structural 
support in a balanced process of synthesis and degradation of fibrils132, and in situations of 
disease, as PAH, their action is potentiated by the action of an array of autocrine and 
paracrine signals, as the TGF-ß produced by inflammatory cells, deregulating the process of 
renewal of collagen and assisting the fibrosis development.131,133  
 Fibroblasts are important cells for the structural support of the heart, constituting also 
a middle for interaction with cardiac myocytes.132 The normal and fibrotic fibroblasts, 
fibrocytes, under instruction of TGF-ß, produce ET-1 that will generate matrix proteins 
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production and drive the contraction of extracellular matrix, conferring to fibroblasts also 
greater resistance to apoptosis.134 The characteristic high levels of ET-1 in plasma of PAH 
patients are associated with the development of cardiac fibrosis, once they promote the 
undue deposition of extracellular matrix and fibroblast recruitment.70,135 In situations of 
diabetes, there is a higher accumulation of collagen and the development of fibrosis135,136, 
however, it was reported that the modulation of ET-1 levels on diabetic patients would be 
able to improve that condition, since the a lack of ET-1 attenuated the development of cardiac 
fibrosis through the reduction of the accumulation of fibroblasts and collagens in 
myocardium, controlling the development of the fibrotic areas.137  
 In situations of injury, the myocardium fibroblasts differentiate into myofibroblasts 
by action of inflammatory mediators, as TGF-ß and IL-1ß and by altered activation patterns, 
and are more susceptible to cytokines action, that themselves also secrete,  maintaining the 
inflammatory response to injury.132 The pathological myocardial remodelling is 
accompanied by an extreme deposition of extracellular matrix proteins by cardiac 
fibroblasts138, what contributes to RV stiffness and to the progression of PAH, that can 
culminate in HF.139  
 As mentioned above, the aldosterone levels follow the increase in ET-1, which 
explains, in part, the increase in aldosterone levels137, which is also involved not only on 
stimulation of perivascular fibrosis through the increase of the expression of profibrotic 
mediators as galectin-3, TGF-ß, connective tissue growth factor (CTGF), and type I and type 
III collagen,  but also on decreasing the expression of two anti-fibrotic peptides, BMP4 and   
brain natriuretic peptide (BNP).54  
 Fibrosis not only affects myocardial area but also the lungs, what results in impaired 
air exchanges.140,141 The pulmonary epithelium also releases TGF-ß in response to stress, 
that interact with fibroblasts and triggers an increase in their production and in profibrotic 
factors as fibronectin, collagen and α-SMA.131,140 The lung vascular remodelling may still 
be associated to events of chronic inflammation.76 The progression of fibrosis on respiratory 
organs and the successive structural and metabolic alterations on microvasculature tease 
diseases as systemic sclerosis, a systemic autoimmune disease associated to PAH.142 The 
association of those diseases occurs due to the functional alterations and the structural 
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fibroproliferative character of this vasculopathy who affects the small and medium sized 
pulmonary arterioles.143   
 
2.6. Endothelial to Mesenchymal transition  
 The EndMT is a process whereby a polarized epithelial cell suffers multiple 
biochemical changes that enable it to assume a mesenchymal cell phenotype144, including 
enhanced migratory capacity, invasiveness and elevated resistance to apoptosis142,144, being 
potentiated by hypoxia conditions.145 The pulmonary arterial remodelling resulting from 
PAH and characterized by the activation of fibroblasts and smooth muscle-like cells in the 
walls of PA, is also associated to EndMT, being this mechanism a starting point for the 
arterial remodelling and PAH.145  
 EndMT, unleashed by Twist Basic Helix-Loop-Helix Transcription Factor 1 
(TWIST1), Snail Family Transcriptional Repressor 1 (SNAIL or SNAI1), and Snail Family 
Transcriptional Repressor 2 (SLUG or SNAI2) transcription factors108, corresponds to an 
aberrant vascular remodelling as consequence of the increased PVR, causing the concentric 
arterial wall thickening, the development of occlusive intimal lesions and 
neomuscularization of precapillary arterioles.108 In this process, EC modify some of their 
molecular features, namely at genic level, occurring downregulation of EC-specific genes as 
platelet EC adhesion molecule 1 (PECAM1 or CD31) and vascular endothelial cadherin 
(VE-cadherin or CD144), but also the upregulation of SMC-specific genes, such as α-SMA 
and fibroblast-specific genes like vimentin.58,108 During EndMT, EC lose their junctions to 
the endothelium and acquire migratory and proliferative abilities as they progressively 
switch from endothelial to a mesenchymal phenotype.108 As EC progress to mesenchymal 
cells, there is an acquisition of the characteristic fibroblastic markers of these cells, as α-
SMA.135 The interaction between ET-1 and TGF-ß pathway also contributes to EndMT.142 
 
3. Metabolism  
 PAH is also associated to a heterogeneity of systemic metabolic derangements such 
as the metabolic syndrome111, the insulin resistance77, hyperglycemia (diabetes) and 
dyslipidemia146, glucose intolerance and alterations in the aerobic glycolysis, also known as 
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Warburg effect147,148, which also implies alterations in tricarboxylic acid (TCA) cycle147,149, 
but also in the FAO.146 Usually, when associated to chronic hypoxia, PH occurs due an 
imbalance among GO, glycolysis, and FAO.150  Besides, the metabolic disruptions may 
trigger the progression of severity for PAH and the resultant metabolites may be used as 
biomarkers to the disease.151 
 To preserve its correct functioning, the heart requires an uninterrupted supply of 
energy and oxygen to keep its intracellular adenosine triphosphate (ATP) standardized, 
which is mandatory for the maintenance of myocardial systolic and diastolic activity152,153, 
what involves the metabolization of a wide range of  energy substrates to fill its energy 
requirements beyond fatty acids and glucose, as ketones and branched chain amino acids.154 
The elements of cardiac energy metabolism comprise the substrate use, the oxidative 
phosphorylation (OXPHOS), and also ATP transfer and utilization.155 Ohira, H. et al., 
describe that the metabolic reprograming that characterizes PAH relates not only with the 
increased glucose utilization along with progressive PH, but also with the increase in fatty 
acid utilization accompanying severe RVD155, which is in part refuted by a previous study 
from Nagaya, N. et al., who described an impaired fatty acid uptake in the failing 
hypertrophied RV.156 
 An adult healthy heart hold very high energy utilization rates; the ATP produced is 
derived not only from GO, but also from other oxidizable energy sources like fatty acids, 
lactate, ketones, and amino acids.69,157 In cardiomyocytes 60 to 90% of the energy comes 
from FAO69,158,159, whereas glucose metabolism is considered a secondary source of energy 
production160, even consuming 12% more oxygen per mole of ATP produced than 
GO.42,69,155 Nevertheless, the rate of glucose utilization is higher than in other tissues, and 
the reduction of glucose uptake and oxidation could be the major pathophysiologic factor 
that contributes for contractile dysfunction in cases of HF161 being this condition an 
hyperadrenergic state, who leads to an increase in plasma levels of free fatty acids (FFA), 
which is implicated in a wide variety of metabolic dysfunctions as impaired fatty acid (FA) 
uptake and oxidation in the myocardium.162 
 The substrate preference for FAO occurs due the inhibition of GO by FAO after the 
child-birth, via Randle cycle, once the long chain FAs oxidation inhibits glucose uptake, 
directing the metabolism toward aerobic glycolysis that has as consequence the lactate 
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accumulation59,62,152, requiring an additional effort from various energy-dependent pumps to 
maintain pH balance.42 However, in the late stages of HF occurs downregulation of 
myocardial FAO while the GO is fomented52,157 and usually when associated to chronic 
hypoxia, PAH usually occurs due an imbalance among GO, glycolysis, and FAO.150  
 
3.1. Fatty acid metabolism  
 Cardiac FAO starts when the FAs are taken up from bloodstream to cytoplasm as 
FFA and bound to albumin, or as FAs released from triacylglycerol (TAG)163, that can 
diffuse through the membrane or be translocated into the cell by cluster of differentiation 36 
(CD36) molecules, the FA transport protein-1 (FATP-1) and -6 (FATP-6).78 In the classical 
pathway of mitochondrial FAO, the metabolism of free long-chain FAs (LCFA) starts in the 
cytosol of cardiomyocytes with their activation by Coenzyme A (CoA) and their conversion 
into fatty acyl-Coenzyme A by acyl-CoA synthetase, an activated FA constituted by a long-
chain molecule.69,164,165 In this step, acyl-CoA may be either esterified to triglyceride.165 
Then, in the outer mitochondrial membrane, carnitine palmitoyl transferase 1 (CPT1), the 
enzyme responsible for mitochondrial FA uptake, converts fatty acyl-CoA into a long-chain 
acylcarnitine, that will move through the porins of mitochondrial membrane to the 
mitochondrial matrix by the action of acylcarnitine translocase, where it will undergo β-
oxidation.69,78,166,167 At mitochondria matrix, fatty acylcarnitine is converted into fatty acyl-
CoA in a reaction catalysed by CPT2, located on the inner mitochondrial membrane, where 
acyl-CoA undergoes β-oxidation, generating acetyl-CoA, that enters to the Krebs 
cycle69,164,166,167 A complete cycle of FAO, with β-oxidation, of a FA containing 6 carbons 
may yield 48 ATPs.62 In the end, fatty acyl-CoA, particularly palmitoyl-CoA, might be used 
for afresh synthesis of ceramides, which plays pleiotropic effects on cellular function.165  
 Myocardial steatosis, an ectopic accumulation of lipids within the 
cardiomyocytes33,166,168, can be related with the impairment of mitochondrial FAO and may 
be a cause and not only a consequence of RVHF33, due to the permanent relocation of CD36, 
a transporter of LCFA, to the sarcolemma.166,169 The increase in CD36 expression is not only 
related with an increase in cardiac FA uptake, once this molecules are one of the responsible 
for inducing cardiac hypertrophy and contractile dysfunction69,166,170 but also the increased 
accumulation of triglycerides in human RV of PAH patients with BMPRII mutation.166,168 
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An increased content of ceramide in RV tissues from those patients was reported too, and 
that, according with the literature, is lipotoxic, an pro-apoptotic mediator, and is also 
involved in the development of insulin resistance, cardiac dysfunction, and HF.33,69,163,168 
Furthermore, the overexpression of peroxisome proliferator–activated receptor alpha 
(PPARα) is associated to a lipid overload due the increase in enzymes involved on FAO163, 
once occurs an increase in FA utilization along the severe RVD155, but also with the 
regulation of glucose transporters (GLUTs), as the GLUT4.153 FAO can also be inhibited by 
GO pathway once the CPT1 is the rate-limiting step in acylcarnitine formation.33   
 The Randle cycle is responsible for the production of citrate during FAO, that is the 
prompter for phosphofructokinase (PFK) inhibition and accumulation of glucose-6-
phosphate.59,69,160 This molecule , in its turn, will inhibit hexokinases (HK) and decrease GO 
and the production of pyruvate. 59,160 Then, the acetyl-CoA generated from FAO has the 
ability to inhibits pyruvate dehydrogenase (PDH), interrupting the cycle of production of 
PDH, leading to the decrease of their concentration and, subsequently, to the inhibition of 
the production of acetyl-CoA and the production of substrates by the Krebs cycle, what 
generates an imbalance on cellular energy59,69,171 through the inhibition of the electron 
transport chain, increasing the reliance on aerobic glycolysis.62  
 In situations of cardiac hypertrophy and HF, downregulation of genes involved in 
mitochondria biogenesis and oxidative metabolism, such as PPARα, peroxisome 
proliferator-activated receptor gamma coactivator 1-alpha (PGC-1α), which is a 
transcriptional coregulator and a master regulator of mitochondria and their targets, has been 
observed and proposed as an important causal mechanism for decrease in FAO under those 
conditions.153,163 It is also mostly expressed in tissues with high energy demands, such as 
skeletal muscle, heart or brain, being its expression increased under conditions of higher 
energy requirements.172 On the other hand, during the development of cardiac hypertrophy, 
upregulation of hypoxia inducible factor 1α (HIF-1α) gene occurs due the development of 
hypoxia conditions.173 
 
3.2. Glucose metabolism and the Warburg effect  
 The metabolic perturbation most reported and studied in PAH is a process designated 
by Warburg effect147, that triggers numerous adaptive and maladaptive downstream effects 
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as a stress response, especially in EC49, supporting the metabolic requirements for 
proliferation characteristic of the disease, what turns PAH into a consequence of this 
process.174 The Warburg effect was firstly described in 1920 by Otto Warburg147, and 
concerns the cessation of mitochondrial OXPHOS, consequently leading to aerobic 
glycolysis29,147,175 akin to what is observed in cancer cells35,68,147, pointing the glycolysis as 
the main source for catabolic needs of hyperproliferative cells.176 This process can be 
considered an aerobic pathway to small amounts of ATP production, indicating that this can 
progress in the absence of molecular oxygen, giving continuity to the production of 
ATP.147,177 Indeed, the suppression of GO and the subsequent increase in glycolysis, once 
the presence of oxygen is compromised in cases of PAH due to hypoxia conditions, causes 
the cells to metabolize glucose into carbon dioxide (CO2) by oxidation of glycolytic 
pyruvate177 in mitochondrial TCA cycle.17,23 The accelerated glycolysis evidenced in PAH 
constitutes an hallmark of the increased glucose metabolism in cardiac hypertrophy and in 
remodelled RV.68,147,177,178 
 The regulation of intracellular and extracellular levels of glucose depends on levels 
of control of expression of the genes that encode the different isoforms of GLUT 
proteins.153,179 Once the rate of glucose utilization in the heart is higher than in other tissues, 
to respond to the high demand of glucose of the myocardium, this process is mediated by 
GLUTs180, who work as uniporter181 and allow the facilitated diffusion of glucose through 
the plasma membrane of the cells179, and its regulation may also be dependent on stimuli 
associated with pathologies.153 The GLUT4 is the major isoform of GLUTs in human heart, 
representing about 70% of the GLUTs.182 The pressure overload inherent to PAH leads to 
the increase in GLUT1 expression, but to a decrease in the GLUT4 expression, and those 
alterations will reflect on their distribution into the plasma membrane, what will reflect in 
alterations on glucose transport and its metabolism.153,183  Therefore, under conditions of 
myocardial disease, ischemia or pressure overload hypertrophy, as the ones that occur in 
PAH, the heart shows an increased dependence on glucose4,180, and a study from Ohira et 
al., demonstrated, in left heart failure, an increase in glycolysis rate to afford an anaerobic 
source of ATP to challenge the decrease in OXPHOS. The same study demonstrated that the 
degree of glucose uptake is related with the degree of overload and dysfunction.155 So, the 
increase in dependence on glucose metabolism in situations of cardiac hypertrophy can be, 
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in part, attributed to impaired FAO due to effect of Randle mechanism on management of 
glucose.153  
 In cases of overload of the RV and myocardial hypertrophy, frequent in PAH, while 
the myocardial glucose uptake and the glycolytic rate are increased, the FFA metabolism 
decreases.155,184 This metabolic increase in glucose uptake has been proved and verified by 
several investigations using 18F-fluorodeoxyglucose (FDG) in combination with positron 
emission tomography (PET), by an increased uptake of PDF in patients with PAH.184–186 The 
glucose may be metabolized in multiple pathways, providing not only energy but also other 
metabolites important for cell functioning.187  
 The glucose metabolism, represented in Figure 3, starts with the import of glucose 
into the cells by GLUT1, an insulin-independent transporter, and GLUT4, an insulin-
sensitive transporter, that is activated and recruited to cellular membrane by insulin 
molecules69,187, but also by stimulus as ischemia or catecholamines.182 Since glucose is in 
the intracellular medium, this molecule is phosphorylated and converted into glucose-6-
phosphate by HKs (1,2 and 3) in a critical step for glucose utilization.69,188 The HK1, HK2 
and HK3 isoforms are located in the outer membrane of mitochondria and inhibited by its 
product glucose-6-phosphate, being the HK1 and HK2 the major cardiac isoforms.189 HK2 
is mainly found in cardiac and skeletal muscle, an insulin-sensitive tissue, whose position 
varies between the mitochondria and cytoplasm in response to changes in intracellular 
glucose-6-phosphate, pH and cardioprotective signalling from Akt pathway.190 HK2 is also 
responsible for glucose phosphorylation after its entrance to the cell.191 The HK3 is located 
in the cytoplasmic and is mainly responsible for anabolic functions.190  Then, a succession 
of reactions mediated by PFK and pyruvate kinase (PK) turns glucose-6-phosphate in 
pyruvate that can be subsequently converted in lactate, with a yield of 2 ATP 
molecules.42,69,192 However, pyruvate may also be transported to the mitochondrial matrix 
via a monocarboxylate acid or pyruvate carrier, it may undergone mitochondrial oxidation 
passing by mitochondrial pyruvate carrier to TCA cycle69,153 or carboxylation to form 
oxaloacetate or malate via ATP-dependent pyruvate carboxylase.165,193  
 The glycolysis provides pyruvate to the mitochondria matrix for GO, where the  PDH 
breaks down pyruvate to produce acetyl-CoA, releasing CO2 and NADH, however, it only 
happens if the PDH is active, producing 36 molecules of ATP.69,78,192,194 The generated 
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NADH is translocated to mitochondria where it regenerates cytosolic NAD+ necessary for 
glycolysis to continue, once it is the electrons acceptor.153 In PAH, there is increased aerobic 
glycolysis due to normoxic upregulation of the transcription factor HIF-1α, which 
upregulates pyruvate dehydrogenase kinase (PDK) to inhibit pyruvate dehydrogenase, and 
epigenetic regulation of the superoxide dismutase 2 (SOD2) gene.78 
 The generated pyruvate may go through different pathways: it may be oxidized 
producing acetyl-CoA, who induces histone modifications, functioning as an epigenetic 
control of gene expression, or inhibit PDK.153 Though, if pyruvate cannot be used by 
mitochondrial PDH to the processing of OXPHOS, lactate is the end product of glycolysis, 
resulting in acidosis of the milieu.192 This may occur due the interaction of PDK and PDH 
in the mitochondria, responsible for GO42, where the first will phosphorylate the second one, 
leading to the constrain of GO, since PDK activation 17,35,195 and FAO activation inhibit 
PDH.39,155 The inhibition of PDH will lead to the suppression of mitochondrial function196, 
to a decrease in the influence of GO in acetyl-CoA production by the TCA cycle and leads 
to the development of a bioenergetically disadvantageous increase in glycolysis in relation 
to GO, the Warburg effect.63,197–199 This will generate an uncoupling between glycolysis and 
GO, altering pyruvate influx into the mitochondria and its metabolism and constitute an 
antiapoptotic environment.196 The suppression of GO and the election of glycolysis as an 
alternative metabolism, reflects the acceptance by the cell of the reduced efficiency for ATP 
generation in PAH62, and the increase in glucose utilization occurs during the progression of 
the disease155, as well as a decrease in mitochondria-derived reactive oxygen species 
(mROS).196  
 Furthermore, mitochondrial OXPHOS defects that impair mitochondrial oxidation 
may occur due to changes in mitochondrial pyruvate dehydrogenase complex (PDC), an 
oxidoreductase that contains PDH who catalyses the irrevocable conversion of pyruvate into 
acetyl-CoA and CO2, which establishes the bridge of communication between glycolysis and 
TCA cycle.200,201 Thus, a disturbance in PDH will result in inappropriate removal of pyruvate 
and lactate from blood and tissues200, causing an increase in glycolysis in relation to GO.202 
Once the impaired PDH is implicated in errors in mitochondrial metabolism200, the 
derangement may be in anyone of the enzymes of PDC, as in the most important enzyme of 
the complex, the PDH (E1)201, which is composed by two α and two β subunits.203–205 The 
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PDHα1 subunit, the most affected by mutations, plays a key role in PDH functioning once 
it contains the binding site for pyruvate203, and the phosphorylation of this subunit by PDK 
is enough to preclude the pyruvate binding to PDH.201 In models of RVHF, the mRNA levels 
of  PDHα1 and PDHα2 are decreased in RV of PAH animal model, being this accompanied 
by an increase in PDK.202 The PDHβ subunit is mostly expressed in the heart and is related 
with lactic acidosis, once an mutation in its gene leads to lactic acid accumulation and 
disturbances in cell proliferation.205 
 In hypoxia conditions, where the oxygen supply becomes inadequate, nicotinamide 
adenine dinucleotide (NAD+) is regenerated into NADH by lactate dehydrogenase a (LDHa) 
in order to maintain glycolysis, generating lactate as sub-product, in a process known as 
anaerobic glycolysis.206 LDH is an enzyme whose function is the increase of the rate of the 
concomitant inter-conversion of pyruvate to lactate and NADH to NAD+, which is usually 
used by cells during anaerobic respiration.206,207 LDH, which favours Warburg Effect207, is 
a tetrameric complex composed by four isoforms:  
-LDHa, also known as M subunit and predominant in skeletal muscle206,207, is regulated by 
transcription factors as the HIF-1, that promotes the transcription of LDHa, cMyc, which 
regulates cell growth, proliferation and apoptosis, and forkhead box protein M1 (FOXM1), 
involved in angiogenesis206, favouring lactate production without being inhibited by it;207 
-LDHb, known as the H subunit and found predominantly in the heart206,  also favours lactate 
production, but unlike LDHa, it is inhibited by high lactate concentrations.207 
-LDHc forms a homotetrameric complex, that despite being testis specific is expressed in 
tissues from heart, lungs and skeletal muscle, and catalyses the lactate production in 
anaerobic glycolysis;206,207 
-LDHd, whose sequence is homologous to the one from yeast d-lactate dehydrogenases, 
have uncharacterized function in human metabolism.207 
The expression of some genes as the TNFα has been shown to also inhibit myocardial 
PDH, resulting in a metabolic disruption that may contribute to the myocardial dysfunction 
that characterizes sepsis, once the body’s response to this metabolic shift may promote 
injures on tissues and organs.196 In patients with PAH was also reported an increased 
expression of PDGF and PDGF receptor (PDGFR) on lung tissue, that interact and activate 
a downstream signalling pathway promoting PASMC proliferation and migration.31 The 
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PI3K/Akt/mammalian target of rapamycin (mTOR) (PI3K/Akt/mTOR) signalling pathway, 
crucial to prevent cell damage and apoptosis208, is downstream of PDGFR, playing an 
essential role in Warburg effect due to inhibition of mitochondrial respiration by 
upregulating HIF-1α, provoked by the hypoxia conditions characteristics of PAH29,62, 
activating transcription factors such as cMyc that induces ischaemia198, also inhibiting the 
mitochondrial electron transport chain.186 In hypoxic environments, HIF-1 promotes the 
transcription of certain target genes for metabolism, cancer and apoptosis, supporting cell 
survival in these conditions, as it occurs in PAH.206 
 The PI3K signalling pathway is linked to both growth control and glucose 
metabolism, regulating the glucose uptake and his use, requiring high levels of glucose 
flux.177 When the metabolism occurs in a normal way by OXPHOS, even in non–insulin-
dependent tissues, PI3K signalling regulates the GLUT expression through the family of 
kinases Akt, enhancing glucose capture by HK, and stimulating PFK activity.147,177,181 Due 
to downstream of the PI3K/Akt/mTOR signalling pathway and upregulation of HIF-1α are 
unleashed alterations in the enzymes essential for the TCA cycle, which lead to the 
interruption of OXPHOS31,209, as the levels of HK and PFK who are higher in in the failing 
RV compared with the hypertrophied RV.38 The regulation of intracellular and extracellular 
glucose also depends on levels of control of gene expression of the genes who encode 
different isoforms of GLUTs179. The upregulation of nuclear FoxO1 that regulates cell cycle 
progression, is also caused by the hypoxia conditions and the upregulation in HIF-
1α114,199,210, which triggers the increase of PDK1 expression198, contributes to PDH activity 
inhibition and prompts shifts of metabolism to aerobic glycolysis.31,62,208 
While the GLUT4 only expresses in after the birth and to the adulthood153, GLUT1 
is the major GLUT expressed in the foetal heart and his expression is re-induced and 
increased in the adult heart in some pathophysiological states, as in response to myocardial 
damage or stress, including pressure overload and hypertrophy.153,180,211 This insulin-
independent GLUT is the mainly responsible for basal cardiac glucose uptake in quiescent 
myocytes211 and its expression has been increased when it is in the plasmalemma, indicating 
that it is active.212 Some researchers had described the existence of adaptative mechanisms 
to the maintenance of glucose concentration homeostasis, based on the recruitment of 
GLUT4, one of the most abundant GLUTs in myocardium, for the plasma membrane of the 
25 
 
cells.183 This mechanism may be controlled by insulin that acts through two intracellular 
signalling transduction pathways, MAPK and the PI3K/Akt, controlling the GLUT4 
translocation to cell membrane213,214, consequently, modulating glucose uptake by the 
cells.179 The knockout of GLUT4 gene triggered cardiac hypertrophy in LV180 and this may 
be one of the reasons for the existence of a high concentration of GLUT4 in animal models 
with PAH during the compensatory state (which precedes cardiac hypertrophy) and the 
variation of GLUT4 according with the disease state and his severity.215 It has also been 
reported that, as cardiac hypertrophy progresses to heart failure, GLUT1 mRNA expression 
is reduced in human healthy hearts, suggesting that decreased GLUT1-mediated glucose 
uptake and utilization could play a role in the transition to heart failure.211,212  
 The SOD2 gene has also been reported and related with PAH  due the existence of a 
polymorphism that alters the SOD2 protein24,147, playing a pivotal role on oxidative stress 
system, which is one of the basis of this disease.24 This antioxidant enzyme, that participates 
in several cellular processes, among which glucose metabolism, has decreased expression in 
PAH24,216 being related with the development of plexiform lesions characteristic of PAH.216 
In PAH, the downregulation of the mitochondrial hydrogen peroxide (H2O2), the generating 
enzyme of SOD2, triggers the decrease on production of the redox signalling molecule H2O2, 
contributing to the generation of an hypoxia-like redox environment that stimulates HIF-
1α.62  
 Sirtuins (Sirt) are enzymes responsible for deacetylate histones and other 
transcriptional regulators217–220, through the regulation mitochondrial functions.220 However, 
in order to exercise its activity, they require NAD+ as substrate, which is also used in 
glycolysis, reducing NAD+ availability for Sirts.219 A study found that Sirt1 exerts a 
antiproliferative role in vascular remodelling in hypoxia conditions in rats and humans, and 
a deficit in Sirt1 can induce an imbalance which favours glycolysis at the expense of 
oxidation, potentiating the vascular remodelling as it occurs in PAH, that is why its 
activation can have beneficial effects in this disease.217 Furthermore, it intervenes in glucose 
metabolism and respond to physiological fluctuations in energy, contributing to the 
maintenance of energetic homeostasis and health219 improving mitochondrial activity 
through the activation of stress signalling pathways.217 Sirt1 has the ability to control 
glycolysis by deacetylating PGC-1α, who directs mitochondrial biogenesis and activity219, 
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resulting in the repression of glycolysis218, increased glucose output220, and downstream of 
pathways that control mitochondrial gene expression.219 This enzyme also suppresses HIF-
1α by deacetylation, causing a repression on GO through TCA cycle219, what trigger the 
prevention of inhibition of the cMyc, the activator of the transcription of mitochondrial 
transcription factor A (Tfam) mediated by HIF-1α, that usually are overexpressed in 
PAH104,217,221, improving the expression of mitochondrial-encoded respiratory genes and 
GO.217 
Investigations also discovered numerous similarities between PAH metabolic 
phenotype and cancer that reflect a shift from oxidative to glycolytic metabolism, such as 
the high expression of cellular growth factors, dysregulated angiogenesis and enhancement 
of antiapoptotic activity.29,38 Despite the similarities, differences between PAH and cancer, 
as the lack of invasion and metastasis, along with genetic causes and degrees of angiogenesis 
impairment, are evident.222,223   
 
 
Figure 3 Cellular metabolism characteristic of PAH. In PAH, cells acquire a metabolic pattern similar to what is 
observed in cancer cells. Glycolysis starts when glucose is taken up by the glucose transporters 1 (GLUT1) and 4 (GLUT4), 
is posteriorly phosphorylated by hexokinase (HK), and then suffers a series of reactions until pyruvate is produced. Pyruvate 
is the substrate for pyruvate dehydrogenase (PDH) in the mitochondria, supporting glucose oxidation. Free fatty acids 
(FFA) are taken up by fatty acid transport protein-1 (FATP-1) and -6 (FATP-6) and then transformed into acyl carnitines 
that are transported across the mitochondrial membrane by carnitine palmitoyltransferase-1 (CPT1) and transformed to acyl 
CoA by carnitine palmitoyltransferase-2 (CPT2). Into the mitochondria, acyl CoA is converted to acetyl CoA during β-
oxidation. In PAH occurs an intensification of aerobic glycolysis due to normoxic upregulation of HIF-1α, which 
upregulates pyruvate dehydrogenase kinase (PDK) to inhibit PDH, and epigenetic regulation of the superoxide dismutase 
2 (SOD2) gene. PFK, phosphofructokinase; PK, pyruvate kinase; LDH, lactate dehydrogenase; ROS, reactive oxygen 
species; ETC, electron transport chain. Adapted from Leopold, J. A. and Maron, B. A. 2016. ‘Molecular mechanisms of 
pulmonary vascular remodelling in pulmonary arterial hypertension’. 
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3.2.1. Glutaminolysis 
  The glutaminolysis induced by the GO224, which is a type of metabolism 
characteristic of cancer cells, has recently been found that is selectively induced in the RV 
during RVH.42,44,62 The continued action of the TCA cycle requires the replenishment of 
carbon intermediates193, which is achieved by anaplerosis through glutaminolysis, resulting 
in a net flow of carbon for the TCA cycle, being this process linked to animal models of 
PAH.42,44,62  
 Glutamine is an additional source of cellular energy, as well as carbon, and nitrogen, 
that is used particularly in rapidly cell-growth and proliferating cells44,224, where occurs 
deamidation of glutamine through the action of the enzyme glutaminase (GLS1).193 During 
the hyperproliferative state, cells go through aerobic glycolysis and glutaminolysis instead 
of the standard OXPHOS pathway, potentiating an extra rapid, although inefficient, 
management of glucose and glutamine for energy and nutrient synthesis.4,225 The resulting 
changes from metabolism in PAH lungs may trigger the use of these glutamine stores and 
increase the glutaminolysis, alike to what  occurs in cancer cells.225 
 Glutaminolysis occurs when glutamine transporters, the solute carrier proteins  
SLC1A5 and SLC7A5, transport glutamine into the cytosol, and then the mitochondria by 
hydrolyzation converts glutamine into α-ketoglutarate, that enters to TCA cycle to restore 
the metabolic intermediates that support rapid cell growth without apoptosis.42,62,198 This 
process has some similarities with glycolysis: when mitochondria faces an impaired PDH, 
occurs an increase in malic acid from the glutamine-fed TCA cycle that is oxidized into 
pyruvate by malic enzyme (Me), increasing lactate levels.44,224 
 This process appears to be induced by an ischemic activation of the cMyc 
transcriptional pathway62,224, that triggers the reactivation of components of the foetal gene 
package, as it is characteristic of RV remodelling42, being also associated with an increase 
in the expression of mitochondrial malic enzyme and the glutamine transporters as SLC1A5 
and SLC7A5, analogous to GLUTs in glicolysis.62,224 Moreover, an impairment with 
increase in cardiac glutaminolysis has been documented in myocytes from maladaptive RVH 
animals in a MCT-induced PAH model, along with an increase in the expression of cMyc. 
The same study demonstrated that the inhibition of glutaminolysis improves GO, however, 
28 
 
the importance of glutamine metabolism in the pathogenicity of PAH has not been well 
defined.193 
 
3.3. Pulmonary arterial hypertension and insulin resistance 
 As result of  the deficiency on glucose uptake caused by alterations on GLUTs due 
the metabolic shifts in PAH, the body will need higher levels of insulin to help glucose enter 
cells and keep the homeostasis226 which may lead to changes in GLUTs.179,180  Likewise, 
several studies report that in patients with PAH there is reduced pulmonary mRNA 
expression of peroxisome proliferator-activated receptor γ (PPARγ) and apolipoprotein E 
(apoE), that regulates adipogenesis and glucose metabolism, and circulating levels of low-
density lipoprotein and atherogenesis in the vessel wall, respectively.50,51,196 Other 
circulating factors associated with insulin resistance, and that are normally repressed by 
PPARγ expression, display elevated levels in PAH, such as the inflammatory cytokine IL-
677,110,127 and ET-1.77,84,227 Furthermore, once the FA modulate the expression of GLUT4, 
the increase in cardiac FAO, due to the overexpression of PPARγ, triggers the inhibition of 
GLUT4 protein and mRNA, what causes a deficit in glucose transport.153 In cases of insulin 
resistance, the cells do not assume the signals that the hormone tries to send out to grab 
glucose out of the bloodstream, for example to activate GLUT4 for glucose transport, and 
place it into cells, leading to a deficit in glucose transport and also in glucose, affecting cell 
bioenergetic availability.181,226 
 The insulin resistance is characterized by the insulin disability in stimulate glucose 
uptake from body peripheral tissues228 due to the inability of the tissue to respond to insulin 
stimulus.115 In this cases, there is an inappropriate response of muscle, fat, and liver cells to 
insulin226, which has to be transported to skeletal muscle to guarantee a provision of insulin 
to myocytes229, and, consequently, the absorbance of glucose from the bloodstream is 
faulty.226 The activated insulin receptor (IR), that plays a crucial role in the regulation of 
glucose homeostasis, creates docking sites with the ability to bind and phosphorylate several 
substrates, as the IRS family proteins (IRS1 to IRS4).182 The IRS are insulin receptors who 
mediate not only insulin signaling230, but also the signals from insulin-like growth factor I 
(IGF-I) to metabolic pathways as the PI3K/Akt and RAS mitogen activated protein kinase 
(RAS/ MAPK) after its phosphorylation.229 However, it is hard to define the role played by 
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each of the IRS, but through knockout models was discovered that IRS1 plays a role in 
cellular growth, mediation of insulin action in peripheral tissues230, and that derangements 
on this gene also induce glucose intolerance and dyslipidaemia.231 In relation to IRS2, it was 
concluded that it is involved in compensatory cellular mechanisms, insulin resistance230 and 
defects on this receptor trigger defects on insulin signalling in EC and impairs glucose 
uptake.229 The IRS1 and IRS2 are also very important in EC, and the pathways activation by 
these receptors culminates in the production of NO and vasodilatation by PI3K/Akt pathway, 
and in RAS/MAPK pathway as it induces endothelial secretion of ET-1, that activates 
protein kinase C in vascular SMC inducing their contraction.229 Furthermore, IRS1 deficient 
mice demonstrated higher blood pressure than IRS2 deficient mice, which allows to infer 
that IRS1 influences blood pressure and may be impaired in PAH.231 
 As mitochondria are crucial to cellular metabolism, several studies mention that the 
typical conditions of insulin resistance may be caused or promoted by mitochondrial 
suppression, that in the case of PAH will inhibit the GO on pulmonary vascular cells.39,68,111 
Indeed, the suppression of GO and the subsequent increase in glycolysis, since in the 
presence of oxygen is usually compromised in PAH due to hypoxia conditions, causes the 
cells to metabolize glucose to CO2 by oxidation of glycolytic pyruvate in mitochondrial TCA 
cycle.147,177 This is one of the hits of PAH, being evidenced in all PA layers and in the 
remodelled RV.68,147,177  
 Some evidences show that vascular cells from individuals with PAH and cancer cells 
share some features in terms of morphology and mitochondrial phenotype, such as the 
increased mitochondrial fragmentation, caused by a fission or fusion imbalance which alters 
the mitochondrial network in cytoplasm.39,62,68,84 Moreover, the mitochondrial fragmentation 
contributes to the pro-proliferative and apoptosis-resistant phenotype of both diseases.62 
Furthermore, some genes may be disrupted and contribute to mitochondrial imbalance. 
There are genes that express proteins who regulate mitochondrial biogenesis and mediate 
several metabolic functions.105,232 The PGC-1α gene, mainly induced by hypoxia conditions, 
is one of those master genes that regulates, interacts and induces the activation of several 
transcription factors, as the nuclear respiratory factor 1 (NRF1) and Tfam, and each of them 
has different characteristics.104,105,232 The NRF1 factor gene encodes mitochondrial 
proteins105 who play a key role on activation of some metabolic target genes who regulate 
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cellular growth, genes who are required for mitochondrial respiration233, and mediates 
mitochondrial DNA (mDNA) transcription and replication through the Tfam.232,233 The 
Tfam is the main responsible for mDNA replication, regulating the expression of 13 gene 
products, including the components of the mitochondrial cytochrome C oxidase complex 
from the electron transport chain.105  
Even knowing that the RV is the main prompter of death by PAH due to RVHF, and 
RVD is characterized by abnormal energy metabolism37,38, there are evidences that RVH has 
impact on metabolism.69  
 
 
4. Right ventricular dysfunction in pulmonary arterial hypertension 
 In PAH, the metabolic derangements and the resulting cellular alterations culminate 
in HF, mostly due to RVHF. However, this process is not so linear and there are several steps 
from the first symptoms of the disease until the HF is reached. 
 In clinical terms, RVHF concerns to the inability of the RV to perfuse the lung 
circulation effectively to maintain LV filling at low venous/diastolic pressures.40 The 
transition from RVH to RVHF involves a huge variability of RV adaptations among patients 
which are exposed to chronic PH according to the aetiology of the PH.41,42 Due to the 
persistent increase on afterload caused by the progression of the disease, the RVH is usually 
accompanied by ischemia, myocardial apoptosis and excessive fibrosis, as well as the 
increased expression of noncontractile proteins that lead to diastolic dysfunction and 
inefficient coupling, triggering a decrease in RV systolic function followed by an acute RV 
dilatation that can culminate in the failure of RV.39,43–45 The response also includes β-
receptor downregulation, an increase in glycolysis, and a decrease in capillary density.198 It 
also occurs an increase in RV glucose uptake in patients and animals with RVH.155,192 Once 
RV ischemia may lead to the generated metabolic switches in carbon utilization that are 
associated with maladaptive hypertrophy, it may potentiate the “hypoxia-like” program of 
gene expression44 activating genes such as HIF-1α and VEGF, who play a central role in 
modulation of myocyte development and in myocardial angiogenesis.43 
 The increase in RV oxidative metabolism is usually associated to several prognostic 
markers such as mean mPAP, PVR, and BNP.234 BNP, from natriuretic peptide family 
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hormone, is the most sensitive marker myocardial stress and injury, more specifically for 
ventricular disorders and HF.86 It is mainly released in response to cardiomyocyte stretch, as 
it occurs in RVH, and high levels of this biomarker reflect right atrial/ventricular volume 
and pressure overload and hypertrophy, as it is characteristic of PAH.25,32,75,235 BNP is 
initially secreted by the cardiac ventricles and is continually cleaved, generating the N-
terminal fragments (NT-proBNP) and the active hormone BNP25,86,235, being involved in 
processes such as natriuresis, vasodilatation and downregulation of RAAS.75 Another 
advantage of this biomarker is that we can relate it with hemodynamic parameters and 
stablish a direct proportional relationship between BNP levels and RV overload, PAP and 
diastolic pressure.25,75 
 Once RV oxidative metabolism may be a prognostic marker234, several studies found 
out that some metabolic characteristics of the RVHF related to PAH are essentially based on 
the decreased level of FAO37,69, increased GO158,183 and intracellular lipid deposition.69,163  
 In PAH, a premature response to increased RV afterload occurs through the adaptive 
RVH.39,41,69 The investigations carried out allowed the identification of two clinical patterns 
of RVH with base on the rate of progression to RVHF and hemodynamic parameters: the 
compensated (or adaptive) (cRVH) and the decompensated (or maladaptive) (dRVH) 
states.41,44 In cRVH, the patients develop RVH but keep RV function, preserving the cardiac 
output (CO) and RV ejection fraction (RVEF), while in  dRVH they rapidly develop RVHF, 
the CO diminishes, the RVEF and the RVSP are reduced, but the mPAP remains elevated, 
being sometimes associated to RV fibrosis and dilatation.35,42,44,192,236 However, once the RV 
compensatory mechanisms reach the saturation point, the RV will transit from adaptive to 
maladaptive RVH, developing RV failure with decreased CO and diminished oxygen 
delivery.44,236  
 The metabolic switch from mitochondrial OXPHOS, to glycolysis that characterizes 
PAH is defined in the compensated phase of RVH35,39, which is shorter than dRVH phase, 
and leads to a rapid alterations on RV, as functional deterioration and dilatation.111 In this 
adaptive stage, mitochondria become more hyperpolarized, what drives to the suppression 
of mitochondria-dependent apoptosis, a decreased production of mROS, which inhibit p53 
protein expression41, and an increase in HIF-1α activity, what will trigger an increase in 
GLUT1 levels and, consequently, in glucose uptake.35,39,42 The decrease in mROS may also 
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be a response to minimize additional sources of stress in myocardium who strives to maintain 
cardiac output39, nevertheless, in RVH, an increase in mROS is enough to inhibits HIF-1α, 
suppressing angiogenesis42 and the activation of ROS-dependent signalling pathways acts as 
a suppressor of myocardial function.237 Along with the activation of HIF-1α during the 
cRVH phase, the NFAT is also activated39, contributing to the proliferation and resistance 
to apoptosis characteristic of the phenotype of this disease.238 Also the VEGF and stromal-
derived factor 1 (SDF1) are activated in cRVH, contributing to the promotion of glucose 
uptake and angiogenesis.35,41 An upregulation of myocyte enhancer factor 2 (Mef2) was also 
documented in this phase, maybe due the enhancement in its transcriptional activity during 
cRVH.42 It has been verified that Mef2 gene is implicated in the regulation of several genes 
involved on metabolic genes of PAH, such as PDK4, GLUT4, PPARγ, PGC-1α, but also 
genes involved on contractility, for example α- and β-myosin heavy chain (MHC)35,42, and 
angiogenic genes like VEGF239, besides playing a role in the transition from compensated to 
decompensated RVH.42 Moreover, Mef2 has been associated to miRNAS that arose as 
determinants of gene regulation in cardiac development and hypertrophy, as miR-208, 
specific from myocardium.42,239 Once Mef2 is a target gene for GLUT4, this followed a 
similar pattern of expression and there has been an increase in translocation of GLUT4 to 
plasma membrane in cRVH, contributing to glucose uptake.35,239 The transcription complex 
formed by the mediator of transcription 13 (MET13) and nuclear receptor corepressor 1 
(NCoR1), MET13/NCoR1, is critical for the regulation of metabolic and angiogenic genes, 
but also for the regulation of Mef2 function via negative feedback loops.239 
 According with a study from Sutendra et. al (2014) that used an animal model of 
monocrotaline (MCT) for PAH, the transition from cRVH to dRVH is marked by an 
exponential increase in mROS, that in association with mitochondrial dysfunction drives to 
an increase in intracellular Ca2+ and Ca2+- dependent signalling, as the NFAT activation 
pathway, inducing hypertrophy and failure.237 The decrease of levels of VEGF, SDF1 and  
HIF-1α, along with the activation of p53, a protein responsible for HIF-1α signalling 
pathway inhibition41, occurs a decrease on the expression of PDK, what triggrs effects on 
GO, mitochondrial function and angiogenesis.35 In this phase, arterial stiffness also increases 
due to the increment of circulating vasoconstrictors, such as ET-1 and serotonin, what 
contributes to the HF state237, being that the transition from cRVH to dRVH is also 
accompanied by a loss in capillary density.195 Throughout the decompensated phase, the 
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Mef2 expression values start declining until they are inhibited, what contrast with the levels 
of TNF- that increase as the disease progresses toward RVHF.239  
 Another study documented that the miR-126 also plays a role in the pathogenicity of 
this disease, since it plays a regulatory role in the angiogenesis and acts by suppressing the 
sprouty-related protein-1 (SPRED-1) and the phosphoinositide-3-kinase regulatory subunit 
2 (PIK3R2), which are two inhibitors of the VEGF signalling pathway, activating MAPK 
and PI3K signalling, promoting angiogenesis.240 The expression of this miR is significantly 
decreased in dRVH comparatively to normal and cRVH in human samples of PAH patients, 
and this downregulation promotes the transition from cRVH to dRVH.240 Moreover, the 
occurrence of an elevated FAO in RVH is demonstrated to be maladaptive mechanism by a 
study in animal models of PAH with PA banding (PAB), since the inhibition of FAO 
increased the ATP concentrations on RV and improved the RV function in vivo.160  
 
 
5. Neuregulin-1 
NRGs are a subclass of transmembrane polypeptide epidermal growth factors (EGF) 
expressed in several systems, that mediate cell-cell interactions in several tissues from breast 
to cardiovascular and nervous system.241–243 From the four forms of NRG (NRG1, NRG2, 
NRG3, and NRG4), the NRG1 is the one that is known to perform cardiovascular functions 
and is produced by cardiac endothelium.242,244,245 The NRG1 mRNA expression and protein 
synthesis is dependent of neurohormones: while ET-1 stimulates NRG1 mRNA expression, 
the angiotensin II and phenylephrine are responsible for NRG1 inhibition, as they are 
released by EC in conditions of low blood pressure, to improve cardiac output and rise 
peripheral resistance.246  
NRG1 is a paracrine factor whose functioning depends on its binding to 
erythroblastic leukaemia viral oncogene homolog (ErbB), a family of tyrosine kinase 
receptors (RTK) (ErbB2, ErbB3, and ErbB4).243 When NRG1 binds to ErbB3 or to ErbB4 
induces a conformational change, allowing the dimerization with ErbB2 or ligand-activated 
ErbB3/ErbB4 receptors, wherein the intracellular kinase domains phosphorylate the 
intracellular C-terminal domain of the dimerization set.242,244 From the receptor dimerization 
results homodimers or heterodimers with docking sites for several proteins, designated as 
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NRG1/ErbB system. The NRG1/ErbB system acts as an initiation bridge for several 
signalling cascades as the MAPK or PI3K/Akt pathways, whose downstream signalling 
mediates numerous cellular processes241,242,244 as survival, migration, proliferation, cellular 
adhesion or differentiation.242,245,247,248 NRG1 is also involved in oxidative stress reduction, 
in mitochondrial activity and in recovering mitochondrial function.245 
 
5.1. Neuregulin-1 and signalling in regulation of glucose metabolism  
 Regarding to the metabolic actions of NRG1 in rat skeletal muscle cells, the chronic 
treatment with NRG1 improved not only oxidative metabolism through the regulation of 
GLUTs expression, but also mitochondrial activity through the stimulation of the expression 
of PGC-1α and peroxisome proliferator-activated receptor delta (PPARδ).241 Furthermore, 
NRG1 is responsible for inducing the activation of Ras/Raf/MEK/MAPK cascade241, being 
also accountable for the modulation of muscle metabolism through the induction of glucose 
uptake by the modulation of the PI3K-PDK1- protein kinase C zeta (PKCζ) pathway, in an 
independent manner of insulin.172 Beyond insulin, NRGs are also responsible for inducing 
the translocation of GLUTs to plasma membrane in muscle cells, potentiating glucose 
transport and myogenesis.241,242  In a model of breast cancer on L6E9 muscle cells from rats, 
the treatment with NRG1 induced the translocation of GLUT4 to the plasma membrane in a 
manner similar to the effect of insulin, increasing the glucose uptake.249 Another study in 
L6E9 muscle cells is consistent with these findings, having further disclosed that the 
treatment with NRG  increased GO and decreased lactate release172, what suggests that the 
chronic treatment with NRG1 could regulate glucose metabolism and homeostasis by 
modulation of glycolysis and control of Warburg effect.  
 
In cardiac muscle, NRG/ErbB signalling have been related with the pathophysiology 
of HF250 and a deficiency in NRG1 signalling increases the likelihood for cardiac injury.251 
NRG1 prevents cardiomyocytes apoptosis through the activation of the ErbB4/PI3K/Akt 
pathway242,251, what may also occur as a repair mechanism after cardiac injury252, and also 
by inhibiting cytochrome c release and caspase-3 activation.242 This effects of NRG1 on 
glucose uptake were assessed in an in vitro study, were the glucose uptake was completely 
abolished in situations of PI3K inhibition.253 PI3K/Akt pathway seems to be involved in the 
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protection of cardiomyocytes against apoptosis, as well as regulation of metabolism and 
growth98,247, and this a reason why PI3K inhibition may also trigger insulin resistance and 
glucose intolerance.254 
However, NRG1 also displays effects in liver through glucose metabolism 
regulation.  Insulin seems to inhibit the effects of NRG1 action in rat hepatocytes due to 
downregulation of ErbB255 by the impairing in NRG1 to the receptor through a PI3K-
dependent pathway.256 In two animal models of insulin deficiency, type I diabetes and 
fasting, the liver ErbB3 expression was inhibited by insulin treatment, what suggests that 
insulin regulates the ErbB expression and that exists an interaction between insulin and 
NRG1/ErbB pathway.257 
 
5.2. Role of neuregulin-1 in Pulmonary Arterial Hypertension 
NRG1 is expressed and released by cardiac endothelium, whereas ErbB2 and ErbB4 
receptors are expressed in cardiomyocytes242, and once NRG1 binds to ErbB4,  induces 
conformational changes in this receptor, that allow its dimerization with ErbB2 or with 
ligand-activated ErbB4.258 Apart from their cardioprotective effects242,245,247, via PI3K/Akt-
dependent mechanism244 and the maintenance of structural and functional integrity in the 
adult heart242, NRG1/ErbB signalling is also determinant for the proper formation of the 
heart and cardiac conduction system245,248, being the main responsible for the correct 
formation of the ventricular trabeculae.249 Furthermore, cardiac NRG-1ß/ErbB signalling 
foment cardiomyocyte survival and proliferation, supporting normal cellular functions.247 
Consistent with this notion, NRG1 administration significantly attenuated neointimal 
formation and vascular injury in a model of atherosclerosis.259 In an MCT model for PAH 
was reported the beneficial effects of NRG1 administration in rats in conditions of 
myocardial stress, since it attenuates some hallmarks of PAH as neointimal hyperplasia and 
vascular remodelling, protecting both smooth muscle and EC but also cardiac dysfunction 
and ventricular dysfunction. However, the highlighted effects were the reduction of the 
severity of PAH and RVH, as well as the expression of genes associated with overload and 
hypertrophy, as ET-1 and BNP, respectively.99  
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 The RVD is also correlated with a decrease in the expression of intermediaries of 
FAO, while RVH is related with an increase in intermediaries of FAO and in FAO 
itself.160,260 Some studies showed that there is an increase in RV glucose uptake in patients 
and animals with RVH192, given the switch to glycolysis that is a less energetically efficient 
process.42 Furthermore, in mouse models, the NRG receptors ErbB2 and ErbB4 are 
expressed in response to pressure overload during compensated RVH phase, and reduce its 
expression in the transition to HF.247 However, a study with in humans detected that in cases 
of advanced HF defined at dRVH phase, while NRG1 increases, the receptors ErbB2 and 
ErbB4 expression and activity is maintained reduced, enhancing the apoptotic susceptibility 
and death.261 
 
 
6. Experimental models to study pulmonary hypertension 
 The existence of animal experimentation on living animal remounts to third and 
fourth centuries as described in manuscripts of Greek philosopher physicians262 and despite 
not being well accepted by all clinicians in the actual times, the animal experiments 
provided, and still provide, a lot of important biological knowledge to our understanding of 
mechanisms of diseases.263 The need for new therapeutic approaches in numerous 
pathophysiologies intensified research using animal models.264 The animal model used 
should be selected taking into account several criteria requires background knowledge of 
their biological properties once they may affect the study.265 
 The different experimental approaches can be subdivided into four groups: single 
pathological-insult (SPI), multiple-pathological insult (MPI), knockout, and 
overexpression.266 Despite numerous animal models are available to study PAH, the most 
performed experimental approaches are from SPI and MPI groups.266–269 Some alternative 
experimental approaches are also performed and involve genetic manipulation of the animal 
models, commonly referred as genetically modified organisms (GMO). Some examples are 
the use of animals with overexpressed genes as the calcium binding proteins, as 
(S100A4/Mts1) or the IL-6, but also knockout animals for BMPRII267,268 or the vasoactive 
intestinal peptide (VIP) that regulates the pulmonary circulation.268 Those alternative models 
are also represented in the Table 2.26  
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 However, even though they are very representative, the animal models still do not 
completely mimic the human PAH.267 A big part of PH animal studies targeted the chronic 
hypoxic exposure model or the MCT PAH-induced rat model, which are SPI models.26 
  
6.1. The monocrotaline model 
 MCT, an anti-mitotic agent270, is an 11-membered macrocyclic pyrrolizidine alkaloid 
extracted from the seeds of the plant Crotalaria spectabilis, who is used to induce PAH in 
rats (Figure 4).268,270,271 This substance requires prior activation for the reactive form of 
pyrrole metabolite dehydromonocrotaline (MCTP), that occurs in the liver, and whose 
reaction is dependent on cytochrome P-450 (Figure 5).267,268,270,271 This model is one of the 
most accomplished models due to its technical simplicity, high reproducibility and because 
it has lower costs associated.268,271 
 
  
  
 MCT can be administered by a single subcutaneous or intraperitoneal injection, that 
induces maladaptive RVH224, causes vascular injuries267 associated to severe ischemia, 
PH224, and widespread pneumotoxicity.272 This model recapitulates many other features of 
human IPAH in 3–4 weeks after MCT injection270,271, such as the EC apoptosis and 
disruption, oxidative stress271, and genetic modulation of the BMPRII, Smad3,4, TGF-β 
receptors and activin receptor-like type 1 (ACVRL1) genes.266,271 MCT induces pulmonary 
arterial medial hypertrophy through the proliferation of PASMC ant their resistance to 
apoptsis266,271, adventitial thickening, caused mainly by  accumulation of inflammatory cells 
in adventitial in the early stages of the development266,267, and obstructive pulmonary 
vascular remodelling224,266,271 which are accompanied by changes in PA pressures (Figure 
5).267,270 Despite causing RVH and RVD as a consequence of pressure overload224,268,270, 
Figure 4 Crotalaria spectabilis. Plant 
that produces the seeds from which the 
monocrotaline (MCT) compound is 
extracted.  
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what helps the scientific community to understand better the mechanisms of pulmonary 
vascular remodelling and its pathophysiology266, this model has some side effects once it 
induces pathological changes in lungs, as interstitial pulmonary fibrosis in mice270 and 
pulmonary oedema273,  triggers the development of myocarditis in both RV and LV267,268, 
fails in the induction of plexiform lesions270 and is also involved in hepatotoxicity 
development266,267, what difficult the study of RVH and RVHF.267 
 
 
Figure 5 Effects of monocrotaline (MCT)-induced pulmonary arterial hypertension (PAH) in rat. The MCT 
reproduces the effects of PAH in cardiorespiratory system, as the increase in pulmonary vascular resistance (PVR) 
provoked by the vascular remodelling of pulmonary artery (PA), the increase in right atrial area (RAA) due the right 
ventricle remodelling, what may culminate in right ventricular hypertrophy (RVH) and right heart failure and death. ESP: 
end-systolic pressure; EDP: end-diastolic pressure. Adapted from Santos-Ribeiro, D. et al. 2016. “Pulmonary arterial 
hypertension: Basic knowledge for clinicians”.  
 
6.2. The hypoxia model 
 The chronic hypoxia is frequently used to induce PH through the exposition of the 
animals to hypoxic conditions in hyperbaric chambers.268 The hypoxic model in rats is only 
performed to study less severe PH, not for PAH, but this does not make it unfeasible for its 
value, once this method is very predictable and reproducible within a selected animal 
strain.267,268 Nevertheless, while the vascular remodelling observed is smooth267,268, the PH 
developed is associated with de muscularization of small arterioles and the increase in the 
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expression of α-SMA in non-muscularized arterioles268,272 due to hypertrophy and/or 
moderate hyperplasia SMC.272 It also results in EndMT268, RV hypertension and 
hypertrophy, not reaching HF267,268, what leads to an increase in mPAP and in structural 
changes in pulmonary vasculature, which are followed by an influx of inflammatory 
cells.268,272 However, the developed condition may return to the normal phenotype if the 
animal is subjected to an environment of normoxia.269 
 The shortcomings that come from this model are the fact that it does not represent 
the pulmonary vascular damage as it is observed in human PH266 and it fails in the generation 
of non-reversible intimal fibrosis or plexiform lesions as those that occur in human PH.267 
 
6.3. The hypoxia/Sugen model 
 Another animal models which combines more than one procedure, designated by 
MPI, can be performed.267 One example of this type of experimental approach is the 
Hypoxia/Sugen5416 model, a model for severe PAH268, that combines Sugen5416, a VEGF 
inhibitor, and exposure to chronic hypoxia.274 This model allows a better understanding not 
only on etiologic mechanisms that cause EC hyperproliferation and plexiform lesions 
formation in human PAH268 but also the study the angioproliferative characteristics of PH 
and hemodynamic changes.266 SU5416 by himself causes smooth PH and pulmonary 
vascular remodelling, but when associated to chronic hypoxia, their effects are irreversible 
PH associated with precapillary arterial endothelial proliferation, SMC proliferation268, and 
the animals develop sustained and progressive PH.269 Due the progressive nature of this 
model and its ability to reproduce key pathophysiological features from human PAH, it is 
used to evaluate new treatments for PAH.268  
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7. Aims of the study 
 Based on the published findings described in the previous sections, this study aimed 
to contribute to the study of the impact of chronic treatment with NRG1 on the metabolic 
changes that occur in the development of PAH. We believe that the beneficial effects of 
chronic treatment with NRG1 in PAH could be associated with the modulation of glycolytic 
metabolism. 
 According to the results obtained in our previous studies in this area, in this thesis 
we aimed to explore the potential involvement of NRG1 in systemic and cellular glucose 
homeostasis as well as in the regulation of the effect of Warburg at the cellular level. 
 
Our specific goals are: 
• To determine the expression of GLUT1 and 4 in different PAH animal models and 
establish correlations between their expression with parameters of cardiac function 
and disease markers; 
• To evaluate the effects of chronic exposure to NRG1 on GLUT1 and GLUT4 
expression in animal models of PAH; 
• To determine whether chronic NRG1 administration affects blood glucose 
homoeostasis and regulates insulin receptors in animal models of PAH; 
• To evaluate and correlate the expression of glycolysis genes in RV with parameters 
of cardiac function in PAH; 
• To evaluate the effects of chronic exposure to NRG1 and determine the changes 
induced by rhNRG1 treatment in glycolysis genes in two animal models for PAH. 
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 Materials and Methods 
 All the procedures in this work followed the recommendations of the Guide for the 
Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH 
Publication No. 85-23, Revised 1996), and are accredited by the Portuguese Direção Geral 
de Alimentação e Veterinária (DGAV) and approved by Fundação para a Ciência e a 
Tecnologia (FCT PTDC/SAU-FCT/100442/2008; IMPAcT-PTDC/MED-
FSL/31719/2017). 
 
1.Animal models 
1.1.MCT model 
 Male Wistar rats (Rattus Norvegicus Albinus, Rodentia, Mammalia) (Charles River 
Laboratories, Barcelona, Spain), weighting 180-200g and seven- to eight-week-old, were 
randomly assigned to receive either a subcutaneous injection of 60mg/kg of body weight 
(BW) of MCT (Sigma Aldrich, Missouri, EUA) or an equivalent volume of vehicle (0.9% 
NaCl). Fourteen days after the first injection, when the animals that received MCT have 
developed PAH, they were again randomly assigned into four subgroups according to 
pharmacological treatment that consisted on a daily intraperitoneal injection of 40μg/kg of 
BW of recombinant human NRG1 (rhNRG1) (Peprotech, Hamburg, Germany) for 7 days, 
while the vehicle treatment consisted of 0.1% bovine serum albumin (BSA) (Sigma Aldrich, 
Missouri, EUA) intraperitoneal injection for 7 days. Were defined four groups of animals: 
control (CTRL) (animals without PAH and without pharmacological treatment, n=10); MCT 
(animals with PAH and without pharmacological treatment, n=20); MCT+rhNRG1 (animals 
with PAH and with pharmacological treatment, n=15); CTRL+rhNRG1 (animals without 
PAH and with pharmacological treatment, n=4). Animals were grouped three per box, in a 
controlled environment, with a light-darkness cycle of 12:12h, controlled temperature at 
22ºC, and water and food ad libitum.  
 
1.2. Sugen/hypoxia model 
 Male Wistar rats (Rattus Norvegicus Albinus, Rodentia, Mammalia) (Charles River 
Laboratories, Barcelona, Spain), weighting 200-230g were placed in a ventilated chamber 
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(Biospherix, Lacona, USA) for up to 21 days and maintained in either normoxic conditions 
(21% O2) or exposed to normobaric hypoxia (10% O2) for three weeks. Sugen 5416 
(SU5416), a VEGF inhibitor, was diluted in dimethyl sulfoxide (DMSO) and administered 
(20mg/kg, s.c.) by injection on the first day prior to hypoxia exposure. Three weeks after 
hypoxia, animals were placed in normoxia conditions for 2 weeks. The three groups of 
animals defined were normoxia (N) (animals in normoxic condition with vehicle (DMSO), 
n=2); normoxia/Sugen5416 (N/S) (animals in normoxic condition with Sugen5416, n=2) 
hypoxia (H) (animals in hypoxia condition with vehicle, n=3); and hypoxia/Sugen5416 
(H/S) (animals in hypoxia condition with Sugen5416, n=4).   
 Another different work was performed, following the same model, 
hypoxia/Sugen5416, but with an additional treatment with rhNRG1, that begun on week 6, 
after hypoxia and normoxia exposition and that lasts for 2 weeks. The treatment consisted 
on a daily intraperitoneal injection of 40μg/kg of BW of rhNRG1 (Peprotech, Hamburg, 
Germany) for 2 weeks, while the vehicle treatment consisted of 0.1% BSA (Sigma Aldrich, 
Missouri, EUA) intraperitoneal injection for 2 weeks. From this work resulted two groups 
of animals: the hypoxia/Sugen5416 H/S) (animals in hypoxia condition with Sugen5416, 
n=5) and the hypoxia/Sugen5416 treated with rhNRG1 (H/S+rhNRG1) (animals in hypoxia 
condition with pharmacological treatment, n=5).  
 In both works, animals were grouped three per box, in a controlled environment, with 
a light-darkness cycle of 12:12h, controlled temperature at 22ºC, and water and food ad 
libitum.  
 
2. Echocardiographic evaluation 
 Before starting the protocols, a transthoracic echocardiographic evaluation was 
performed to allow a basal evaluation to compare experimental groups and to prevent the 
inclusion of potential ill animals (cardiac pathology or other). At the end of the protocols, 
the animals were submitted again to transthoracic echocardiographic evaluation to confirm 
and define the degree of disease development. 
 Before the echocardiography the BW of each animal was checked, and posteriorly, 
rats were anaesthetized by inhalation of sevoflurane (8%) SevoFlo® lot 6055792 (Abbott, 
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Berkshire, United Kingdom) in O2. Then, animals were orotracheally intubated and 
mechanically ventilated. Anaesthesia was maintained with sevoflurane (1-2.5%) titrated 
according to the toe-pinch reflex. Rats were placed in left lateral decubitus on the heating 
pad (temperature maintained at 38ºC) and the skin was shaved and depilated. After applying 
warm echocardiography gel, a 15MHz sensorial probe Sequoia 15L8W (Siemens, Erlangen, 
Germany) was gently placed on the thorax. The echocardiographic evaluation was 
performed with an Acuson Sequoia C512 ultrasound system (Siemens, Erlangen, Germany) 
and acquisitions were averaged from three consecutive heart beats.  
 Bi-dimensional and M-mode images were obtained, in short axis of LV at the 
papillary muscle level. In apical projection of 4 and 5 cavities, after previous acquisition of 
bi-dimensional image, tricuspid valve flow and pulmonary valve flow, were evaluated by 
conventional Doppler. Right atria area was evaluated in the 4-chamber view and tricuspid 
annular plane systolic excursion (TAPSE) in M-mode following alignment of the gate to the 
tricuspid valve. The right ventricular inner diameter in diastole (RVIDd) was assessed in 4-
chamber view projection on tricuspid valve and measured as the distance from the right 
ventricular free wall to the interventricular septum. 
 The PA flow was measured with pulsed-wave Doppler positioned within the main 
PA at a distal plan from the pulmonary valve and parallel to the flow, allowing the 
acquisition of pulmonary arterial acceleration time (PAAT), the interval of blood flow time 
from the start to the peak velocity, pulmonary arterial ejection time (PAET), from the start 
to the cessation of flow275 to determine the PAAT/PAET ratio, and PA velocity-time integral 
(PAVTI). CO and cardiac index (CI) were also calculated.276  
 
3. Morphometric analysis and sample collection 
 After the echocardiographic evaluation, the animals were euthanized with overdose 
of the anesthetizing substance and immediately exsanguinated. Posteriorly, heart and lungs 
were excised and was performed a morphometric evaluation of the organs, were it was 
assessed the weights of the lungs, heart, LV + septum (LV+S), RV, soleus and gastrocnemius 
muscles. Tibial length (TL) was also achieved and used for normalization, once tibia is not 
affected by the presence or absence of the pathological lesions resulting from MCT during 
the lifetime of the rat, being this parameter independent of the other changes that occur in 
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body weight.277 Tissue samples from different organs were collected, snap frozen in liquid 
nitrogen and stored at -80ºC. The samples collected to molecular biology studies, as gene 
expression studies by mRNA quantification, were obtained from organ fragments, such as 
lung, RV, soleus muscle and gastrocnemius muscle and stored with RNA stabilizing reagent 
RNAlater (Qiagen, Hilden, Germany) to prevent tissue and genetic material degradation. 
 
4. Oral glucose tolerance tests 
 Oral glucose tolerance tests (OGTT) were performed to evaluate whole-body glucose 
tolerance in vivo. Rats were fasted overnight (12 hours) and OGTTs was performed through 
glucose loading by gastric gavage (2g/kg BW). Blood glucose levels were determined using 
a FreeStyle Precision system glucometer (Abbott, Berkshire, United Kingdom) at the time 
of glucose loading (0), and then at 15, 30, 60, 90 and 120 minutes after loading.  
 
5. Gene expression studies 
5.1. Total RNA extraction 
 The total RNA was isolated from the different tissues through the phenol–chloroform 
extraction method with NZYol® ref MB18501, lot 14031 (Nzytech, Lisboa, Portugal) and 
TripleXtractor ref GB23.0050, lot 7E20109A (GRiSP, Porto, Portugal) with 1.4mm 
zirconium oxide beads ref KT03961-1-103.BK, lot160811-890 (Precellys, Montigny-le-
Bretonneux, France) following the Protocol 1 in Appendix section. 
 
5.2. Total RNA quantification and quality assessment 
 Concentration and purity of RNA were evaluated using the NanoDrop® ND-2000 
spectrophotometer (Thermo Fisher Scientific, Wilmington, DE, USA). The purity of the 
mRNA was evaluated by the A260/A280 ratio obtained from spectrophotometry analysis. 
Only the samples with ratio between 1.8 and 2.1 were considered suitable for molecular 
studies. 
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5.3. Total RNA electrophoresis 
 To verify the presence of genomic DNA, samples were loaded in a 1% agarose gel 
and run at 70V for 1 hour. The gel was scanned with ChemiDoc™ XRS+ Imaging System 
(Bio-Rad Laboratories Inc., Hercules, California, USA) and analysed with equipment 
software, Image Lab™ (Bio-Rad Laboratories Inc., Hercules, California, USA). 
 
5.4. mRNA reverse transcriptase 
 The mRNA relative expression quantification was performed by two-step RT-qPCR. 
The first step, the reverse transcription, was performed in a conventional thermocycler 
(Biometra, Göttingen, Germany) with the SensiFast™ cDNA synthesis kit lot RA653-
B051360 (Bioline, London, United Kingdom) following the protocol and PCR program 
recommended by the kit manufacturer, that consisted in denaturation for 10 minutes at 25ºC, 
annealing for 15 minutes at 42ºC, and extension for 5 minutes at 85ºC. 
 
5.5. RT-qPCR 
 From each sample obtained from reverse transcription, 1µl (50ng) was amplified and 
detected by RT-qPCR equipment StepOne™ (Applied Biosystems, California, USA) in 
MicroAmp® Fast 96-Well Reaction Plates (0.1mL) ref 4346907 (Applied Biosystems, 
California, USA), using the probe SYBR Green SensiFast™ Hi-ROX Kit lotSF576-B048530 
(Bioline, London, United Kingdom) according with the manufacturer instructions. Gene 
analysis expression to understand the metabolic alterations observed in PAH was divided 
into three categories according to gene function: biomarkers for PAH (HIF-1α, ET-1 and 
BNP), genes who intervein on glucose metabolism (GLUT1, GLUT4, HK1, HK2,  muscle 
type PFK (PFKm), muscle type PK (PKm), LDHa, LDHb, LHDc, LDHd, PDHa1a and 
PDHb), insulin receptors (IRS1 and IRS2) genes involved in mitochondrial function (PGC-
1α, NRF1, Sirt1 and Tfam).  
 Using RV, skeletal muscle, lung and soleus muscle samples from the CTRL groups, 
standard curves were built to each target gene, correlating the initial total cDNA quantity 
and the threshold cycle with the values of each sample. To perform the standard curves for 
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each gene, we have prepared 7 dilutions with different concentrations of cDNA template 
(400, 200, 100, 50, 25, 12.5 and 6.25 ng) from a control sample, that we know to express the 
gene of interest and the we determined their threshold cycle values. Amplification curves 
were analysed with StepOne™ software version 2.3 (Applied Biosystems, California, USA), 
through absolute quantification. Melting curves of each PCR reaction were used to exclude 
the formation of primer-dimers and unspecific products, confirming the purity of the 
amplified product. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a housekeeping 
gene, was chosen as reference gene, since no significant changes were observed between the 
different groups. Gene expression results were presented in Arbitrary Units (AU), being the 
CTRL group means values after GAPDH normalization correspondent to 1AU. The primers 
used in the molecular analysis (see Table 3) were designed in-house with the appropriated 
software, Oligo Analyzer 3.1 (Integrated DNA Technologies, Inc., California, USA). 
 
6. Statistical analysis 
 Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software, 
San Diego, CA). Two-way ANOVA with Tukey’s post-test was used to statistically analyse 
echocardiographic and molecular parameters, which followed a normal distribution. One-
way ANOVA nonparametric analysis of variance with Tukey’s post-test was used for 
mRNA analysis in hypoxia model. Correlations were determined using Pearson correlation 
tests. Group data are presented as means ± SEM. Only differences with p<0.05 were 
considered statistically significant.  
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Results 
1. Metabolic changes in the development of pulmonary arterial hypertension in MCT 
model - Effects of the treatment with Neuregulin-1  
1.1. Characterization of the MCT model  
a. Evaluation of disease markers 
 The MCT animal group was divided into two subgroups according to their RVEF 
and ventricular functioning (Figure 6A): (i) compensated right ventricular function (CRV), 
that displayed an EF above of 35% with preserved ejection fraction despite the RVH, and 
(ii) with decompensated right ventricular function (DRV) characterized by exhibiting EF 
values below 35%, being the decrease in EF a characteristic of HF.278 The transition point 
between compensated and decompensated animals defined as 35% was determined with base 
in the hemodynamic, morphological and clinical analysis performed. A significant 
difference on EF was found between the CTRL group (C) and both with CRV and DRV, 
reflecting the disease state as being more evolved in the DRV group. 
 The evaluation of mRNA expression in the RV showed a significant increase in 
mRNA expression of the main cardiac disease markers in DRV groups comparing to both 
CTRL and CRV groups: HIF-1α, an indicator for hypoxia122 (Figure 6B); ET-1, an indicator 
for overload and hypertrophy279 (Figure 6C); and BNP, an indicator for myocardial stress, 
overload , injury and hypertrophy86 (Figure 6D). 
 
b. Evaluation of GLUT1 and GLUT4 expression 
 In both MCT groups has occurred a significant increase in GLUT1 mRNA 
expression, being this increase incremented in DRV group when compared with CTRL and 
CRV groups (Figure 7A). Conversely, GLUT4 mRNA expression was significantly 
decreased in DRV group in comparison with CTRL group (Figure 7B). 
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Figure 7 RV alterations on glucose transporters (GLUTs) 1 and 4 gene expression are evidenced in MCT model 
of PAH. C: control group; CRV: compensated right ventricular function group; DRV: decompensated right ventricular 
function group; GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 
Bars represent mean ± SEM of 10 rats per control group and 20 rats per MCT group. *P<0.05 vs C; **P<0.01 vs C; 
*** P<0.001 vs C; ## P<0.01 vs CRV. Two-way ANOVA analysis of variance with Tukey’s posttest was used for all 
the parameters presented. 
 
Figure 6 Alterations on ejection fraction (EF) and in the gene expression of disease markers are clearly 
evidenced in the RV from MCT model of PAH. C: control group; CRV: compensated right ventricular function 
group; DRV: decompensated right ventricular function group; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; 
HIF-1α: hypoxia inducible factor 1α; ET-1: endothelin-1; BNP: brain natriuretic peptide. 
Bars represent mean ± SEM of 10 rats per control group and 20 rats per MCT group. *P<0.05 vs. C; #P<0.05 vs. CRV. 
Two-way ANOVA analysis of variance with Tukey’s posttest was used for all the parameters presented. 
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c. GLUT1 and GLUT 4 correlation with markers of disease  
 The correlation between the GLUT1 and GLUT 4 expression in DRV group and 
markers of cardiac disease was also determined. The ejection fraction values correlate 
negatively with mRNA levels of GLUT1 (r = -0.8465, p<0.001) (Figure 8A). We also found 
a positive correlation between RV GLUT1 and HIF-1α mRNA expression (r = 0.7622, 
p<0.001) (Figure 8B).  
 Unlike GLUT1, the GLUT4 mRNA expression was positively correlated with EF (r 
= 0.5043, p<0.05), once both decrease as the disease progresses (Figure 8C). GLUT4 mRNA 
expression is also related with the expression of BNP (r = -0.6832, p<0.001) (Figure 8D) 
and ET-1 (r = -0.6127, p<0.01) (Figure 7E).  
 
       
 
               
 
 
 
 
 
 
Figure 8 The gene expression of RV glucose transporters 1 and 4 (GLUT1 and GLUT4) in MCT-induced PAH 
animals is correlated with markers of cardiac disease. GAPDH: glyceraldehyde 3-phosphate dehydrogenase; EF: 
ejection fraction; HIF-1α: hypoxia inducible factor 1α; ET-1: endothelin-1; BNP: brain natriuretic peptide. 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
A B 
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1.2. Effects of the chronic treatment with Neuregulin-1  
a. Morphometric characterization of MCT model 
 MCT-induced PAH resulted in a decrease of BW of the diseased animals in 
comparison with CTRL animals (CTRL-BSA: 272.4±28.89g; MCT-BSA: 240.24±13.86g) 
(Figure 9A), however, the treatment with rhNRG1 did not attenuated the weight loss 
significantly (MCT-rhNRG1: 241.88±14.77g). Furthermore, Fulton index calculated trough 
morphological parameters evaluated (RV/LV+S) and which is an indicator for RVH280,281, 
was significantly increased in PAH-induced group, having been markedly attenuated by the 
treatment with rhNRG1 (Figure 9B). The Lung/TL ratio (Figure 9C), allows to verify the 
existence of pulmonary oedema99, was also reduced by the rhNRG1 treatment when 
comparing with MCT group. The MCT animals also presented greater values of RV/TL 
ratio, which is also an indicator of RVH277, being this increase attenuated in MCT-treated 
animals (Figure 9D).  
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Figure 9 rhNRG1 treatment attenuated right ventricle (RV) and lung remodelling in MCT-induced PAH. BW: 
body weight; TL: tibial length. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group for the morphometric data. *P<0.05 vs. CTRL-BSA; **P<0.01 vs CTRL-BSA; ***P<0.001 vs. CTRL-BSA; 
#P<0.05 vs. MCT-BSA; ##P<0.01 vs. MCT-BSA. Two-way ANOVA analysis of variance with Tukey’s posttest was 
used for all the parameters presented. 
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b. Echocardiographic characterization of MCT model 
 MCT-induced PAH resulted in a significant decrease in PAVTI in MCT animals 
(Figure 10A), that represents a decrease in velocity-time integral of blood flow in PA, almost 
normalized by rhNRG1 to control values, indicting a restoring on pulmonary circulation on 
rhNRG1 treated animals. PAAT/PAET ratio varies with RV dilatation and RVH, and since 
PAH animals presented altered PA flow, the PAAT/PAET ratio significantly decreased in 
MCT animals in comparison to CTRL animals (Figure 10B), being this decrease also 
attenuated by rhNRG1 treatment. The assessment of RVIDd revealed the existence of 
dilatation in RV of MCT-induced PAH animals, as it is characteristic of this pathology34, 
with rhNRG1 treatment reverting the dilatation (Figure 10C). MCT animals presented a 
significant decrease on TAPSE, an indicator of RVD281 related with the RV contractility 
capacity249 (Figure 10D). 
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Figure 10 rhNRG1 treatment improves pulmonary flow and right ventricle (RV) structural changes in MCT-
induced PAH. CTRL: control group; MCT: monocrotaline group; PAVTI: pulmonary artery velocity time integral; 
PAAT: pulmonary artery acceleration time; PAET: pulmonary artery ejection time; RVIDd: right ventricle inner 
diameter during diastole; TAPSE: tricuspid annular plane systolic excursion.  
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group for the morphometric data. *P<0.05 vs. CTRL-BSA; **P<0.01 vs. CTRL-BSA; ***P<0.001 vs. CTRL-BSA; 
#P<0.05 vs. MCT-BSA. Two-way ANOVA analysis of variance with Tukey’s posttest was used for all the parameters 
presented. 
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1.3. Evaluation of the effects of the administration of Neuregulin-1 on systemic glucose 
metabolism 
a. Oral glucose tolerance test 
 There were no significant differences in fasting plasma glucose when comparing 
MCT with CTRL group (Figure 11A). When compared with CTRL animals, MCT animals 
presented a tendency to higher blood glucose concentrations for the time points between 60 
and 120 min, but this increase was not significant (Figure 11B). There is also a tendency for 
higher postprandial glucose concentrations in MCT animal group when compared with 
CTRL animals, as we can see by the area under the curve (AUC) (Figures 11B and 11C).   
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Figure 11 rhNRG1 attenuated whole-body glucose tolerance in MCT-induced PAH animals. CTRL: control 
group; MCT: monocrotaline group; AUC: area under the curve.  
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group for the OGTT. *p<0.05 vs CTRL+BSA; #p<0.05 vs MCT+BSA. Two-way ANOVA analysis of variance with 
Tukey’s posttest were used for all the parameters presented. 
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b. Evaluation of IRS1 and IRS2 expression 
1. Insulin receptor substrate mRNA expression in soleus muscle 
 The IRS, mediators of insulin signalling230 and glucose uptake229, presented 
variations on the expression in soleus muscle. MCT-induced PAH group presented a 
significant decrease in IRS1 mRNA expression when compared with CTRL-BSA group, as 
well as the rhNRG1 treated MCT group (Figure 12A). A significant decrease in IRS2 mRNA 
expression also occurred in MCT-BSA group when compared with CTRL-BSA group of 
animals (Figure 12B). 
  C T R L M C T
0 .0
0 .5
1 .0
1 .5
IR
S
1
//
G
A
P
D
H
 m
R
N
A
 (
A
U
)
*
*
   C T R L M C T
0 .0
0 .5
1 .0
1 .5
IR
S
2
/G
A
P
D
H
 m
R
N
A
 (
A
U
)
*
 
 
 
 
2. Insulin receptors substrate mRNA expression in RV 
 No significant changes were observed in both IRS1 (Figure 13A) and IRS2 (Figure 
13B) expression in the RV from the different experimental groups.  
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Figure 12 Alterations on insulin receptors substrate (IRS) 1 and 2 are evidenced in soleus muscle from animals 
in MCT model of PAH. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase. Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per 
MCT+rhNRG1 group. *P<0.05 vs CTRL-BSA. Two-way ANOVA was used for all the parameters presented. 
 
Figure 13 Alterations on insulin receptors 1 and 2 (IRS 1 and 2) were not evident in right ventricle (RV) from 
animals in MCT model of PAH. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 
15 rats per MCT+rhNRG1 group. Two-way ANOVA was used for all the parameters presented. 
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1.4. Study of gene expression from the glycolytic pathway 
a. mRNA expression on soleus muscle 
 In this tissue, no significant changes were observed in the expression of GLUT1 
(Figure 14A), GLUT4 (Figure 14B) or HIF-1α (Figure 14C) of the four different 
experimental groups.  
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 The first enzymes to act during glycolysis are HKs; the mRNA from HK1 did not 
presented expression alterations between the groups in this tissue (Figure 15A). However, 
the treatment with rhNRG1 attenuated the expression of HK2 mRNA and significantly 
reduced its gene expression in comparison with the MCT-induced PAH non-treated animals 
(Figure 15B). No differences were noticed in mRNA expression of PFKm, involved in the 
production of fructose 1,6-phosphate an allosteric activator of PK, between CTRL and MCT-
induced PAH groups (Figure 15C). The PKm, which is involved in the formation of pyruvate 
C 
A 
B 
Figure 14 No alterations on glucose transporters (GLUT) 1 and 4 and hypoxia inducible factor 1α (HIF-1α) have 
been evidenced in soleus muscle of MCT-induced PAH animals. CTRL: control group; MCT: monocrotaline group; 
GAPDH: glyceraldehyde 3-phosphate dehydrogenase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
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when activated by PFK, followed the same pattern of expression of PFKm, with no 
expression alterations between the experimental groups studied (Figure 15D).  
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 mRNA expression of each subunit of LDH complex, which is involved in lactate 
production, was evaluated. No significant changes were found in the expression of mRNA 
from LDHa (Figure 16A), LDHc (Figure 16C) or LDHd (Figure 16D) subunits. However, 
the treatment with rhNRG1 significantly decreased LDHb mRNA expression (Figure 16B) 
in soleus muscle from MCT-induced PAH animals.  
Figure 15 rhNRG1 attenuated the overexpression of hexokinase 2 (HK2) in soleus muscle of MCT-induced PAH 
animals. CTRL: control group; MCT: monocrotaline group; PFKm: muscle type phosphofructokinase; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; PKm: muscle type pyruvate kinase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
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 From the analysis of PDH in soleus muscle, who is responsible for catalyse pyruvate 
into acetyl-CoA and CO2
200,201, no expression changes were found in both subunits PDHa1 
(Figure 17A) or PDHβ (Figure 17B).  
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Figure 16 rhNRG1 reduced the expression of lactate dehydrogenase b (LDHb) in soleus muscle from MCT-
induced PAH animals. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group.  *P<0.05 vs. CTRL-BSA. Two-way ANOVA was used for all the parameters presented. 
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Figure 17 No alterations on pyruvate dehydrogenase complex (PDH) have been identified in soleus muscle of 
MCT-induced PAH animals. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
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 Relatively to mitochondrial function genes that were analysed, no changes were 
observed in the expression of PGC-1α in the soleus muscle of the four different experimental 
groups (Figure 18A). Neither NRF1 that regulates mitochondrial respiration233 (Figure 18B) 
or Sirt1 that controls PGC-1α219 (Figure 18C) presented variations between the MCT-
induced PAH or control groups in this tissue.  
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b. mRNA expression on RV 
 Most of significant variations in gene expression were detected in RV tissue.  
 As expected, MCT-induced PAH resulted in a significant increase in mRNA 
expression of GLUT1 in MCT-BSA group, which has been attenuated by rhNRG1 in MCT-
treated animals (Figure 19A). There was also a significant decrease in GLUT4 mRNA 
expression in MCT-BSA group when compared with CTRL-BSA, which was significantly 
reversed by the treatment with rhNRG1 in MCT animals (Figure 19B). The HIF-1α mRNA 
expression significantly increased in MCT-BSA animals (Figure 19C). MCT-BSA animals 
Figure 18 There were no changes in mitochondrial function genes in soleus muscle of MCT-induced PAH 
animals. CTRL: control group; MCT: monocrotaline group; PGC-1α: peroxisome proliferator-activated receptor 
gamma coactivator 1α; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; NRF1: nuclear respiratory factor 1; 
Sirt1: sirtuin 1. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
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demonstrated significantly increased levels of BNP mRNA expression (Figure 19D). In 
relation to ET-1 mRNA expression, a vasoconstrictor, there were no significant changes 
between the CTRL and MCT-induced PAH groups (Figure 19E). 
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 The mRNA levels of HK1 presented greater expression in both MCT groups when 
compared with CTRL-BSA group (Figure 20A). MCT-induced PAH animals displayed an 
increased mRNA expression of HK2 when comparing with CTRL-BSA group, and the 
Figure 19 rhNRG1 treatment induced significant alterations on glucose transporters (GLUT) 1 and 4, hypoxia 
inducible factor 1α (HIF-1α) and brain natriuretic peptide (BNP) mRNA expression in right ventricle (RV) of 
MCT-induced PAH animals. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase; ET-1: endothelin-1. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. *P<0.05 vs. CTRL-BSA; **P<0.01 vs. CTRL-BSA; #P<0.05 vs. MCT-BSA; ###P<0.001 vs. MCT-BSA. Two-
way ANOVA was used for all the parameters presented. 
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treatment with rhNRG1 increased the expression of HK2 mRNA in MCT-induced PAH 
treated animals in comparison with CTRL-treated group (Figure 20B).  
 In MCT-BSA group a significant decrease in PFKm mRNA expression was found 
when compared with CTRL-BSA group (Figure 20C). The PKm mRNA expression 
significantly increased in MCT-induced PAH animals, being the most marked increase in 
the group of PAH animals treated with rhNRG1 (Figure 20D).  
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 No significant changes were detected in the expression of mRNA from LDHb (Figure 
21A) or LDHd (Figure 21B).  
 
 
Figure 20 rhNRG1 modulated the expression of glycolysis rate-limiting enzymes in right ventricle (RV) of MCT-
induced PAH animals. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-phosphate 
dehydrogenase; HK: hexokinase; PFKm: muscle type phosphofructokinase; PKm: muscle type pyruvate kinase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. *P<0.05 vs. CTRL-BSA; #P<0.05 vs. MCT-BSA. Two-way ANOVA was used for all the parameters presented. 
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 In the RV tissue, as in the soleus muscle, no significant changes were reported in the 
expression of both PDHa1 (Figure 22A) and PDHβ (Figure 22B). 
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 From the gene analysis in RV, no significant changes were observed in the gene 
expression of the mitochondrial function genes analysed, namely PGC-1α (Figure 23A), 
NRF1 (Figure 23B) or Sirt1 (Figure 23C) between the MCT-induced PAH or control groups.  
 
 
A B 
A B 
Figure 22 No significant alterations on pyruvate dehydrogenase complex (PDH) have been identified in right 
ventricle (RV) of MCT-induced PAH animals. CTRL: control group; MCT: monocrotaline group; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
 
 
Figure 21 No significant changes on mRNA expression of lactate dehydrogenase (LDH) in right ventricle (RV) 
from MCT animals were found. CTRL: control group; MCT: monocrotaline group; GAPDH: glyceraldehyde 3-
phosphate dehydrogenase. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. *P<0.05 vs. CTRL-BSA. Two-way ANOVA was used for all the parameters presented. 
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c. Correlation of RV gene expression from glycolytic pathway genes with morphometric and 
echocardiographic parameters  
 The correlation between the genes with significant changes in RV and morphometric 
and echocardiographic parameters was also performed. The results presented refer only to 
the variables that presented significant correlations with each other.  
 GLUT1 expression is correlated with morphometric and echocardiographic 
parameters. It was verified that there is a positive and strong correlation between GLUT1 
and Fulton index (r = 0.618, p<0.001) (Figure 24A), once both are increased in MCT-
induced rhNRG1 non-treated animals, associating this gene to the increase in the RV area 
and RVH.281 The GLUT1 and TAPSE displayed a negative correlation (r = -0.5284, p<0.05) 
(Figure 24B), also reflecting RV dysfunction. The correlation between GLUT1 and CO is 
negative and strong (r = -0.7322, p<0.001), once as the disease progresses the GLUT1 
increases and the CO decreases (Figure 24C). 
Figure 23 There were no changes in mitochondrial function genes mRNA expression in right ventricle (RV) of 
MCT-induced PAH animals. CTRL: control group; MCT: monocrotaline group; PGC-1α: peroxisome proliferator-
activated receptor gamma coactivator 1α; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; NRF1: nuclear 
respiratory factor 1; Sirt1: sirtuin 1. 
Bars represent mean ± SEM of 10 rats per CTRL+BSA group, 20 rats per MCT group and 15 rats per MCT+rhNRG1 
group. Two-way ANOVA was used for all the parameters presented. 
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 GLUT4 gene expression correlated negatively with Fulton index since they have 
opposite behaviours in PAH, but without statistical significance (r = -0.2414, p ns) (Figure 
25A). The correlation between GLUT4 and TAPSE was positive and significant (r = 0.6528, 
p<0.05) (Figure 25B). Regarding to the correlation between GLUT4 and CO, it was no 
significant (r = 0.1964, p ns) (Figure 25C).  
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 HIF-1α gene expression is positively correlated with Fulton index (r = 0.4840, 
p<0.05), what relates HIF-1α with the presence RVH (Figure 26A). There was no significant 
correlation between HIF-1α and TAPSE (r = -0.3991, p ns) (Figure 26B). Relatively to the 
correlation between HIF-1α and CO, this is negative (r = -0.5324, p<0.05) (Figure 26C).  
Figure 24 Glucose transporter 1 (GLUT1) mRNA expression is corelated with Fulton index, tricuspid annular 
plane systolic excursion (TAPSE) and cardiac output (CO). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
 
 
 
 A (Y = 6,862*X - 0,1583) B (Y = -19,59*X + 7,316) C (Y = -0,05923*X + 7,276) 
 
Figure 25 Glucose transporter 4 (GLUT4) mRNA expression is corelated with Fulton index, tricuspid annular 
plane systolic excursion (TAPSE) and cardiac output (CO). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
 
A (Y = -0,4271*X + 0,9368) B(Y = 2,9*X + 0,02345) C(Y = 0,001997*X + 0,5625) 
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 The existence of correlation between GLUTs and HIF-1α was also assessed. GLUT1 
gene expression is negatively correlated with GLUT4 expression, as expected (r = -0.4326, 
p<0.05), what reveals a potential compensation mechanism in PAH (Figure 27A). On the 
other hand, the correlation between GLUT1 and HIF-1α is positive and strong (r = 0.7264, 
p<0.001) (Figure 27B). Relatively to the correlation between GLUT4 and HIF-1α, it has no 
statistical significance (r = -0.262, p ns) (Figure 27C).  
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 HKs demonstrated to be only correlated with TAPSE. HK1 gene expression is 
negatively correlated with TAPSE (r = -0.6318, p<0.01) (Figure 28A). The correlation 
between HK2 and TAPSE is also negative (r = -0.5222, p<0.05) (Figure 28B). 
Figure 26 The increased mRNA expression of hypoxia inducible factor (HIF-1α) is correlated with Fulton index, 
tricuspid annular plane systolic excursion (TAPSE) and cardiac output (CO). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
 
 
Figure 27 Glucose transporter 1 (GLUT1) mRNA expression is correlated with GLUT4 and with hypoxia 
inducible factor (HIF-1α).  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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 PFKm gene expression is negatively correlated with the Fulton index (r = -0.5961, 
p<0.001), relating this gene with the RVH (Figure 29A). We also found a positive correlation 
between PFKm and TAPSE (r = 0.6377, p<0.01) (Figure 29B), what reinforces the previous 
correlation.  
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 The PKm gene expression is positively correlated with Fulton index (r = 0.5666, 
p<0.01) (Figure 30A), which may reveal the involvement of this gene in the development of 
disturbances in glucose metabolism that may trigger RVH. Concerning to the correlation 
between PKm and TAPSE, it is negative (r = -0.5527, p<0.05) (Figure 30B). The correlation 
between PKm and CO is also negative (r = -0.475, p<0.05) (Figure 30C), which is in 
agreement with the other correlations obtained for this gene.  
Figure 28 Both hexokinase 1 and 2 (HK1 and HK2) are correlated with the tricuspid annular plane systolic 
excursion (TAPSE).  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
Figure 29 Phosphofructokinase muscle type (PFKm) mRNA expression is correlated with both Fulton index 
and the tricuspid annular plane systolic excursion (TAPSE). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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 Despite the absence of changes in LDH mRNA expression in the RV of animals with 
MCT-induced PAH, LDHb mRNA expression is positively correlated with TAPSE (r = 
0.5628, p<0.05) (Figure 31A). Relatively to the correlation between LDHd and Fulton Index, 
this is negative (r = -0.3878, p<0.05) (Figure 31B). On the other hand, the correlation 
between LDHd and TAPSE is positive and strong (r = 0.6756, p<0.01) (Figure 31C).  
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Figure 30 The increased mRNA expression of pyruvate kinase muscle type (PKm) is correlated with Fulton 
index, tricuspid annular plane systolic excursion (TAPSE) and cardiac output (CO). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
Figure 31 Lactate dehydrogenase b (LDHb) mRNA expression is correlated with tricuspid annular plane 
systolic excursion (TAPSE), while LDHd is correlated with both Fulton index and TAPSE.  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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 Although there were no differences in mRNA expression between experimental 
groups, PDHb is correlated with CO and their correlation is positive (r = 0.463, p<0.05) 
(Figure 32). 
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 Despite there were no changes in the IRS1 mRNA expression in the RV between 
experimental groups, its gene expression is negatively correlated with Fulton index (r = -
0.4743, p<0.01) (Figure 33A), which may reveal the involvement of this gene in disturbances 
in glucose transport and metabolism that may trigger RVH. The correlation between IRS1 
and CO is positive (r = 0.5401, p<0.05) (Figure 33B). 
 The correlation between IRS2 and TAPSE is negative (r = -0.5384, p<0.05) (Figure 
33C).  
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Figure 32 Pyruvate dehydrogenase β (PDHβ) mRNA expression is correlated with cardiac output (CO).  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
 
 
Figure 33 The insulin receptor 1 (IRS1) mRNA expression is correlated with both Fulton index and cardiac 
output (CO), while mRNA expression of IRS2 is correlated with tricuspid annular plane systolic excursion 
(TAPSE).  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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 We also verified that PGC-1α mRNA expression displays a positive correlation 
with CO (r = 0.4923, p<0.05) (Figure 34). 
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d. Correlation of RV markers of disease gene expression, BNP and ET-1, with 
morphometric and echocardiographic parameters  
 The presented results only refer to the variables that presented significant correlations 
with each other. 
 BNP expression is strongly correlated with morphometric and echocardiographic 
parameters. There was a strong positive correlation with Fulton index (r = 0.6308, p<0.001) 
(Figure 35A), evidencing its role in RVH. The BNP and TAPSE exhibited a negative 
correlation (r = -0.6719, p<0.01) (Figure 35B), that also reflect the involvement of these two 
variables in RVD. Furthermore, the correlation between BNP and CO is negative (r = -
0.5479, p<0.05) (Figure 35C).  
 
0 .0 0 .2 0 .4 0 .6 0 .8 1 .0
0
2 0
4 0
6 0
F u lto n  In d e x
B
N
P
/G
A
P
D
H
 (
A
U
)
r= 0 .6 3 0 8 ; p = 0 .0 0 0 7
 
0 .1 0 .2 0 .3 0 .4
-2 0
0
2 0
4 0
6 0
T A P S E
B
N
P
/G
A
P
D
H
 (
A
U
)
r= -0 .6 7 1 9 ; p = 0 .0 0 4 4
5 0 1 0 0 1 5 0
-2 0
0
2 0
4 0
6 0
C O
B
N
P
/G
A
P
D
H
 (
A
U
)
r= -0 .5 4 7 9 ; p = 0 .0 2 2 8
 
 
 
Figure 34 Peroxisome proliferator-activated receptor gamma coactivator 1α (PGC-1α) mRNA expression is 
correlated with cardiac output (CO).  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
Figure 35 The increased mRNA expression of brain natriuretic peptide (BNP) is correlated with Fulton index, 
tricuspid annular plane systolic excursion (TAPSE) and cardiac output (CO). 
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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 Ultimately, ET-1 mRNA also was found to be related with Fulton index and their 
correlation is positive (r = 0.4972, p<0.01) (Figure 36). 
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Figure 36 The increased levels of endothelin-1 (ET-1) are correlated with Fulton index.  
Data used for the correlation analysis were obtained from animals that had both echocardiographic and mRNA analysis. 
Correlations were determined using Pearson correlation test. 
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2. Metabolic Changes in the Development of Pulmonary Arterial Hypertension in 
Hypoxia/Sugen model  
a. Morphometric characterization of Hypoxia/Sugen model 
 The chronic hypoxia exposure resulted in a decrease of BW in H/S animals, in 
comparison with N animals (N: 401±12,78g; H/S: 328±11,49g) (Figure 37A). The indicator 
for RVH, Fulton index, was significantly increased in H/S group in comparison with H and 
N animal group (Figure 37B). The Lung/TL ratio was also increased in hypoxia animal 
group, being evidenced and significant in H group (Figure 37C). The RV weight of H/S 
animals presented a sharp increase in relation to H animals, meaning that RV was 
significantly dilated and remodelled in this animal group (Figure 37D).          
 
N o r m o x ia H yp o x ia
0
1 0 0
2 0 0
3 0 0
4 0 0
5 0 0
B
W
 (
g
)
D M S O
S u g e n
*
    N o r m o x ia H yp o x ia
0 .0
0 .2
0 .4
0 .6
0 .8
F
u
lt
o
n
 I
n
d
e
x
B S A
S u g e n
**
# #
 
 
N o r m o x ia H yp o x ia
0 .0 0
0 .0 2
0 .0 4
0 .0 6
L
u
n
g
/T
L
 (
g
/c
m
)
B S A
S u g e n*
 N o r m o x ia H yp o x ia
0 .0 0 0
0 .0 0 5
0 .0 1 0
0 .0 1 5
R
V
/T
L
 (
g
/c
m
)
B S A
S u g e n
*
# #
 
 
 
 
 
b. mRNA expression in gastrocnemius muscle 
 The differences between the groups in study are notorious in what concerns 
molecular alterations. The mRNA levels of GLUT1 in gastrocnemius muscle are 
A B 
C D 
Figure 37 The hypoxia/Sugen5416 animal model reproduced the morphometric conditions verified in MCT-
induced PAH. BW: body weight; TL: tibial length; RV: right ventricle. 
Bars represent mean ± SEM of 2 rats per each normoxia group, 3 rats per hypoxia group and 4 rats per 
hypoxia/Sugen5416 group for the morphometric data. *P<0.05 vs. N+BSA; **P<0.01 vs. N+BSA; ##P<0.01 vs. 
H+BSA. Two-way ANOVA analysis of variance with Tukey’s posttest was used for all the parameters presented. 
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significantly decreased in hypoxia-induced PAH animals when compared to the H/S-induced 
PAH group (Figure 38A). However, the GLUT4 mRNA expression was not altered between 
the different animal groups (Figure 38B). No significant differences were found on the 
mRNA expression of HIF-1α (Figure 38C) and PGC-1α (Figure 38D) between the different 
groups.  
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c. mRNA expression in lung 
 In the lung were not detected differences in GLUT1 mRNA expression between the 
hypoxia-induced PAH and N animal group (Figure 39A), as well as no differences in GLUT4 
mRNA expression were found between the three different groups (Figure 39B). However, it 
occurred a significant increase in HIF-1α in H/S-induced PAH animals when compared with 
the N group (Figure 39C), and PGC-1α followed a similar pattern of expression and 
significantly increased in H/S when compared to N group (Figure 39D).  
A 
Figure 38 Glucose transporter 1 (GLUT1) presented altered mRNA expression in gastrocnemius muscle in 
hypoxia/Sugen model. N: normoxia group; H/S: hypoxia/Sugen5416 group; H: hypoxia group; GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; HIF-1α: hypoxia inducible factor 1α; PGC-1α: peroxisome proliferator-
activated receptor gamma coactivator 1α.  
Bars represent mean ± SEM of 4 rats per normoxia group, 3 rats per hypoxia group and 4 rats per hypoxia/Sugen5416 
group. *P<0.05 vs. H/S. One-way ANOVA nonparametric analysis of variance with Tukey’s posttest was used for all 
the parameters presented. 
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d. mRNA expression in RV 
 In the same way as it occurred in MCT model, the RV is the tissue where most of the 
metabolic alterations were detected. The GLUT1 mRNA expression is significantly 
increased in H/S animal group when compared to N group, while the hypoxia-induced PAH 
group displayed GLUT1 levels considerably lower when comparing to hypoxia/Sugen-
induced PAH animal group (Figure 40A). Relatively to GLUT4 mRNA expression, it was 
significantly decreased in H/S animals when compared to N animals (Figure 40B). In the 
same way as it was occurred in the other analysed tissues, HIF-1α (Figure 40C) and PGC-
1α (Figure 40D) followed a similar pattern of expression and exhibited significantly decrease 
in hypoxia/Sugen-induced PAH animals when compared with the N group.  
C D 
Figure 39 Hypoxia inducible factor 1α (HIF-1α) and peroxisome proliferator-activated receptor gamma 
coactivator 1α (PGC-1α) presented altered mRNA expression in lungs from the animals of hypoxia/Sugen5416 
model. N: normoxia group; H/S: hypoxia/Sugen5416 group; H: hypoxia group; GLUT: glucose transporter. 
Bars represent mean ± SEM of 4 rats per normoxia group, 3 rats per hypoxia group and 4 rats per hypoxia/Sugen5416 
group. *P<0.05 vs. N. One-way ANOVA nonparametric analysis of variance with Tukey’s posttest was used for all 
the parameters presented. 
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2.1. Metabolic Changes in the Development of Pulmonary Arterial Hypertension in 
Hypoxia/Sugen model - Effects of the treatment with Neuregulin-1 
a. Oral glucose tolerance test  
 As in MCT model, in chronic hypoxia model fasting plasma glucose presented 
similar values between two animal groups in study, H/S+BSA and H/S+rhNRG1 group, 
without variations between groups (Figure 41A). However, when comparing H/S+BSA with 
H/S+rhNRG1 animal group, the first one presented significant greater blood glucose 
concentrations for time points between 15 and 120 min (Figure 41B). Unlike what occurred 
in the MCT model, there is also a tendency for higher postprandial glucose concentrations 
in rhNRG1 treated animal group when compared with H/S+BSA animals, as AUC 
demonstrates with statistical significance (Figures 41B and 41C).  
C D 
Figure 40 The mRNA expression changes are evident in RV from rats of hypoxia model. N: normoxia group; HS: 
hypoxia/Sugen 5416 group; H: hypoxia group; GAPDH: glyceraldehyde 3-phosphate dehydrogenase; GLUT: glucose 
transporter; HIF-1α: hypoxia inducible factor 1α; PGC-1α: peroxisome proliferator-activated receptor gamma 
coactivator 1α. 
Bars represent mean ± SEM of 4 rats per control group, 3 rats per hypoxia group and 4 rats per hypoxia/Sugen5416 
group. *P<0.05 vs. N; #P<0.05 vs. H/S. One-way ANOVA nonparametric analysis of variance with Tukey’s posttest 
was used for all the parameters presented. 
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b. mRNA expression in RV from hypoxia rhNRG1 treated animals 
 Contrary to what was verified in the mRNA analysis of the RV of the MCT model 
and was expected, GLUT1 mRNA expression in RV is significantly increased in 
H/S+rhNRG1 treated animal group when compared to H/S+BSA group (Figure 42A). 
Relatively to GLUT4 mRNA expression, it was significantly decreased in H/S+rhNRG1 
animals when compared to H/S+BSA animals (Figure 42B) and, once again, occurred a 
discrepancy between hypoxia and the MCT model, but also with what was expected in the 
animals treated with rhNRG1. The levels of NRG1 mRNA expression on RV were also 
decreased in H/S+rhNRG1 animal group comparing to H/S+BSA animals (Figure 42C). 
 
A 
C B 
Figure 41 rhNRG1 attenuated whole-body glucose tolerance in hypoxia animals. H/S+BSA: hypoxia/Sugen5416 
animals with bovine serum albumin (BSA) group; H/S+rhNRG1: hypoxia/Sugen5416 animals treated with 
recombinant human neuregulin-1 (rhNRG1). 
Bars represent mean ± SEM of 5 rats per H/S+BSA group and 5 rats per H/S+rhNRG1 group for the OGTT. *p<0.05 
vs H/S+BSA. 
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C 
Figure 42 The mRNA expression was altered by rhNRG1 treatment in hypoxia/ Sugen 5416 animal model of 
pulmonary arterial hypertension (PAH). H/S+BSA: hypoxia/Sugen5416 animals with bovine serum albumin (BSA) 
group; H/S+rhNRG1: hypoxia/Sugen5416 animals treated with recombinant human neuregulin-1 (rhNRG1); GAPDH: 
glyceraldehyde 3-phosphate dehydrogenase; GLUT: glucose transporter; HIF-1α: hypoxia inducible factor 1α; PGC-
1α: peroxisome proliferator-activated receptor gamma coactivator 1α. 
Bars represent mean ± SEM of 5 rats per H/S+BSA group and 5 rats per H/S+rhNRG1 group. *P<0.05 vs. H/S+BSA. 
One-way ANOVA nonparametric analysis of variance with Tukey’s posttest was used for all the parameters presented. 
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Discussion 
 This study provided data on the pathophysiological alterations and molecular 
changes on glucose metabolism resultant from the development of PAH, as well as the 
effects of the treatment with NRG1. The study was conducted in two well characterized rat 
models of PH: the MCT and the chronic hypoxia models.   
 
1. Metabolic changes in the development of PAH in monocrotaline model and effects 
of the treatment with rhNRG1  
a. MCT-induced PAH markers and glucose transporters expression vary according to the 
disease state   
 The RV is the main prognostic determinant in PAH.37,38 Despite the continuum 
remodelling in RV as the disease progresses, it is normal to proceed to the differentiation of 
two patterns of ventricular remodelling and hypertrophy based on morphometric, 
echocardiographic and molecular characteristics. In our study, we defined a RVEF of 35% 
to differentiate this two patterns: the animals with adaptive remodelling/hypertrophy that 
displayed CRV function, with normal to mildly decreased RVEF, above 35%, in comparison 
to healthy animals, and the ones with maladaptive remodelling hypertrophy, who displayed 
DRV function, with RVEF below 35% and sharply decreased comparing with healthy 
animals.27 The decrease in RVEF in DRV animal group may also be associated with an 
increase in RV wall stress and in RV diameter.278,282 These findings are in accordance with 
the information provided in a study in MCT-induced PAH that characterized the RV function 
in rats, where the animal groups were divided according two different doses of MCT 
injection, a lower dose of 30mg/kg of BW (MCT30) and a higher dose of 80 mg/kg of BW 
(MCT80). The authors concluded that the animal group with the lower dose of MCT 
displayed a compensatory RVH and a lesser reduction in RVEF in comparison with the 
animal group treated with the higher dose of MCT, whose RVEF was significantly decreased 
comparing with control and MCT30 group, being  RVH more evident  MCT80 group.282 
 The metabolic switch from mitochondrial OXPHOS to glycolysis that characterizes 
PAH is defined in the compensated phase of RVH.35,39 The increase in HIF-1α expression 
and activity in DRV in relation to CRV phase, which was also documented by other authors, 
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is related with the development and establishment of an hypoxic environment and 
hypertrophy of the RV, and triggers for itself an increase in GLUT1 mRNA expression to 
increase glucose uptake35,42,173, and the HIF-1α activation and increased expression is an 
evidence for the metabolic switch from mitochondria-based GO to a glycolytic phenotype, 
the Warburg effect.35,147 In fact, we verified an increment in HIF-1α mRNA expression in 
DRV group in relation to both control and CRV groups, what reinforces the development of 
hypoxia conditions and RVH in the animals of this group, which are characteristics of PAH 
development.  
 The transition from CRV to DRV is also marked by variations of indicators of cardiac 
function, ET-1 and BNP, that are related with overload and hypertrophy.86,279 We identified 
an increase in circulating vasoconstrictors as ET-1 and observed an increase in the mRNA 
expression of this gene DRV group. A study that analysed RV from both MCT-induced PAH 
rats and human samples, identified an increase in ET-1 production in the samples from 
hypertrophied RV, and discovered that this may be implicated in the maintaining of 
cardiomyocyte survival due to its inotropic effects. The same study also proposed that the 
modulation of ET-1 receptors is responsible for a decrease in RV afterload by the reversal 
of PA obstruction and remodelling101, what evidenced the role of ET-1 in RVH development. 
Furthermore, the levels of BNP also accompanied the molecular alterations identified at the 
RV level, contributing to an increased myocardial stress and injury in this group86 as it was 
previously described in the analysis of the RVEF. Since cardiac BNP mRNA expression is 
markedly upregulated in response to RVH or overload32, this contributed to the 
establishment of the disease phenotype and confirmed the role of MCT in the development 
of PAH characteristics. In addition, the studies mentioned above support, in part, our 
findings and is in accordance with the morphological analysis that we performed, and which 
indicates for the presence of hypertrophy in RV from the DRV group.   
 The regulation of intracellular and extracellular levels of glucose depends on levels 
of expression of GLUT proteins, that are variable as the disease progresses153,179 and the 
increase in glucose uptake and utilization that follows cardiac hypertrophy may occur as a 
cardioprotective mechanism.211 In RVH, the increase in glucose uptake for glycolysis is 
achieved with the compensated expression and activity of GLUTs, as the GLUT1, in order 
to maintain the energy supply, accompanied by an increase in PDH phosphorylation.39,44,192 
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The expression of GLUT1, which is expressed in foetal heart and whose expression is re-
induced in the adult heart in some pathophysiological states180,211, and GLUT4, as it is the 
major isoform of insulin-dependent GLUT in human heart182 were assessed. In our study 
and as expected, GLUT1 presented increased expression in both MCT groups being more 
evidenced in DRV group, which can be explained by the development of RVH.212 Based on 
the results obtained, we could verify that there is an increase in GLUT1 mRNA expression 
as the cardiac hypertrophy develops and the RV progresses from a compensated to a 
decompensated state. This may occur due the less efficient ATP production by glycolysis, 
as it triggers lactate production rather than pyruvate, and does not fuels Krebs’ cycle, giving 
rise to the metabolic switch, the Warburg effect.192,212 In its turn, the decrease in GLUT4 
expression levels was also related with the development of cardiac hypertrophy and with the 
transition to the decompensated state215, as we verified. Still, a study in RV MCT-induced 
remodelling documented an increase in GLUT4 mRNA expression183, however, it is known 
that the expression levels of this transporter fluctuate according with the disease state and 
severity.215 
 
 
b. GLUT1 and GLUT4 expression is correlated with cardiac markers of disease 
The reactivation of components of the foetal gene package during RV remodelling 
and hypertrophy42, provides useful information to establish some comparisons between the 
GLUTs and markers of disease. The obtained results showed a negative correlation between 
GLUT1 mRNA expression and RVEF, as expected according with the literature information, 
that reports a downregulation of GLUT1 after birth.153 However, the GLUT4 correlation 
with RVEF is positive, indicating proportionality between them, once both have decreased 
activity in animals of the DRV group, but also due to the fact that the hypertrophied heart 
acts as the foetal heart. In addition to GLUT4 expression, the values of RVEF are also lower 
in hypertrophied right heart283, which also contributes to the positive correlation between 
them.  
We also found that GLUT1 gene expression is positively correlated with the 
expression of HIF-1α, what is in accordance with the information that the increased 
expression of HIF-1α transcriptionally upregulates GLUT1 and glucose uptake in situations 
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of RVH.284 Furthermore, as cancer cells exhibit the same metabolic pattern of PAH 
characterized by high rates of glucose consumption and glycolysis, and once hypoxia plays 
a crucial role in the cancer cells proliferation, the expression of GLUT1 has revealed to be 
regulated by hypoxia conditions in a HIF-1α-dependent manner285, explaining the similar 
pattern of expression that we obtained.  
The correlation between GLUT4 expression and cardiac functional markers, ET-1 
and BNP was also established. Both correlations were negative, since the decrease in GLUT4 
expression is accompanied by increased expression of ET-1 and BNP due the development 
of RVH and overload. 
 
c. Treatment with rhNRG1 modulated the morphophysiological changes in monocrotaline-
induced PAH 
 Although we found a significant decrease in the BW of the animals due to MCT-
induced PAH consistent with other works183,282, the treatment with rhNRG1 did not 
attenuated this decrease in BW observed in the MCT animal group. 
 According with Fulton et al., (1952) “ventricular hypertrophy is estimated by 
weighing the heart as a whole and by measuring the thickness of the ventricular walls”.286 
The rhNRG1 treatment attenuated RV hypertrophy induced by MCT, as shown by the 
decreased Fulton index and the RV/TL ratio in MCT-induced PAH rhNRG1 treated animals. 
Due to the persistent increase on afterload caused by the progression of the disease and RVH, 
the wall stress increases at the same time and the RV becomes thicker due the accumulation 
of muscle mass287, which leads to an increase in its weight.  rhNRG1 treatment also 
attenuated the increased weight of lungs due to the development of marked pulmonary 
oedema in MCT-induced PH, a side effect of MCT. The previous findings are also in 
agreement with other investigations on MCT-induced PAH animals from our group, were 
the treatment with rhNRG1 displayed beneficial effects at structural level, namely in the 
reduction of the hypertrophy and dilatation of RV.99 
 The information provided by the PAVTI and PAAT/PAET echocardiographic 
parameters, allowed us to verify that the rhNRG1 treatment ameliorated the alterations on 
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PA blood flow induced by MCT, through the recovery of the pulmonary circulation on those 
animals by attenuating vascular remodelling.99 A decrease in both parameters due to MCT-
induced PAH was also verified in other two works of our group in the same animal model 
and is indicative of PA dysfunction.99,288 Furthermore, the PAAT/PAET ratio is related with 
RV dilatation and hypertrophy, taking lower values as the degree of hypertrophy 
progresses275,289, allowing us to say that the animals from MCT-induced PAH group 
developed RVH and that the MCT administration had the desired effects. Beyond being 
associated to the disease severity, the reduction of PAAT may be related with the decrease 
in capacitance and an increase in impedance of the pulmonary vascular bed, that causes a 
deceleration of blood flux at early systole.275,289 Moreover, the increased stiffness of PA may 
also be a cause for short PAAT.275 The inner RV diameter (RVIDd), assessed to verify 
ventricular dysfunction270, was also increased MCT animals and attenuated by NRG1, which 
is in line with earlier findings of the role of NRG1 in restoring RV function.99  
 Concerning to TAPSE, a marker for systolic RV function281,290 related with the RV 
contractility capacity249, it was also decreased in MCT group constituting an evidence for 
RV decompensation. However, the effects of rhNRG1 did not attenuated this decrease. 
Usually, the decrease in the displacement of the tricuspid ring towards the apex of the RV 
during systole, occurs as a consequence of RVH, once in this state the radial forces 
increasingly contribute to maintain RVEF and to wall stress, what may be an explanation for 
the decrease in TAPSE.269 Furthermore, the elliptical deformation of the tricuspid valve 
supporting structures due to RVH that occurs in PAH, predispose the patients to tricuspid 
valve leaflet tenting that triggers tricuspid regurgitation.291 The reflux of blood by the 
tricuspid valve at each systole is a condition that affects about 60% of patients with severe 
symptomatic idiopathic PAH, which is also associated with adverse RV remodelling and 
worst outcome of the disease.291,292  
 So, the treatment with rhNRG1 attenuated the severity of this disease, as it evidenced 
from the beneficial effects of rhNRG1 on PA and RV remodelling and in overall cardiac 
function. Beneficial effects of rhNRG1 were evident both at the functional and at the 
structural level. An experiment that evaluated the expression of NRG receptors ErbB2 and 
ErbB4 revealed that in failing human heart myocardium the expression of this receptors is 
downregulated due to their reduced phosphorylation.261 These findings may constitute a 
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reason for the phenotype observed in the animals treated with rhNRG1, once it is known that 
the signalling cascades as the MAPK or PI3K/Akt pathways activation depends on 
NRG1/ErbB system and its activation by phosphorilation.241,242,244 
 
d. rhNRG1 regulated systemic glucose concentration in MCT-induced PAH 
 The suppression of mitochondrial GO and the subsequent increase in glycolysis, due 
to hypoxia conditions in PAH, constitutes an hallmark of the increased glucose metabolism 
in cases of cardiac hypertrophy and in remodelled RV, being also associated with the 
impairment of RV function.147,178,192  
 The OGTT allowed the acquisition of essential data to evaluate the systemic glucose 
metabolism and the detection of glucose intolerance in healthy and diseased animals. The 
fasting blood glucose analysis was performed to evaluate if the all animals are in the same 
conditions and were fasted at the beginning of the test. As no differences were found between 
MCT-induced PAH animals and non-diseased control animals, it means that all of them are 
in the same conditions at the beginning of the test. If differences were detected in this 
parameter, as an increase of fasting blood glucose in MCT animal group, we would be 
dealing with hyperinsulinemia and impaired glucose metabolism.178  
 After the oral glucose load, glucose values increased in all animals from all the 
experimental groups. However, the metabolization of glucose administered was slower in 
MCT-induced PAH animals compared with MTC rhNRG1-treated group, as expected. 
Furthermore, blood glucose concentrations did not fall to baseline levels after the 120 
minutes as it was supposed, pointing to an the presence of a insulin resistant phenotype293 in 
both MCT-induced PAH groups. Based on these results, we can conclude that in our study, 
the MCT animals demonstrated insulin resistance and that rhNRG1 treatment reduced 
insulin resistance in MCT animals, but not for CTRL group values. 
 Glucose response in each group was given by the area under the curve (AUC) 
obtained from the postprandial glucose test, which represents an index of whole glucose 
excursion after glucose loading that allows the acquisition of glycaemic index.294 From this 
analysis we obtained that the AUC in the MCT-induced PAH group was significantly 
increased in comparison with the control individuals, indicating the existence of insulin 
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resistance in this animal group. However, the treatment with rhNRG1 influenced the whole-
body glucose metabolism and the MCT animals treated with rhNRG1 demonstrated a 
significant improvement in glucose tolerance following oral glucose loading, what turns our 
study consistent results are consistent with studies showing improved glucose uptake in 
animals treated with NRG1. Although the studies that correlate insulin resistance with PAH 
are scarce, our findings are in accordance with a recent study from Heresi et al., that 
evaluated the glucose tolerance and the insulin resistance in humans with IPAH, and 
concluded that the individuals with IPAH had a higher rate of impaired glucose tolerance.178 
In an in vivo model of diabetes/dyslipidaemia in mice, the acute treatment with NRG1 also 
improved glucose tolerance in fasted mice, and in conditions of glucose intolerance the 
NRG1 markedly reduced the glycaemic response, reducing the AUC.295 Furthermore, an in 
vitro study that evaluated the effects of the treatment with NRG1 in glucose tolerance in 
adult and old rats, revealed that the treatment with NRG1 improved the glucose tolerance in 
both groups256, demonstrating the same effects of NRG1 in glucose metabolism as ours. This 
effects of NRG1 may be due to his role on the modulation of glucose uptake, as NRGs may 
induce the GLUTs translocation to plasma membrane in muscle cells, especially GLUT4, 
exerting a role similar to insulin.241,242 At least, in a study in a model of breast cancer on 
L6E9 muscle cells in rats, the treatment with NRG1 induced the translocation of GLUT4 to 
the plasma membrane via the ErbB3/PI3K-dependent signalling pathway to the same extent 
as insulin, what increased the glucose uptake. In the same study samples of soleus muscle 
were incubated in the absence or presence of NRG and/or insulin, and NRG treatment 
significantly increased glucose uptake due to effects on glucose transport by modulation of 
GLUTs.249  
 mRNA levels of IRS 1 and 2 are also related with insulin resistance. While we did 
not detected differences in their expression in RV, their expression in the soleus muscle has 
followed a different pattern. In the soleus muscle from MCT non-treated group, we found 
decreased IRS1 and IRS2 mRNA expression in comparison with control group. As the IRS1 
and IRS2 play a role in the mediation of insulin action in peripheral tissues230 these results 
are in agreement with the OGTT results for MCT non-treated group.  
 According with the literature, the IRS1 and IRS2 downregulation may be related with 
insulin resistance mechanisms. For example, in skeletal muscle, an increase in aldosterone 
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concentration has the ability to downregulate IRS1 and 2, once it targets pancreatic β-cells 
insulin producers, downregulating insulin production, that will decrease the phosphorylation 
of IRS and interfere the PI3K/Akt signalling pathway. This inactivation of PI3K/Akt 
signalling culminates in a decrease in NO and can interfere with the muscle contractility. So, 
insulin resistance is responsible for impairing the input of glucose into the cell as well as the 
sensitivity of IRS/PI3K/NO signalling pathway.115 In soleus muscle from MCT rhNRG1-
treated group animals, IRS1 mRNA expression remained decrease in comparison with the 
CTRL group, so, in our study the treatment did not demonstrated modulation of the 
expression of this gene. However, a study that evaluated IRS1 expression in L6E9 and 
C2C12 myocytes, revealed that the cells treated with NRG demonstrated an increased 
expression of IRS1 due to its increased insulin-stimulated phosphorylation, what promoted 
the IRS1 binding to the p85 subunit of PI3K Ser473-PKB phosphorylation at a submaximal 
insulin concentration, and the continuity of the signalling pathway.136 Furthermore, a study 
in transgenic Ren2 rat revealed that in situations of insulin resistance, the decreased 
phosphorylation of IRS1 in muscle cells will decrease the Akt activation and 
phosphorylation, what may be related with the decreased GLUT4 expression, once they are 
not recruited due to insulin resistance, what results in glucose uptake impairment.296 Thus, 
based the findings from other studies, the treatment with rhNRG1 on MCT-induced PAH 
animals could have modulated the IRS1 expression by the regulation of PI3K/Akt pathway, 
however, we did not verified this in our study. 
 
e. rhNRG1 is involved in the regulation glycolytic pathway genes expression  
 In PAH, the RV is characterized by abnormal energy metabolism.37,38 The Warburg 
effect concerns the cessation of mitochondrial OXPHOS, supplying catabolic needs of 
hyperproliferative cells with an alternative glucose metabolism, the glycolysis.53,139 The 
accelerated glucose metabolism under aerobic conditions is one of the hallmarks of cells 
from RV and maybe skeletal muscle in PAH situations.177,297 In PAH, the underlying 
metabolic derangements originated evolve from the progress of this disease to the end-
stages4, encompassing not only the RV but other tissues of the organism, such as pulmonary 
arteries, LV or skeletal muscle.39 However, glycolytic metabolism mechanism in RV in PAH 
is not clear and is still unknown. Once that little is known about the details of the molecular 
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mechanism of PAH development, we evaluated the mRNA expression of several genes to 
relevant to the glycolytic pathway, aiming to identify metabolic shifts, like the enhanced 
glycolysis and glucose uptake that follows the suppression of mitochondrial GO. The 
evaluation was performed in four different tissues: RV, soleus muscle, gastrocnemius muscle 
and lung. Information about the mRNA gene expression analysis of the gastrocnemius 
muscle and lung are not shown once no significant data were obtained. Furthermore, we also 
studied the effects of the treatment with rhNRG1 in the expression of each gene analysed to 
assess if there is any modulation by this treatment. 
 
-rhNRG1 modulates glycolytic pathway genes expression in soleus muscle in PAH 
 In PAH, the elevated glycolysis is required to provide sufficient amounts of 
metabolic intermediates to support anabolic processes of the cells.297 We evaluated the 
expression of the glycolytic genes in soleus muscle, and the biggest part of them did not 
demonstrated alterations between the different experimental groups.  
 Surprisingly and contrary to expectations face to the alterations on RV, in soleus 
muscle we did not detect any differences in mRNA expression of HIF-1α, GLUT1 and 
GLUT4 between the animal groups in study. The transcription factor HIF-1 is the main 
inductor of glycolysis under low oxygen conditions, acting through the upregulation of genes 
that encode GLUTs.298,299 The levels of HIF-1α are similar between all animal groups in 
study, what means that the hypoxia conditions were not as much severe in this tissue, once 
HIF-1α expression only increase during exposure to hypoxia.298 However, it is know that the 
HIF-1α can be stabilized in many cell types during systemic hypoxia.341 One example of this 
stabilization in hypoxia was detected by two studies in cultured cell lines, HeLa, SiHa, Sk-
Hep-1, HT1080 and Hep3B in one study, and line cells from hepatocarcionoma. Both 
investigations showed an interaction between Sirt1 and HIF-1α proteins that modulate their 
gene expression, in what the first one binds to the second one, deacetylating it, what 
diminishes the accumulation of HIF-1α and decreases the expression of its target genes, as 
GLUT1. This allow us to say that Sirt1 activation is necessary for the accumulation of HIF-
1α in hypoxia conditions.300,301 Though, we also analysed Sirt1 in soleus muscle tissue and 
we do not detect significant alterations in its mRNA expression. 
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 Glycolysis is a multi-regulated pathway, composed by three rate-liming steps 
catalysed by HK1 and HK2, PFKm and PKm, which act sequentially throughout the 
metabolic process.302 Of these four enzymes analysed, only the HK2, which is mainly found 
in skeletal muscle190, displayed a decreased expression in the MCT-induced PAH group 
treated with rhNRG1, to values similar to those in CTRL group. In a study in humans with 
type 2 diabetes mellitus and insulin resistance, the analysis of mRNA expression of HK2 in 
skeletal muscle from basal and insulin-stimulated states revealed a decrease in its 
expression.191 The literature reported that the NRG1 is responsible for inducing the 
activation of  Ras/Raf/MEK/MAPK and PI3K signalling cascades.172,241 A study described 
the involvement of these pathways in the regulation of HK2 expression in embryonic 
fibroblasts, were the oncogenic Ras expression significantly increased HK2 expression 
through the activation of PI3K and MAPK signalling, and the deletion of HK2 after the 
expression of oncogenic Ras reversed oncogenic transformation.297 The investigators 
concluded that HK2 is required for oncogenic KRas-driven lung tumorigenesis.297 The same 
study investigated the effects of HK2 in a mouse model for breast cancer were induced by 
activated oncogenic driver ErbB2/Neu, and the HK2 expression is significantly elevated in 
the tumour tissues and non-expressed in the control. When they deleted HK2, a regression 
in tumour development occurred, they conclude that HK2 is required for the oncogenic 
ErbB2-driven mammary gland tumorigenesis in vivo.297 In our study, these findings may be 
a clue on how the HK2 and rhNRG1 interact and how this interaction could be beneficial to 
ameliorate PAH.  
 From the different LDH isoforms of the enzyme responsible for the conversion of 
pyruvate into lactate, only LDHb mRNA expression has demonstrated alterations between 
groups. Although no changes were detected in LDHb expression in MCT-induced PAH non-
treated animal group, we observed that the treatment with rhNRG1 attenuated the expression 
of LDHb in MCT-induced PAH animals in comparison with CTRL group, what implies an 
increase in pyruvate. This attenuation in LDHb mRNA expression by rhNRG1 evidences 
one of the interactions of this treatment with the Warburg effect, once in this metabolic shift, 
the pyruvate is catalysed into lactate by LDH, and then lactate is transported to extracellular 
ambient, rising the acidity of the medium and favouring the abnormal proliferation of cells. 
Once the rhNRG1 decreases lactate production, the pyruvate is transported to the 
mitochondria, were it may be catalysed into acetyl-CoA by PDH and enter to the TCA cycle 
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to complete oxidization to CO2, H2O, and ATP.
78,147 In a study with muscle-specific 
transgenic mouse lines and primary skeletal myotubes in culture, the investigators 
discovered that beyond being involved in lactate homeostasis in the skeletal muscle, LDHb 
is a GO biomarker regulated by the PGC-1α, being negatively correlated with pH, that 
increases due to lactate accumulation, and associated to a reduced muscle performance. In 
the same study, the investigators suggest that LDHb is a regulator of mitochondrial function 
who acts downstream of the PGC-1α/nuclear receptor regulatory pathway. However, its 
functional significance in skeletal muscle physiology remains unclear.303 This decrease in 
LDHb will reflect in a disadvantage to Warburg effect and, consequently, to the PAH 
phenotype cells: first, once that lactate concentrations will decrease, this triggers a decrease 
in NAD+, co-factor produced by LDH, which is necessary for glycolysis to occur; second, 
the decreased lactate production, will normalize the acidity values of the cellular 
environment, constituting a disadvantage for PAH proliferating cells.207 However, in PAH-
associated with RVH, the metabolic switch towards aerobic glycolysis is mediated by the 
increased expression and activity of PDK, what results in the inhibition of PDH and the 
formation of acetyl-CoA feed TCA cycle, leading to the accumulation of pyruvate in the 
inside of the cell.224 Moreover, in initial stages of PAH, where RVH is not established, the 
treatment with rhNRG1 may improve the glucose metabolism by the modulation of Warburg 
effect. 
 The remaining analysed genes did not show differences between the experimental 
groups in our study, however, another study in MCT-induced PAH, demonstrated 
differences in mRNA expression of Sirt1, PGC-1α, NRF1 and Tfam in gastrocnemius 
muscle from MCT animals with compensated and decompensated RV function.104 One 
explanation for this difference may reside in the time of response of MCT to the disease 
development, once these modifications were observed after 4 weeks of treatment with MCT, 
while our study only had the duration of 3 weeks. 
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-rhNRG1 is responsible for the modulation of some glycolytic pathway genes 
expression in RV 
  When cells are subjected to hypoxia conditions as the ones observed in PAH, they 
must undergo metabolic adaptations to survive. Indeed, part of this adaptation involves 
upregulation of genes that encode the enzymes required for anaerobic glycolysis.304  
 In the present study, the RV GLUT1 mRNA expression was significantly increased 
in MCT animals and was attenuated by the treatment with rhNRG1, as explained above. The 
data about mRNA expression of GLUT1 that we obtained are consistent with the literature, 
that explains that GLUT1 mRNA increases in PAH due to pressure overload and 
hypertrophy103,135, that we also verified in MCT-induced PAH animals. Furthermore, the 
HIF-1α activation favours glycolysis through the increase in GLUT1 transcription.192 Piao 
et al., (2013) detected an increased mRNA expression of GLUT1 in MCT-RVH induced 
group of rats224, which makes our data consistent with those from other authors. 
Furthermore, in two different studies with a model for RVH without PAH, that was achieved 
through the PAB characterized by a metabolic shift from GO to FAO and glycolysis, an 
increased expression of GLUT1 was also found, what was consistent with the elevated rates 
of glycolysis measured in RVH.160,212 In another model of MCT-induced PAH, the results 
were concordant with the ones from the PAB study; it was discovered that the increased 
glycolysis in the RV of MCT group, that was achieved by FDG uptake, was accompanied 
by the increased levels of GLUT1 mRNA expression.212 This allow us to say that our MCT-
group displayed elevated levels of GLUT1 to respond to the high glucose demands necessary 
for glycolysis in cells. The attenuation of GLUT1 expression by rhNRG1 treatment was due 
the inhibition of PI3K/Akt signalling pathway, once PI3K/Akt is involved in the promotion 
of cellular glucose uptake by GLUT1305, what plays effects on the reduction of glucose 
uptake, cell growth and proliferation. Furthermore, NRG1 effects on glucose uptake were 
assessed in an in vitro study, were the glucose uptake was completely abolished in situations 
of PI3K inhibition.253 In contrast, the PI3K inhibition may also trigger insulin resistance and 
glucose intolerance.254 This increase in GLUT1 expression in RV is necessary for increase 
glucose transport into the cytosol to support the less energetically efficient glycolytic 
metabolism of RVH. Furthermore, the increase in glycolysis will produce more lactate that 
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will reduces RV contractility160, what was also proven by the reduction of TAPSE in MCT-
induced PAH groups. 
 We found a decreased GLUT4 mRNA expression in MCT-induced PAH animals that 
was attenuated and increased by rhNRG1. During the adaptation to the high demand of 
glucose, as it occurs in the initial stages of PAH, the GLUT4 expression increases183, 
however, there is a tendency to a decrease  in its expression as the disease progresses to 
cardiac hypertrophy and to HF.215 This decrease in GLUT4 is also associated with a decrease 
in the contractility capacity of the cardiomyocytes, which will translate into changes in 
TAPSE.249 In a model of transverse aortic constriction in mice, to describe metabolic 
alterations due to pressure overload in cardiac metabolism, the investigators reported the 
existence of reduced GLUT4 in plasma membrane due to reduced Akt phosphorylation, 
which is induced by PI3K and performed by PDK, what reduces the levels of GLUT4. It 
demonstrates that the glucose uptake due to GLUT4 translocation was a downstream effect 
of the PI3K/Akt pathway.306 The decrease in GLUT4 mRNA expression may also be a 
predictor for severity of whole-body insulin resistance.307 Beyond insulin, NRGs are also 
responsible for inducing the translocation of GLUTs to plasma membrane in muscle cells, 
potentiating glucose transport and myogenesis.241,242 This is a reason for the increase in 
mRNA expression levels of GLUT4 in MCT-induced PAH treated with rhNRG1 group. In 
an in vitro study with L6E9 rat skeletal muscle cell line, the mRNA analysis revealed that in 
the cellular group treated with NRG the abundance of GLUT4 significantly increased in the 
plasma membrane, what is consistent with the fact that NRG induces GLUT4 
translocation.249 As GLUT4 depends on insulin or other stimuli from to be activated and 
translocated from the storage vesicles to the cell membrane through PI3K153, the treatment 
with rhNRG1 can act as an intermediary for the activation and translocation of GLUT4, 
increasing its expression in RV cardiac muscle in order to normalize glucose uptake and 
metabolism. 
 The induction and activation of HIF-1α is associated with the development of cardiac 
hypertrophy.173 Contrary to what has been observed in soleus muscle, in RV of MCT-
induced PAH group we found increased mRNA expression of HIF-1α. Its involvement in 
the development of PAH was also supported by a study in mice that lack HIF-1α, as they 
have not developed hypertrophy because they were resistant to hypoxia-induced PH.308 In a 
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study with transgenic mice for HIF-1α overexpression, the transgenic group demonstrated 
an increased rate of anaerobic glycolysis309, what is correlated with PAH development. The 
HIF-1α expression was also evaluated in a PAB model to mimic chronic progressive RV 
pressure overload, such as that which develops in human PAH, and was also increased when 
compared with non-diseased controls, what demonstrates an uniformity of HIF-1α in both 
models.310 Indeed, the increased  HIF-1α expression could be an indicator for the increased 
glucose uptake, once HIF-1α induces the expression of GLUT1, and also for the metabolic 
switch characteristic of PAH, once it is reported that HIF-1α inhibits PDK and GO.192 An in 
vitro study developed in C2C12 myocytes in which HIF-1α is knocked down by short-
hairpin RNA, revealed that the knockdown of this gene in the skeletal muscle cells resulted 
in abolition of insulin-stimulated glucose uptake due to the impaired translocation of GLUT4 
to the plasma membrane, maybe as a consequence of the reduced phosphorylation of the Akt 
substrate. From this study, the authors concluded that the HIF-1α is also a key element for 
GLUT4-mediated glucose uptake in the skeletal muscle cells and may be a target to improve 
impaired glucose metabolism.311 
 
 HKs are crucial glycolytic enzymes that play an important role in survival 
pathways312, and several reports demonstrated the protective effects of an increased 
expression of HK, such as the improved resistance of cardiomyocytes against ischemic 
injury and apoptosis.313 Insulin is responsible for the activation of HKS in isolated rat 
hearts314 and the HIF-1α activation favours glycolysis through the increase in HKs 
transcription.192  In comparison with the CTRL group, we found increased HK1 and HK2 
mRNA expression in both MCT-induced PAH groups. The MCT-induced PAH rhNRG1 
treated group also displayed increased expression of HK2 in relation to MCT-induced PAH 
group. Our analysis is, in part, coherent with other studies, in what they found that both HK1 
and HK2 mRNA expression were increased in an MCT model.224 Furthermore, in a study 
with a model of PAB, was also evidenced an increased expression of HK1, being this 
increase highlighted as one of the indications for RVH.160 In an MCT-induced PH model in 
rats, the increased expression of HK1 was also reported in the MCT animal group.38 As 
previously mentioned, the elevated mRNA expression of HK2 is related with some cancers, 
and a study in human cancer lung cell line A549 demonstrated that their expression is 
dependent of HIF-1 mechanisms, relating increased expression of HK2.315 A study in 
cardiomyocytes demonstrated that the increase in HK2 occurs due to the association of the 
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Akt with the mitochondria, that posteriorly recruits and phosphorylates HK2, activating it. 
Then, the activated HK2 displays kinase activity and protects cardiomyocytes against 
apoptotic Bcl-2 proteins, such as Bax and Bak.313 Furthermore, the HKs are speed-limiting 
enzymes of the glycolytic pathway, and its expression can induce a downstream cascade 
amplification reaction, providing more ATP to remodel myocardial cells, being this a reason 
to have increased RV expression oh HKs in cases of hypertrophy.38,160 So, the increased 
expression of HKs may be a mechanism for the maintenance of remodelled cells in the RV, 
that was not attenuated by NRG1.  
 The PFKm is one of the primary regulators of glycolytic rate.  In contrast with soleus 
muscle, in RV of MCT-induced PAH group there was a decrease in PFKm mRNA 
expression and no changes in its expression were evidenced by rhNRG1. A study in 
hypoxia/Sugen5416 model demonstrated an increased mRNA expression of PFKm in RV.173 
However, in a knockout model for PFKm gene, the decreased levels of PFKm trigger an 
increase in glucose-6-phosphate and in glycogen storage, and in young mice, the knockout 
of this gene lead to the development of cardiac hypertrophy and enlargement.316 A study in 
mice with transgenic HIF-1α to analyse its influence if overexpression of this gene, showed 
that the increase in HIF-1α mRNA expression is accompanied by an increased expression of 
PFK in transgenic mice, as the cellular metabolism changed dramatically in response to 
hypoxia to increase anaerobic glycolysis.309 So, our evaluation of mRNA expression of 
PFKm demonstrates some disparity between the expression of PFKm and the other 
glycolytic pathway genes, since all others point to an increase in glycolysis in MCT animals. 
 
 PKm is responsible for catalyse the final and irreversible step of glycolysis: the 
dephosphorylation of phosphoenolpyruvate into pyruvate.182,207,298 The mRNA expression 
of PKm was also altered in the RV analysis and rhNRG1 accentuated the increase in its 
expression observed in MCT-induced PAH group. In both MCT groups, the increase in PKm 
expression will lead to an increase in pyruvate production, that may be converted into lactate 
and favour the exacerbated cellular proliferation. 
 The mRNA expression of the glycolysis implicated genes analysed in RV that 
displayed significant differences between experimental groups, have in common the fact that 
they are related to the development of RV hypertrophy in MCT-induced PAH group. As 
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BNP overexpression at cardiac level is markedly upregulated in response to ventricular 
hypertrophy or overload, is expected that it is upregulated in PAH.32  
 Although we have found no alterations in the RV mRNA expression of the other 
genes involved in glucose metabolism, there are studies that refer the existence of changes 
in its expression in situations of RVH. We do not find differences in ET-1 mRNA expression 
maybe due to the great standard deviation associated with the MCT group. 
 In an MCT rat model for the study of PH induced RV failure, the mRNA expression 
of LDHa was found to be significantly increased in MCT animals. A study in MCT-induced 
PH in male Wistar rats, demonstrated differences in mRNA expression of Sirt1, PGC-1α, a 
transcriptional coregulator and a master regulator of mitochondria153,163, and Tfam in RV 
form MCT animals with compensated and decompensated RV function.104 However, the 
duration of the protocol of this study was 4 weeks, while in our study sample collection was 
performed at the end of the third week after MCT administration. This might be a reason for 
the different results, as the disease progression stage induced by MCT may be variable 
depending on several factors. 
 Two different models, an MCT-induced PH and a PAB model revealed that the RV 
reliance on glycolysis is evidenced by the increased expression of GLUT1 and HK1.160,212 
So, as we obtained the same results in our study, we may relate the results with the other 
genes which are altered and infer that our MCT-induced PAH group switched their glucose 
metabolism towards glycolysis, as expected. However, we were not able to confirm if the 
RV of the animals in study had significant impairment of mitochondrial metabolism, 
especially the animals of the MCT-induced PAH group, once we did not verify alterations 
in both PDHα1 or PDHβ expression.  The inhibition of PDHα1 or PDHβ activity is 
characteristic of Warburg effect and one of the causes for mitochondrial impairment in PAH, 
switching cell metabolism toward glycolysis.317  
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-Glycolytic pathway genes mRNA expression in RV is related with 
morphophysiological changes resulting from the development of PAH in 
monocrotaline model 
 Our data demonstrated a significant correlation between the RV hypertrophy 
indicator, Fulton index, and genes as GLUT1103,135, GLUT4215, HIF-1α173,308, PFKm316, 
PKm318, LDHd317, IRS1319, BNP32,201,257 and also ET-186, as both are indicators of 
hypertrophy, which is in line with the literature analysed. These data confirmed that 
increased RV glucose uptake and metabolism are related to the impairment of RV and with 
RVH, as we previously demonstrated in the analysis of mRNA expression and in the 
morphophysiological evaluation performed. 
 Moreover, our data showed that there is a significant correlation between TAPSE and 
gene expression of genes as GLUT1160, GLUT4249, HIF-1α, HK1, HK2, PFKm, PKm, 
LDHb, LDHd, IRS2 and BNP. These data confirm that in RV, the glycolysis is related with 
RV function during hypertrophy and that all of them might contributed to a decrease TAPSE 
values, what is reflected in alterations on the contractile cappacity of the RV in PAH. 
 The CO also displayed a correlation with GLUT1, GLUT4283, HIF-1α35,39,42, PKm, 
PDHβ, PGC-1α and BNP277. These data confirm that as the disease progresses, CO gradually 
decreases as long as the RVH transits from cRVH to dRVH.44,236 
 RV mRNA expression also shown that there are genes whose expression is correlated 
with each other, such as the GLUT1 and GLUT4153,183, the GLUT1 and HIF-1α304, and 
GLUT4 and HIF-1α311, as we mentioned above during analysis of gene expression.  
 
 
2. Characterization of the chronic hypoxia model  
 As explained before, in our study we performed the evaluation of morphological 
characteristics of the MCT model. A similar methodology was performed in a hypoxia model 
for PH, in order to investigate the existence of differences in the development of the disease 
between the two experimental models. Thus, in the same way that we did in MCT model, 
we started the model evaluation by its morphometric characterization.  
92 
 
 As previously mentioned in materials and methods section, some animals were 
treated with Sugen5416 and exposed to hypoxia. Due to Sugen5416, an antiproliferative 
treatment, H/S rats develop progressive pulmonary vascular angio-obliterative lesions, PH 
and RV dysfunction, that may culminate in HF.92,290 As the hypoxia model is more specific 
for PH development, the treatment with Sugen5416 in hypoxia model induced the 
development of a severe and sustained form of PAH and reproduce with greater degree of 
similarity the model of MCT-induced PAH.320,321  
 
a. Progression of PAH in chronic hypoxia/Sugen5416  
 The morphological analysis revealed that at the end of the experimental protocol, the 
BW of the H/S animals was decreased, similarly to wat occurred in MCT animals, and as it 
is characteristic of PAH. There are experiments in this animal model that revealed a decrease 
in BW in H/S group310, while that in others the decrease is so smooth and without statistical 
significance to infer that the combination of Sugen5416 with hypoxia exerts effects on BW 
reduction in the same way as MCT.322 Through this evaluation, we also can conclude that 
the hypoxia treatment severity is lower than hypoxia/Sugen5416, once the loss of BW is one 
of the consequences of the disease development. 
 The RV hypertrophy was evident in H/S animal group by the increased Fulton index. 
The same results were achieved by other studies in hypoxia/Sugen5416 models320,322–324, 
relating the development of PH and hypertrophy with Sugen5416, as it was suggested by the 
literature.92,290,325 The RV/TL index, also proportional to the hypertrophy degree, has 
demonstrated to be coherent with Fulton index data for the increased hypertrophy 
development in H/S animal group. Once again, through this analysis, we can perceive a clear 
difference in the development of hypertrophy caused by chronic hypoxia, which is very 
similar to the control animals. The verified alterations reflect that chronic hypoxia and 
hypoxia/Sugen methods lead to development of PAH with different pathogenicity levels, 
being chronic hypoxia-induced PAH less severe than hypoxia/Sugen-induced PAH, as it was 
previously described by other study. 288 
 In MCT model, Lung/TL ratio was also evaluated to infer adverse changes in lungs 
triggered by the MCT administration.270,326 However, the analysis of this parameter in H 
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group revealed that the animal exposed to hypoxia developed pulmonary oedema, which was 
reflected in the increase in lung weight of this animal groups.  
 Therefore, our results confirmed that hypoxia/Sugen5416 model is also able to 
reproduce RV functional changes that are generated in PAH development. 
 
b. GLUT1 mRNA expression is altered in gastrocnemius muscle from chronic 
hypoxia/Sugen5416 animals 
 In normal situations, the prolonged exposure to hypoxia is related with an 
enhancement of transcription of GLUT1 and GLUT4 in the skeletal muscle.327 During the 
analysis performed in gastrocnemius muscle, we only found alterations in GLUT1 
expression, that surprisingly was decreased in H group. The only difference between the 
results of mRNA analysis in skeletal muscle of this model and MCT model, was the 
decreased expression of GLUT1 in hypoxia model. It may suggest that maybe the skeletal 
muscle is not the primary tissue to develop the glycolytic switch in PAH, once the glucose 
uptake was not increased, otherwise we would have obtained different expression values for 
GLUTs. 
 
c. HIF-1α and PGC-1α mRNA expression is decreased in lung from chronic 
hypoxia/Sugen5416 animals 
 A study in a model of PAH in mice induced by hypoxia/Sugen5416 revealed that 
after 3 weeks of hypoxia exposure, the lungs from H/S and H animals demonstrated 
significantly higher FDG uptake than in N group, being this increase more significant in the 
animals of H/S group and indicative of increased glycolysis.321 Hence, we performed the 
analysis of some target genes involved in glycolysis, and it doesn’t revealed altered 
expression of GLUT1 and GLUT4, what means that is unlikely to have increased glucose 
metabolism in the lung, once one of the glycolysis characteristics is the increased in glucose 
uptake to support the energetic demands.  
 We found a decrease in both pulmonary HIF-1α and PGC-1α mRNA expression in 
the H/S animal group. Despite the exact role of HIF-1α in lung injury is not well stablished, 
it is known that it is an important mediator of the hypoxic response in animal cells and plays 
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a central role in controlling the glycolysis pathway in hypoxia conditions.328 So, as the other 
genes analysed point to the absence of glycolytic metabolism, this decreased mRNA 
expression of HIF-1α may have occurred by the same reason. We did not find any 
publication showing variations in these two genes expression in hypoxia models. However, 
increased PGC-1α expression is reported in tissues with high energy demands, and its 
expression is increased in conditions of higher energy requirements.172  Thus, as we were 
able to verify through the GLUTs mRNA expression in lungs, the glucose uptake did not 
increased in any animal group and the glucose metabolism did not switched toward 
glycolysis, what may be a reason for a decrease in PGC-1α expression. 
 
   
d. Glycolysis is impaired in RV from hypoxia/Sugen5416 animals  
 The rate-limiting step for glucose metabolism relies on its transport into the 
cardiomyocytes through specific carrier-mediated transporters, the GLUT1 and GLUT4. In 
parallel with the increased PVR due to PAH development, RV myocytes also develop a 
mitochondrial metabolic phenotype similar to that observed in lung samples. Faced with this, 
we performed GLUT1 and GLUT4 analysis in RV in the animals from chronic hypoxia 
model. While the mRNA expression of GLUT1 was increased in the H/S group, the GLUT4 
expression was decreased. In a study in a model of chronic hypoxia, an increase in GLUT1 
mRNA expression was also found in both 2 and 14 days after hypoxia exposure, and GLUT4 
mRNA expression seemed not to be influenced by hypoxia.329 Our results demonstrated a 
variation in GLUT1 and GLUT4 very similar to the occurred in the RV hypertrophied in 
MCT-induced PAH model and are, in part, concordant with the study mentioned. Thus, these 
alterations may suggest an increase in glycolysis in RV, in the same way that occurs in MCT-
induced PAH model. 
 During the exposure to chronic hypoxia, the HIF-1α expression contributes to de 
development of PH.299 However, in our study the HIF-1α demonstrated a decreased mRNA 
expression in RV from H/S animals. The HIF-1α expression was evaluated in a PAB model 
to mimic chronic progressive RV pressure overload, such as that which develops in human 
PAH and compared with a model of chronic hypoxia/Sugen5416, and it was found that HIF-
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1α mRNA expression was increased in both conditions, but with more magnitude in the RV 
from chronic H/S animals.310  
 It is known that mitochondria plays a critical role in energy metabolism and responds 
to hypoxia damage stimulus.232 PGC-1α, which is abundantly expressed in heart tissue, plays 
a critical role in the control of the expression of genes involved in the mitochondrial ATP-
generating pathway in the heart. Furthermore, in a chronic hypoxia model developed in H9c2 
cell line and in cultured primary cardiac myocytes to study Tetralogy of Fallot, which is also 
characterized by RVH, the hypoxia conditions significantly induced the expression of PGC-
1α, being this increase accompanied by an improvement in mitochondrial biogenesis in the 
cultured cardiac myocytes.330 However, it was documented that in situations of cardiac 
hypertrophy and HF, the mitochondria response is based on the downregulation of genes 
involved in mitochondria biogenesis and oxidative metabolism, and PGC-1α is one of those 
genes.153,163 Moreover, in our study we found that PGC-1α mRNA expression was decreased 
in the RV from H/S group in comparison with N group. This decreased mRNA expression 
suggests the existence of decrease in FAO under hypoxia/Sugen5416 conditions, evidencing 
the metabolic switch towards glycolysis in RV of the animals in this group. 
 Furthermore, a study in rats with severe PH also clarified the metabolic switch 
characteristic of PAH by using glucose analogue FDG and 14-(R,S)-[18F]fluoro-6-thia-
heptadecanoic acid (18F-FTHA), glucose and FA analogues metabolism, respectively. It 
revealed that a significant decrease in 18F-FTHA uptake was accompanied by an increase in 
FDG uptake in the RV, what supports the metabolic switch towards glycolysis in RV 
cardiomyocytes325, as we also demonstrated in MCT and hypoxia/Sugen5416 animal 
models.  
 
e. rhNRG1 regulated plasma glucose concentration in hypoxia/Sugen5416 animals 
 An additional work was performed to evaluate the effects of the treatment with 
rhNRG1 in glucose metabolism in chronic hypoxia/Sugen5416 animal model, having been 
defined two groups of animals were defined: H/S+BSA and H/S+rhNRG1. To evaluate the 
differences in systemic glucose metabolism and detect glucose intolerance between the two 
groups, we performed an OGTT. The fasting blood glucose analysis, that was performed to 
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evaluate if all the animals are the same conditions and were fasted at the beginning of the 
test, did not revealed differences between the two groups, as expected.  
 After the oral glucose load, glucose values increased in both animal groups. 
However, the metabolization of glucose administered was slower in H/S+BSA group, in the 
same way that it has occurred in MCT-induced PAH rats non-treated with rhNRG1. 
Furthermore, the blood glucose concentrations of H/S+rhNRG1 group were significantly 
lower when compared to the H/S+BSA group, what means that the animals that received the 
treatment of rhNRG1 displayed improved glucose metabolism, in the same way it has 
occurred in MCT model. Additionally, blood glucose concentrations did not fall to baseline 
levels after the 120 minutes, meaning that the animals may have developed insulin 
resistance.293 Based on these findings, we can suggest that the H/S+BSA animals developed 
insulin resistance that was attenuated by rhNRG1 treatment, as we verified in the 
H/S+rhNRG1 group, similarly to what we found in the MCT model. 
 The analysis of the AUC allowed us to infer the response to glucose load in each 
group294 and the data revealed that in H/S+rhNRG1 group the response to glucose was better 
in comparison with H/S+BSA group, that displayed higher values for glucose AUC. These 
data demonstrate that the H/S+rhNRG1 animals have a higher glucose tolerance which is 
consistent with studies showing improved glucose uptake in animals treated with NRG1.256 
 
f. rhNRG1 treatment effects in RV GLUTs expression in hypoxia/Sugen model 
 The treatment of H/S animals with rhNRG1 did not modulated the RV expression of 
GLUT1 and GLUT4 as it was previously demonstrated in MCT model. The GLUT1 
maintained it high expression in the H/S+rhNRG1 animal group in comparison with the 
H/S+BSA group, while the GLUT4 followed the inverse pattern of expression in the same 
groups, and its decrease was no attenuated by the effects of the treatment with rhNRG1. 
 However, when we examined the mRNA expression of rhNRG1 in the RV, it also 
displayed lower values of expression in H/S+rhNRG1 treated animals in comparison with 
H/S+BSA group. Similar results were verified in other study of our group in an MCT-
induced PAH model, where was also found a significant decrease in NRG1 expression in 
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the diseased animal group treated with rhNRG1.99 The increased expression of NRG1 in RV 
from H/S+BSA animals may be associated with poorer RV function as a consequence of the 
increase in afterload and myocardial stress.99 A decrease in mRNA expression of rhNRG1 
in the treated group may occur due to a mechanism of negative feedback related to the 
rhNRG1 exogenous administration.  
 
3. Limitations 
 During the development of this work we faced some limitations. Some of them were 
proper of the models used and are described previously, as the development of pathological 
changes in lungs as pulmonary oedema, that we identified through the morphological 
analysis in both models used. Another limitation was the number of animals in each 
experimental group, which can be countered by an increase in the number of animals for 
each group. 
 During the molecular analysis performed, although the primers used were 
specifically designed for this animal model, some primers did not work properly. The Tfam 
primer did not work and for this reason, no data regarding Tfam expression are documented. 
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Conclusion 
 In the present study, we observed that RV GLUT1 and GLUT4 mRNA expression is 
altered in PAH and was similar between the MCT and hypoxia/Sugen5416 animal models, 
being this related with the development of RVH. However, the treatment with rhNRG1 only 
attenuated GLUTs expression toward normal values in MCT-induced PAH model. The 
expression of GLUT1 and GLUT4 is correlated with cardiac markers of disease, while the 
glycolytic pathway genes are correlated with the morphophysiological changes resulting 
from the development of PAH in MCT model. 
 Little is known about the details of the molecular mechanism of PAH development 
and how the expression of some genes relevant to the glycolytic pathway are related with 
this pathophysiology. From the analysis of some glycolytic pathway genes, we conclude that 
beyond GLUTs, several genes are related, not only with the Warburg effect, but also with 
the disease progression. We also found that the treatment with rhNRG1 attenuated the 
changes in some glycolytic pathway genes, resulting in an improvement in glucose 
metabolism. 
 The glucose tolerance evaluation revealed that the animals with PAH from both 
models are insulin resistant, and the treatment with rhNRG1 regulated systemic glucose 
concentration in both animal models. 
 Besides, as our study was performed in two animal models, we conclude that MCT-
induced PAH and hypoxia/Sugen5416-induced PAH induced similar changes on RV, both 
at the morphophysiological and at the metabolic level. 
 
 We can conclude that NRG1 pathway may represent a potential therapeutic target in 
PAH mainly in the reduction of insulin resistance associated with this disease.
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Table 1 Updated classification of pulmonary hypertension and characteristics* 
WHO 
Group 
Clinical 
Group 
Origin Clinical Definition Hemodynamic 
Definition 
 
 
 
 
 
 
 
 
 
 
1 
 
 
 
 
 
 
 
 
Pulmonary 
arterial 
hypertension 
 
1.Idiopathic PAH 
2.Heritable PAH 
BMPRII mutations 
ALK-1, ENG, SMAD9, CAV1, KCNK3 
Unknown 
3.Drug and toxin induced 
4.Associated with: 
Connective tissue disease 
HIV infection 
Portal hypertension 
Congenital heart diseases 
Schistosomiasis 
5.Pulmonary venoocclusive disease and/or pulmonary capillary 
hemangiomatosis 
Idiopathic 
Heritable 
EIF2AK4 mutations, other mutations 
Drugs, toxins and radiation induced 
Associated with: 
Connective tissue disease 
HIV infection 
1”.Persistent PH of the new-born 
 
 
 
 
 
 
 
 
 
 
 
 
 
Precapillary PH 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
mPA ≥ 25 mmHg 
mPAWP < 15 mmHg 
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2 
 
 
Pulmonary 
hypertension 
due to left heart 
disease 
1.Left ventricular systolic dysfunction 
2.Left ventricular diastolic dysfunction 
3.Valvular disease 
4.Congenital/acquired left heart inflow/outflow tract obstruction 
and congenital cardiomyopathies 
5.Congenital/acquired pulmonary vein stenosis 
 
 
  Postcapillary PH 
  Isolated postcapillary PH 
  Combined postcapillary and 
  precapillary PH 
mPA ≥ 25 mmHg 
mPAWP > 15 mmHg 
 
DPG < 7 mmHg and/or 
PVR ≤ 3Wood units 
 
DPG < 7 mmHg and/or 
PVR ≥ 3Wood units 
 
 
 
3 
 
Pulmonary 
hypertension 
due to lung 
diseases or 
hypoxia 
1.Chronic obstructive pulmonary disease 
2.Interstitial lung disease 
3.Other pulmonary diseases with mixed restrictive and 
obstructive pattern 
4.Sleep-disordered breathing 
5.Alveolar hypoventilation disorders 
6.Chronic exposure to high altitude 
7.Developmental lung diseases 
 
 
 
Precapillary PH 
 
 
 
mPA ≥ 25 mmHg 
mPAWP < 15 mmHg 
 
 
4 
 
 
Chronic 
thromboem_ 
-bolic PH 
1.Chronic thromboembolic pulmonary hypertension 
2.Other pulmonary artery obstructions 
Angiosarcoma 
Other intravascular tumours 
Arteritis 
Congenital pulmonary artery stenosis 
Parasites (hydatidosis) 
 
 
Precapillary PH 
 
 
 
mPA ≥ 25 mmHg 
mPCWP < 15 mmHg 
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*Defined in 5th WSPH, Nice, 2013.  
ALK1: activin-like receptor kinase-1; BMPRII: bone morphogenetic protein receptor type 2; CAV1: caveolin-1; DPG: diastolic pulmonary gradient; ENG: endoglin; 
EIF2AK4: eukaryotic translation initiation factor 2 alpha kinase 4 HIV: human immunodeficiency virus; KCNK3: potassium two pore domain channel subfamily K member 
3; mPAP: mean pulmonary artery pressure; mPAWP: mean pulmonary artery wedge pressure; mPCWP: mean pulmonary capillary wedge pressure PAH: pulmonary arterial 
hypertension; PH: pulmonary hypertension; PVR: pulmonary vascular resistance; SMAD9: mothers against decapentaplegic 9; WHO: World Health Organization.   
 
Based on the tables from Simonneau, G. et al,. 2013. “Updated Clinical Classification of Pulmonary Hypertension”; Leopold, J. A. & Maron, B. A. 2016. “Molecular 
mechanisms of pulmonary vascular remodelling in pulmonary arterial hypertension”; McLaughlin, V. V., Shah, S. J., Souza, R. & Humbert, M. 2015. “Management of 
pulmonary arterial hypertension” and Galiè, N. et al,. 2015. “ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension”. 
 
 
 
 
 
 
 
5
5
5
5 
 
 
 
5 
 
Pulmonary 
hypertension 
with unclear 
multifactorial 
mechanisms 
1.Hematologic disorders: chronic haemolytic anaemia, 
myeloproliferative disorders, splenectomy 
2.Systemic disorders: sarcoidosis, pulmonary histiocytosis, 
Lymphangioleiomyomatosis 
3.Metabolic disorders: glycogen storage disease, Gaucher 
disease, thyroid disorders 
4.Others: tumoral obstruction, fibrosing mediastinitis, chronic 
renal failure, segmental PH 
  Precapillary PH 
  Postcapillary PH 
  Isolated postcapillary PH 
  Combined postcapillary and 
  precapillary PH 
mPA ≥ 25 mmHg 
mPAWP < 15 mmHg 
 
mPA ≥ 25 mmHg 
mPAWP > 15 mmHg 
 
DPG < 7 mmHg and/or 
PVR ≤ 3Wood units 
 
DPG < 7 mmHg and/or 
PVR ≥ 3Wood units 
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Table 2 Experimental models for pulmonary arterial hypertension 
Animal model Species Histological features Advantages Disadvantages 
 
Monocrotaline 
 
Sheep; 
dog; rat 
Medial hypertrophy 
muscularization of non-
muscular arteries 
Vascular inflammation 
Severe PH 
RV failure 
Predictable and 
reproducible 
 
Toxic stimulus 
No plexiform lesions 
 
Monocrotaline + 
pneumonectomy 
 
Rat 
Medial hypertrophy 
Muscularization of non-
muscular arteries 
Neointima formation 
Severe PH 
RV failure 
Proliferation of 
endothelial cells 
 
Toxic stimulus 
Difficult 
manipulation 
 
BMPRII knockout 
 
Mouse 
 
Increased muscularization 
Well-suited to 
study the genetic 
factors that 
contribute to PH 
 
Homozygous 
knockouts die in 
utero 
 
Fawn-hooded rat 
 
Rat 
 
Increased muscularization 
Well-suited to 
study the genetic 
factors that 
contribute to PH 
 
Presence of systemic 
hypertension 
 
Overexpression of 
S100A4 
 
Mouse 
 
Plexiform lesions 
Presence of 
plexiform lesions 
Only 5% of S100A4 
overexpressing mice 
develop PH 
 
Chronic Hypoxia + 
SU5416 
 
Rat 
Medial hypertrophy 
Muscularization of non-
muscular arteries 
Neointima formation 
Plexiform lesions 
Physiological 
stimulus 
Proliferation of 
endothelial cells 
 
Not clear which 
group it mimics 
 
Schistosomiasis 
 
Mouse 
 
Perivascular inflammation 
Medial thickening 
Formation of plexiform-
like lesions 
Comparable to 
human 
schistosomiasis 
associated with 
PAH 
 
Not significant PH 
 
 
Left-to-right shunt 
 
 
Sheep; 
pig; dog; 
rat 
 
Medial hypertrophy 
Increased VSMC 
proliferation 
Intimal proliferation 
Plexiform lesions can be 
seen 
 
Imitate the 
formation of 
plexiform lesions 
in human severe 
PAH 
 
Sophisticated 
surgical approaches 
Pathological 
alterations can 
appear at a late stage 
 
Closure of the 
ductus arteriosus 
 
Foetal 
and new-
born 
lambs 
 
Medial hypertrophy 
Muscularization of non-
muscular arteries 
Adventitial fibrosis 
Relatively large 
size of the foetal 
lamb 
Uterine surgical 
intervention is 
well tolerated 
 
Sophisticated 
surgical approaches 
Pathological 
alterations can 
appear at a late stage 
BMPRII: bone morphogenetic protein receptor type II gene; PAH: pulmonary arterial hypertension; PH: 
pulmonary hypertension; RV: right ventricle; S100A4: S100 calcium-binding protein A4 gene; SU5416: 
vascular endothelial growth factor receptor inhibitor; VSMC: vascular smooth muscle cells. 
Based on the table from Santos-Ribeiro, D. et al. 2016. “Pulmonary arterial hypertension: Basic knowledge for 
clinicians”. 
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Table 3 Primers used in the molecular analysis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Oligo name Sequence (5’→ 3’) Direction Gene Symbol Length bp Tm (ºC) 
RnGAPDH_F1 CCA TCA ACG ACC CCT TCA T forward 
GAPDH 
19 54,79 
RnGAPDH_R1 CTT CCC ATT CTC AGC CTT G reverse 19 53,19 
Rn_Nppb_F1 CTG TCG CCG CTG GGA GGT CAC T forward 
BNP 
19 65,73 
Rn_Nppb_R1 AGC CAT TTC CTC TGA CTT TTC TC reverse 23 54,98 
Rn_Edn1_F1 GCT GGT GGA GGG AAG AAA AC forward 
ET-1 
20 56,10 
Rn_Edn1_R1 GTG TAT CAA CTT CTG GTC TCT GTA reverse 24 53,84 
RnHif1a_F1 CAA CTG CCA CCA CTG ATG forward 
HIF-1α 
18 53,83 
RnHif1a_R1 CCA CTG TAT GCT GAT GCC TTA reverse 21 54,67 
RnPpargc1a_F1 CAG CCA CTC CAC CAA GAA AG forward 
PGC-1α 
20 56,05 
RnPpargc1a_R1 TCA CCA AAC AGC CGT AGA CT reverse 20 56,12 
rat_GLUT1_P1 GCA GAA GGG CAA CAG GAT AC forward 
GLUT1 
20 60,2 
rat_GLUT1_P2 TCC TTA TTG CCC AGG TGT TC reverse 20 59,3 
rat_GLUT4_P1 ATA GCC CTT TTC CTT CCC AA forward 
GLUT4 
20 58,5 
rat_GLUT4_P2 AGG CAC CCT CAC TAC CTT TT reverse 20 60,6 
Rn_Hk1_F1 GTG GAG CCG TCT GAT GTT G forward 
HK1 
19 56,03 
Rn_Hk1R1 GTG GTG TGC CCT TGT TGT reverse 18 56,01 
Rn_Hk2_F1 CGG AAG GAG ATG GAG AAA GG forward 
HK2 
20 54,83 
Rn_Hk2_R1 GAG CAC ACG GAA GTT GGT T reverse 19 55,63 
Rn_Ldha_F1 CAG CAA GAG GGA GAG AGC forward 
LDHa 
18 55,01 
Rn_Ldha_R1 GGT TTG AGA CGA TGA GCA GTT TG reverse 23 56,38 
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Rn_Ldhb_F1 TGG GGA AGT CTC TGG CTG forward 
LDHb 
18 56,74 
Rn_Ldhb_R1 TGG CTG TCA CGG AGT AAT CT reverse 20 55,69 
Rn_Ldhc_F1 GGT CGG AGT TGG AAA TGT GG forward 
LDHc 
20 56,07 
Rn_Ldhc_R1 GAG TGC TGA GGA AAA GGC T reverse 19 54,96 
Rn_Ldhd_F1 TTG AGG GGG GAG TGT GTG forward 
LDHd 
18 57,01 
Rn_Ldhd_R1 GCA GGT GGG TAT TGA GAC C reverse 19 55,66 
Rn_Pfkm_F1 GGT TGT GTT CTG GGG ATG C forward 
PFKm 
19 56,46 
Rn_Pfkm_R1 TGG GGA TTC GGT GCT CAA AA reverse 20 57,11 
Rn_Pkm_F1 TGT GGA GAT GCT GAA GGA GAT forward 
PKm 
21 55,61 
Rn_Pkm_R1 AGG TCG GTA GAG AAT GGG AT reverse 20 54,82 
Rn_Irs1_F1 GCA GGC ACC ATC TCA ACA ATC forward 
IRS1 
21 56,63 
Rn_Irs1_R1 GTT TCC CAC CCA CCA TAC T reverse 19 54,50 
Rn_Irs2_F1 ATG CGA ATG TGG TGT GGC T forward 
IRS2 
19 57,73 
Rn_Irs2_R1 AGA AGA AGT CAG GTG GGG T reverse 19 55,46 
Rn_Nrf1_F1 AGA GAC AGC AGA CAC GGT TG forward 
NRF-1 
20 57,12 
Rn_Nrf1_R1 TTG GGT TTG GAG GGT GAG AT reverse 20 56,15 
Rn_Tfam_F1 TGG GGC GTG CTA AGA ACA forward 
Tfam 
18 56,86 
Rn_Tfam_R1 CGG AAT ACA GAT AAG GCT GAC AG reverse 23 54,98 
RnSirt1_F1 GAA CCT CTG CCT CAT CTA CA forward 
SIRT1 
20 53,69 
RnSirt1_R1 CAT ACT CGC CAC CTA ACC TA reverse 20 53,45 
Rn_Pdha1_F1 ATG GTG ATG GTG CTG CTA forward 
PDHα1 
18 55,38 
Rn_Pdha1_R1 GTA GTA ATC CGT GCT GGC T reverse 19 54,43 
Rn_Pdha2_F1 CCC ACA GAC CAC ATC ATC AC forward 
PDHα2 
20 55,60 
Rn_Pdha2_R1 AAA GGA GGC TGT GCT AAA GG reverse 20 55,07 
Rn_Pdhb_F1 TGC TAG AGA ATG AAC TGA TGT ATG G forward 
PDHβ 
25 54,37 
Rn_Pdhb_R1 GTG ATG TGG GTC CCT TGC  reverse 18 56,24 
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Protocol 1 – total RNA extraction  
1. Add the beads (1.4 mm, 3 small spoons) to 30-40mg of each tissue sample and 500µL of 
phenol solution (fume hood); 
2. Homogenise sample at 6500 rpm for 3 cycles of 30 seconds using a tissue disruptor. 
Between cycles, incubate samples on ice for 30 seconds; 
3.Incubate 5 min on ice after the tissue disruption;  
4.Add 100µL of chloroform and mix (fume hood); 
5.Incubate for 10 min at room temperature; 
6.Centrifuge for 15 min at 4°C 15000rpm; 
7.Collect the aqueous phase (upper) to a new Eppendorf with 500µL of isopropanol and mix; 
8.Incubate 10 min at room temperature; 
9. Centrifuge for 10 min at 4°C, 15000 rpm; 
10. Discard supernatant paying attention to the pellet; 
11. Wash the pellet with 500µL of ethanol 70%; 
12. Centrifuge for 5 min at 4°C, 15000 rpm; 
13. Discard supernatant with a pipette; 
14. Spin the RNA samples and remove ethanol excess with a pipette; 
15. Dry RNA at room temperature by leaving the cap open for 5-10 min; 
16. Resuspend RNA with 50 µL of ultrapure H2O; 
